{"a18e34ec971f76e8104bd5836763ec157b0cd0fb": [["All rights reserved necessity, closure of all non-essential shops.", [["closure", "TREATMENT", 31, 38], ["non-essential shops", "OBSERVATION", 46, 65]]], ["The healthcare system was put under pressure and healthcare professionals faced a variety of changes and challenges involving also the conduct of clinicalResults and DiscussionWe collected 136 surveys (74.3% response rate).", [["response rate", "TEST", 208, 221]]], ["The main changes in the management of patients occurred in the conduct of visits.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Indeed, the latter that were converted into phone/video visits -as answered by 56.3% of PIs -, postponed (52.6% of PIs) orAccepted ArticleThis article is protected by copyright.", [["PIs", "TEST", 88, 91]]], ["These alternatives, though preventing the discontinuation of the trial, are not devoid of risks that may derive from delays in the scheduled visits, differences with in-person visits, incomplete visit data.Accepted ArticleReassuringly, halt of trial sites was a rare event (3.8% of PIs) and trial site closure was not reported ( Fig 1A) .Accepted ArticleModerate changes occurred in the execution of laboratory tests with 20% of PIs who declared that the centralization of laboratory tests was not carried out and 12.7% who reported a transfer of laboratory tests in a different location (Fig 1A) .", [["halt of trial sites", "TREATMENT", 236, 255], ["a rare event", "PROBLEM", 260, 272], ["PIs", "TREATMENT", 282, 285], ["trial site closure", "TREATMENT", 291, 309], ["ArticleModerate changes", "PROBLEM", 347, 370], ["laboratory tests", "TEST", 400, 416], ["PIs", "TREATMENT", 429, 432], ["laboratory tests", "TEST", 473, 489], ["laboratory tests", "TEST", 547, 563], ["closure", "OBSERVATION", 302, 309]]], ["The PIs commented that the service was preserved mainly by storing the samples or performing the tests locally.", [["samples", "ANATOMY", 71, 78], ["the tests locally", "TEST", 93, 110]]], ["Notwithstanding, these different procedures may result in lack of uniformity in sample processing and affect assay results.Accepted ArticleIn the section dedicated to protocol specific questions, we queried about minimal residual disease quantification that, according to a low number of respondents (8% of LAL2317 PIs, 17.4% of LAL2116 PIs),Accepted Articlewas not regularly performed.", [["sample", "ANATOMY", 80, 86], ["these different procedures", "TREATMENT", 17, 43], ["sample processing", "TEST", 80, 97], ["minimal residual disease quantification", "PROBLEM", 213, 252], ["PIs", "TEST", 315, 318], ["residual", "OBSERVATION_MODIFIER", 221, 229], ["disease", "OBSERVATION", 230, 237]]], ["A discontinuation of such a pivotal activity may lead to an inadequate disease monitoring and compromise the achievement of the primary objective of the studies.Accepted ArticleNevertheless, to draw definitive conclusions, it is warranted to go beyond aggregated data and analyze patients' data: to this purpose, GIMEMA is collecting COVID-19 related information in dedicated Case Report Forms (CRFs).Accepted ArticleAn alarming data came from the analysis of new enrollments: indeed, starting from April we registered a decline equal to 25% that continued also in May, when restrictive measures were released.", [["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 280, 288], ["an inadequate disease monitoring", "PROBLEM", 57, 89], ["the studies", "TEST", 149, 160], ["restrictive measures", "TREATMENT", 575, 595], ["inadequate", "OBSERVATION_MODIFIER", 60, 70], ["disease", "OBSERVATION", 71, 78]]], ["The PIs ascribed this reduction to the stay-at-home measures that produced a reduction of first visits and diagnostic tests.Accepted ArticleThis issue may have an impact on sample size and may introduce selection biases towards the patients with severer symptoms that require access to hospitals.Accepted ArticleWith regards to the workload, almost half of PIs judged as mild the burden the study-staff had to bear.Accepted ArticlePerforming visits was reported as the most frequent problem the study-staff had to face (42.6% of PIs), followed by filling CRFs (22.8% of PIs) and complying with the protocol (15.4% of PIs, Fig 2A) , hence indicating the likelihood of missing/delayed data and protocol deviations.Accepted ArticleFrom patients' standpoint, 13.4% of PIs reported the cancellation of visits by patients, thus indicating some difficulties/reluctancies in visiting hospitals.", [["patients", "ORGANISM", 232, 240], ["patients", "ORGANISM", 733, 741], ["patients", "ORGANISM", 807, 815], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 733, 741], ["patients", "SPECIES", 807, 815], ["this reduction", "TREATMENT", 17, 31], ["diagnostic tests", "TEST", 107, 123], ["severer symptoms", "PROBLEM", 246, 262], ["the study", "TEST", 387, 396], ["the study", "TEST", 491, 500], ["PIs", "TEST", 529, 532], ["filling CRFs", "TEST", 547, 559], ["PIs", "TEST", 570, 573], ["the protocol", "TEST", 594, 606], ["PIs", "TEST", 617, 620], ["missing/delayed data", "PROBLEM", 667, 687], ["size", "OBSERVATION_MODIFIER", 180, 184], ["mild", "OBSERVATION_MODIFIER", 371, 375]]], ["This occurred and especially in the trials for chronic leukemias, thus mirroring an effect of the disease status.", [["leukemias", "ANATOMY", 55, 64], ["leukemias", "DISEASE", 55, 64], ["leukemias", "CANCER", 55, 64], ["chronic leukemias", "PROBLEM", 47, 64], ["the disease status", "PROBLEM", 94, 112], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["leukemias", "OBSERVATION", 55, 64]]], ["Notably, even during this emergency, the psychological support was preserved (Fig 2B) .Accepted ArticleThe measures to moderate the spread of infections to study-staff included: limitation of access to public places (81.5% of PIs), smart-working for data managers (79.9% of PIs), self-isolation/quarantine of theAccepted ArticleThis article is protected by copyright.", [["infections", "DISEASE", 142, 152], ["the psychological support", "TREATMENT", 37, 62], ["PIs", "TEST", 274, 277], ["self-isolation", "TREATMENT", 280, 294], ["moderate", "OBSERVATION_MODIFIER", 119, 127], ["infections", "OBSERVATION", 142, 152]]], ["All rights reserved staff (51.5% of PIs, Fig 2C) .Accepted ArticleThe comparison of the regions with the highest number of deceased patients with the others revealed that the strategies adopted were homogenous.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["PIs", "TREATMENT", 36, 39], ["homogenous", "OBSERVATION_MODIFIER", 199, 209]]]], "4ae8479c3cef7cc97b7edb7cb3e9f86ec51d140e": [["IntroductionSevere acute respiratory syndrome (SARS) has affected more than 8 thousand patients in 22 countries causing 774 deaths between July 2002 and September 2003 [1].", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["deaths", "DISEASE", 124, 130], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["SARS-associated Coronavirus (SARS-CoV) has been identified as the causative agent [2] .", [["SARS", "DISEASE", 0, 4], ["SARS-associated Coronavirus", "GENE_OR_GENE_PRODUCT", 0, 27], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 0, 4], ["Coronavirus", "PROBLEM", 16, 27]]], ["Typical clinical manifestations include fever, cough, dyspnea and rapid progression of pulmonary infiltration or consolidation [3] .", [["pulmonary", "ANATOMY", 87, 96], ["fever", "DISEASE", 40, 45], ["cough", "DISEASE", 47, 52], ["dyspnea", "DISEASE", 54, 61], ["pulmonary infiltration", "DISEASE", 87, 109], ["pulmonary", "ORGAN", 87, 96], ["Typical clinical manifestations", "PROBLEM", 0, 31], ["fever", "PROBLEM", 40, 45], ["cough", "PROBLEM", 47, 52], ["dyspnea", "PROBLEM", 54, 61], ["pulmonary infiltration", "PROBLEM", 87, 109], ["consolidation", "PROBLEM", 113, 126], ["fever", "OBSERVATION", 40, 45], ["rapid", "OBSERVATION_MODIFIER", 66, 71], ["progression", "OBSERVATION_MODIFIER", 72, 83], ["pulmonary", "ANATOMY", 87, 96], ["infiltration", "OBSERVATION", 97, 109], ["consolidation", "OBSERVATION", 113, 126]]], ["The mean mortality rate is 9.6% [1], mostly attributed to hypoxemic respiratory failure.", [["respiratory", "ANATOMY", 68, 79], ["hypoxemic respiratory failure", "DISEASE", 58, 87], ["The mean mortality rate", "TEST", 0, 23], ["hypoxemic respiratory failure", "PROBLEM", 58, 87], ["mostly attributed to", "UNCERTAINTY", 37, 57], ["hypoxemic", "OBSERVATION_MODIFIER", 58, 67], ["respiratory failure", "OBSERVATION", 68, 87]]], ["In the acute phase, typical pathological findings in the lungs include mononuclear cells infiltration, alveolar cell desquamation and hyaline membrane formation [4] .", [["lungs", "ANATOMY", 57, 62], ["mononuclear cells", "ANATOMY", 71, 88], ["alveolar cell", "ANATOMY", 103, 116], ["hyaline membrane", "ANATOMY", 134, 150], ["lungs", "ORGAN", 57, 62], ["mononuclear cells", "CELL", 71, 88], ["alveolar cell", "CELL", 103, 116], ["hyaline membrane", "CELLULAR_COMPONENT", 134, 150], ["mononuclear cells", "CELL_TYPE", 71, 88], ["typical pathological findings in the lungs", "PROBLEM", 20, 62], ["mononuclear cells infiltration", "PROBLEM", 71, 101], ["alveolar cell desquamation", "PROBLEM", 103, 129], ["hyaline membrane formation", "PROBLEM", 134, 160], ["acute phase", "OBSERVATION_MODIFIER", 7, 18], ["typical", "OBSERVATION_MODIFIER", 20, 27], ["pathological", "OBSERVATION", 28, 40], ["lungs", "ANATOMY", 57, 62], ["mononuclear cells infiltration", "OBSERVATION", 71, 101], ["alveolar cell desquamation", "OBSERVATION", 103, 129], ["hyaline membrane formation", "OBSERVATION", 134, 160]]], ["Those mononuclear cells may develop into multinucleated giant cells [4] .", [["mononuclear cells", "ANATOMY", 6, 23], ["multinucleated giant cells", "ANATOMY", 41, 67], ["mononuclear cells", "CELL", 6, 23], ["multinucleated giant cells", "CELL", 41, 67], ["mononuclear cells", "CELL_TYPE", 6, 23], ["multinucleated giant cells", "CELL_TYPE", 41, 67], ["multinucleated giant cells", "PROBLEM", 41, 67], ["mononuclear cells", "OBSERVATION", 6, 23], ["multinucleated", "OBSERVATION_MODIFIER", 41, 55], ["giant cells", "OBSERVATION", 56, 67]]], ["Proinflammatory cytokines released by alveolar macrophages may play a prominent role in the pathogenesis in SARS [5] .", [["alveolar macrophages", "ANATOMY", 38, 58], ["SARS", "DISEASE", 108, 112], ["alveolar macrophages", "CELL", 38, 58], ["Proinflammatory cytokines", "PROTEIN", 0, 25], ["alveolar macrophages", "CELL_TYPE", 38, 58], ["Proinflammatory cytokines", "PROBLEM", 0, 25], ["alveolar macrophages", "OBSERVATION", 38, 58], ["prominent", "OBSERVATION_MODIFIER", 70, 79]]], ["Marked elevation of inflammatory cytokines such as IL-1, IL-6 and IL-12, of the Th1 cytokine, IFN-\u03b3, and of chemokines IL-8, monocyte chemoattractant protein-1 (MCP-1), and IFN-\u03b1induced protein-10 (IP-10) have been reported [6] .", [["IL-1", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-12", "GENE_OR_GENE_PRODUCT", 66, 71], ["Th1", "GENE_OR_GENE_PRODUCT", 80, 83], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-8", "GENE_OR_GENE_PRODUCT", 119, 123], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 125, 159], ["MCP-1", "GENE_OR_GENE_PRODUCT", 161, 166], ["IFN-\u03b1induced protein-10", "GENE_OR_GENE_PRODUCT", 173, 196], ["IP-10", "GENE_OR_GENE_PRODUCT", 198, 203], ["inflammatory cytokines", "PROTEIN", 20, 42], ["IL", "PROTEIN", 51, 53], ["IL-12", "PROTEIN", 66, 71], ["Th1 cytokine", "PROTEIN", 80, 92], ["IFN-\u03b3", "PROTEIN", 94, 99], ["chemokines", "PROTEIN", 108, 118], ["IL-8", "PROTEIN", 119, 123], ["monocyte chemoattractant protein-1", "PROTEIN", 125, 159], ["MCP", "PROTEIN", 161, 164], ["IFN", "PROTEIN", 173, 176], ["Marked elevation of inflammatory cytokines", "PROBLEM", 0, 42], ["IL", "TEST", 51, 53], ["IL", "TEST", 57, 59], ["IL", "TEST", 66, 68], ["the Th1 cytokine", "TEST", 76, 92], ["IFN", "TEST", 94, 97], ["chemokines IL", "TEST", 108, 121], ["monocyte chemoattractant protein", "TEST", 125, 157], ["MCP", "TEST", 161, 164], ["IFN", "TEST", 173, 176], ["protein", "TEST", 186, 193], ["IP", "TEST", 198, 200], ["elevation", "OBSERVATION_MODIFIER", 7, 16], ["inflammatory cytokines", "OBSERVATION", 20, 42], ["Th1 cytokine", "ANATOMY", 80, 92]]], ["High resolution Computed tomography (HRCT) findings at presentation include as unilateral or bilateral groundglass opacities or focal unilateral or bilateral areas of consolidation [7] [8] [9] .", [["opacities", "DISEASE", 115, 124], ["High resolution Computed tomography (HRCT) findings", "TEST", 0, 51], ["bilateral groundglass opacities", "PROBLEM", 93, 124], ["focal unilateral or bilateral areas of consolidation", "PROBLEM", 128, 180], ["bilateral", "ANATOMY_MODIFIER", 93, 102], ["groundglass", "ANATOMY", 103, 114], ["opacities", "OBSERVATION", 115, 124], ["focal", "OBSERVATION_MODIFIER", 128, 133], ["unilateral", "OBSERVATION_MODIFIER", 134, 144], ["bilateral", "OBSERVATION_MODIFIER", 148, 157], ["areas", "OBSERVATION_MODIFIER", 158, 163], ["consolidation", "OBSERVATION", 167, 180]]], ["Such residual abnormalities have been described also after discharge from hospital at 36.5 days and at 6-months [10, 11] .", [["Such residual abnormalities", "PROBLEM", 0, 27]]], ["However, limited information is available on recovery of inflammatory abnormalities during recovery from SARS, particularly at 60 days and beyond..IntroductionIn the current study, we conducted a study to examine HRCT changes in patients who recovered from the acute phase of SARS at days 60 and 90, and measured the associated inflammatory profiles directly by examining bronchoalveolar lavage fluid (BALF).", [["bronchoalveolar lavage fluid", "ANATOMY", 372, 400], ["BALF", "ANATOMY", 402, 406], ["SARS", "DISEASE", 105, 109], ["SARS", "DISEASE", 276, 280], ["patients", "ORGANISM", 229, 237], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 372, 400], ["BALF", "ORGANISM_SUBSTANCE", 402, 406], ["patients", "SPECIES", 229, 237], ["inflammatory abnormalities", "PROBLEM", 57, 83], ["SARS", "PROBLEM", 105, 109], ["the current study", "TEST", 162, 179], ["a study", "TEST", 194, 201], ["HRCT changes", "PROBLEM", 213, 225], ["SARS", "PROBLEM", 276, 280], ["the associated inflammatory profiles", "PROBLEM", 313, 349], ["bronchoalveolar lavage fluid", "TEST", 372, 400], ["inflammatory", "OBSERVATION", 57, 69], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["inflammatory", "OBSERVATION", 328, 340], ["bronchoalveolar lavage", "OBSERVATION", 372, 394]]], ["We also examined the presence of coronavirus in BALF.", [["BALF", "ANATOMY", 48, 52], ["coronavirus", "DISEASE", 33, 44], ["coronavirus", "ORGANISM", 33, 44], ["BALF", "ORGANISM_SUBSTANCE", 48, 52], ["BALF", "CELL_TYPE", 48, 52], ["coronavirus in BALF", "PROBLEM", 33, 52], ["coronavirus", "OBSERVATION", 33, 44]]], ["We found persistence of HRCT abnormalities and of lung inflammation at day 60, and determined retrospectively the potential influence of pulse corticosteroid therapy in this process.Study subjectsTwelve (9 women and 3 men, aged 18 to 51 years) of 28 confirmed SARS patients who were treated in Chang Gung Memorial Hospital in Taiwan between April and May 2003 during the last epidemic of SARS in Taiwan, agreed to participate in this study.", [["lung", "ANATOMY", 50, 54], ["lung inflammation", "DISEASE", 50, 67], ["SARS", "DISEASE", 260, 264], ["SARS", "DISEASE", 388, 392], ["lung", "ORGAN", 50, 54], ["corticosteroid", "SIMPLE_CHEMICAL", 143, 157], ["women", "ORGANISM", 206, 211], ["men", "ORGANISM", 218, 221], ["patients", "ORGANISM", 265, 273], ["women", "SPECIES", 206, 211], ["men", "SPECIES", 218, 221], ["patients", "SPECIES", 265, 273], ["HRCT abnormalities", "PROBLEM", 24, 42], ["lung inflammation", "PROBLEM", 50, 67], ["pulse corticosteroid therapy", "TREATMENT", 137, 165], ["Study subjects", "TEST", 182, 196], ["this study", "TEST", 429, 439], ["persistence", "OBSERVATION_MODIFIER", 9, 20], ["HRCT abnormalities", "OBSERVATION", 24, 42], ["lung", "ANATOMY", 50, 54], ["inflammation", "OBSERVATION", 55, 67], ["corticosteroid therapy", "OBSERVATION", 143, 165]]], ["All the patients met the modified Centers for Disease Control and Prevention (CDC) case definition of SARS [12] .", [["SARS", "DISEASE", 102, 106], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["Disease Control", "TREATMENT", 46, 61], ["SARS", "PROBLEM", 102, 106]]], ["SARS was confirmed by either positive real-time polymerase chain reaction (PCR) assays or elevated serum anti-coronavirus antibody by ELISA or both.", [["serum", "ANATOMY", 99, 104], ["SARS", "DISEASE", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["serum anti-coronavirus antibody", "PROTEIN", 99, 130], ["SARS", "PROBLEM", 0, 4], ["positive real-time polymerase chain reaction", "PROBLEM", 29, 73], ["PCR", "TEST", 75, 78], ["assays", "TEST", 80, 86], ["elevated serum anti-coronavirus antibody", "PROBLEM", 90, 130], ["ELISA", "TEST", 134, 139]]], ["Nasopharyngeal-aspirate samples were obtained from all study patients to exclude common viruses including influenza viruses A and B, respiratory syncytial (RSV) virus, adenovirus, and parainfluenzavirus types 1, 2, and 3, using commercially-available immunofluorescence assays (IFA).", [["Nasopharyngeal-aspirate samples", "ANATOMY", 0, 31], ["influenza viruses", "DISEASE", 106, 123], ["respiratory syncytial (RSV) virus", "DISEASE", 133, 166], ["Nasopharyngeal-aspirate samples", "CANCER", 0, 31], ["patients", "ORGANISM", 61, 69], ["influenza viruses A and B,", "ORGANISM", 106, 132], ["respiratory syncytial (RSV) virus", "ORGANISM", 133, 166], ["adenovirus", "ORGANISM", 168, 178], ["patients", "SPECIES", 61, 69], ["RSV) virus", "SPECIES", 156, 166], ["RSV", "SPECIES", 156, 159], ["adenovirus", "SPECIES", 168, 178], ["Nasopharyngeal-aspirate samples", "TEST", 0, 31], ["all study", "TEST", 51, 60], ["common viruses", "PROBLEM", 81, 95], ["influenza viruses A and B, respiratory syncytial (RSV) virus", "PROBLEM", 106, 166], ["adenovirus", "PROBLEM", 168, 178], ["immunofluorescence assays", "TEST", 251, 276], ["aspirate", "OBSERVATION", 15, 23], ["influenza viruses", "OBSERVATION", 106, 123], ["respiratory syncytial", "ANATOMY", 133, 154]]], ["Sputum and blood cultures were performed on all the cases to exclude bacterial or fungal infections.", [["Sputum", "ANATOMY", 0, 6], ["blood cultures", "ANATOMY", 11, 25], ["fungal infections", "DISEASE", 82, 99], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["Sputum", "TEST", 0, 6], ["blood cultures", "TEST", 11, 25], ["bacterial or fungal infections", "PROBLEM", 69, 99], ["fungal infections", "OBSERVATION", 82, 99]]], ["At 90 days, all the close contact relatives of the study SARS patients had their serum anti-coronavirus antibody measured by ELISA.Study subjectsNine non-smoking healthy volunteers (5 women and 4 men, aged 18 to 40 years) without evident current or past history of pulmonary diseases based on history as well as physical, chest radiographic and bronchoscopic examinations were selected as controls for this study.", [["serum", "ANATOMY", 81, 86], ["pulmonary", "ANATOMY", 265, 274], ["SARS", "DISEASE", 57, 61], ["pulmonary diseases", "DISEASE", 265, 283], ["patients", "ORGANISM", 62, 70], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["volunteers", "ORGANISM", 170, 180], ["women", "ORGANISM", 184, 189], ["men", "ORGANISM", 196, 199], ["pulmonary", "ORGAN", 265, 274], ["serum anti-coronavirus antibody", "PROTEIN", 81, 112], ["patients", "SPECIES", 62, 70], ["women", "SPECIES", 184, 189], ["men", "SPECIES", 196, 199], ["the study", "TEST", 47, 56], ["their serum anti-coronavirus antibody", "TEST", 75, 112], ["Study subjects", "TEST", 131, 145], ["pulmonary diseases", "PROBLEM", 265, 283], ["physical, chest radiographic", "TEST", 312, 340], ["bronchoscopic examinations", "TEST", 345, 371], ["this study", "TEST", 402, 412], ["pulmonary", "ANATOMY", 265, 274], ["diseases", "OBSERVATION", 275, 283], ["chest", "ANATOMY", 322, 327]]], ["None of them had any upper respiratory tract infection within the last 6 weeks or was on antibiotics or other medications at the time of evaluation.Study protocolThe study protocol was approved by Chang Gung Memorial Hospital Ethical Committee.", [["upper respiratory tract", "ANATOMY", 21, 44], ["respiratory tract infection", "DISEASE", 27, 54], ["upper", "ORGANISM_SUBDIVISION", 21, 26], ["respiratory tract", "ORGANISM_SUBDIVISION", 27, 44], ["any upper respiratory tract infection", "PROBLEM", 17, 54], ["antibiotics", "TREATMENT", 89, 100], ["other medications", "TREATMENT", 104, 121], ["evaluation", "TEST", 137, 147], ["Study protocol", "TEST", 148, 162], ["The study protocol", "TEST", 162, 180], ["upper", "ANATOMY_MODIFIER", 21, 26], ["respiratory tract", "ANATOMY", 27, 44], ["infection", "OBSERVATION", 45, 54]]], ["Treatment of SARS patients on admission to our unit included broad spectrum antibiotics to target common pathogens causing communityacquired pneumonia, according to current recommendations [13, 14] .", [["SARS", "DISEASE", 13, 17], ["pneumonia", "DISEASE", 141, 150], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["SARS", "PROBLEM", 13, 17], ["broad spectrum antibiotics", "TREATMENT", 61, 87], ["target common pathogens", "PROBLEM", 91, 114], ["communityacquired pneumonia", "PROBLEM", 123, 150], ["pneumonia", "OBSERVATION", 141, 150]]], ["These patients received variable therapy regimens, including oral ribavirin (1 g twice a day for 5-7 days), or intravenous immunoglobulin (IVIG, 1 g/kg body weight/day for 2 days), pulse steroid therapy (methylprednisolone 500 mg twice a day for 3 days and then prednisolone 1 mg/kg body weight/day for 5 days), or maintenance corticosteroid therapy (prednisolone 10 mg twice a day for more than 3 weeks).", [["oral", "ANATOMY", 61, 65], ["intravenous", "ANATOMY", 111, 122], ["body", "ANATOMY", 152, 156], ["body", "ANATOMY", 283, 287], ["ribavirin", "CHEMICAL", 66, 75], ["steroid", "CHEMICAL", 187, 194], ["methylprednisolone", "CHEMICAL", 204, 222], ["prednisolone", "CHEMICAL", 262, 274], ["prednisolone", "CHEMICAL", 351, 363], ["ribavirin", "CHEMICAL", 66, 75], ["steroid", "CHEMICAL", 187, 194], ["methylprednisolone", "CHEMICAL", 204, 222], ["prednisolone", "CHEMICAL", 262, 274], ["prednisolone", "CHEMICAL", 351, 363], ["patients", "ORGANISM", 6, 14], ["oral", "ORGANISM_SUBDIVISION", 61, 65], ["ribavirin", "SIMPLE_CHEMICAL", 66, 75], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 111, 137], ["IVIG", "SIMPLE_CHEMICAL", 139, 143], ["body", "ORGANISM_SUBDIVISION", 152, 156], ["steroid", "SIMPLE_CHEMICAL", 187, 194], ["methylprednisolone", "SIMPLE_CHEMICAL", 204, 222], ["prednisolone", "SIMPLE_CHEMICAL", 262, 274], ["body", "ORGANISM_SUBDIVISION", 283, 287], ["prednisolone", "SIMPLE_CHEMICAL", 351, 363], ["patients", "SPECIES", 6, 14], ["variable therapy regimens", "TREATMENT", 24, 49], ["oral ribavirin", "TREATMENT", 61, 75], ["intravenous immunoglobulin", "TREATMENT", 111, 137], ["IVIG", "TREATMENT", 139, 143], ["pulse steroid therapy", "TREATMENT", 181, 202], ["methylprednisolone", "TREATMENT", 204, 222], ["prednisolone", "TREATMENT", 262, 274], ["maintenance corticosteroid therapy", "TREATMENT", 315, 349], ["prednisolone", "TREATMENT", 351, 363]]], ["Pulse steroid therapy was administered within 3 days of the onset of fever in some patients, depending on the attending physicians' decision irrespective of severity of presentation.", [["steroid", "CHEMICAL", 6, 13], ["fever", "DISEASE", 69, 74], ["steroid", "CHEMICAL", 6, 13], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Pulse steroid therapy", "TREATMENT", 0, 21], ["fever", "PROBLEM", 69, 74], ["steroid therapy", "OBSERVATION", 6, 21], ["fever", "OBSERVATION", 69, 74]]], ["Some patients who did not receive pulse steroid therapy were given a short course of corticosteroid therapy (hydrocortisone 100 mg 3 times/day for 3 days) if there was rapid deterioration of pulmonary infiltration or hypoxemia.", [["pulmonary", "ANATOMY", 191, 200], ["steroid", "CHEMICAL", 40, 47], ["hydrocortisone", "CHEMICAL", 109, 123], ["pulmonary infiltration", "DISEASE", 191, 213], ["hypoxemia", "DISEASE", 217, 226], ["steroid", "CHEMICAL", 40, 47], ["hydrocortisone", "CHEMICAL", 109, 123], ["patients", "ORGANISM", 5, 13], ["corticosteroid", "SIMPLE_CHEMICAL", 85, 99], ["hydrocortisone", "SIMPLE_CHEMICAL", 109, 123], ["pulmonary", "ORGAN", 191, 200], ["patients", "SPECIES", 5, 13], ["pulse steroid therapy", "TREATMENT", 34, 55], ["corticosteroid therapy", "TREATMENT", 85, 107], ["hydrocortisone", "TREATMENT", 109, 123], ["pulmonary infiltration", "PROBLEM", 191, 213], ["hypoxemia", "PROBLEM", 217, 226], ["pulmonary", "ANATOMY", 191, 200], ["infiltration", "OBSERVATION", 201, 213], ["hypoxemia", "OBSERVATION", 217, 226]]], ["Maintenance steroid therapy (prednisolone 10 mg per day for one week) was given after pulse or short course corticosteroid therapy in all patients.", [["steroid", "CHEMICAL", 12, 19], ["prednisolone", "CHEMICAL", 29, 41], ["steroid", "CHEMICAL", 12, 19], ["prednisolone", "CHEMICAL", 29, 41], ["steroid", "SIMPLE_CHEMICAL", 12, 19], ["prednisolone", "SIMPLE_CHEMICAL", 29, 41], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["Maintenance steroid therapy", "TREATMENT", 0, 27], ["prednisolone", "TREATMENT", 29, 41], ["pulse", "TREATMENT", 86, 91], ["short course corticosteroid therapy", "TREATMENT", 95, 130], ["steroid therapy", "OBSERVATION", 12, 27]]], ["Two patients were intubated with ventilator support because of hypoxemic respiratory failure.Study protocolPatients underwent HRCT and BAL on the 60 th and 90 th day after the onset of disease.", [["respiratory", "ANATOMY", 73, 84], ["BAL", "ANATOMY", 135, 138], ["hypoxemic respiratory failure", "DISEASE", 63, 92], ["patients", "ORGANISM", 4, 12], ["Patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 4, 12], ["Patients", "SPECIES", 107, 115], ["intubated", "TREATMENT", 18, 27], ["ventilator support", "TREATMENT", 33, 51], ["hypoxemic respiratory failure", "PROBLEM", 63, 92], ["Study protocol", "TEST", 93, 107], ["HRCT", "TEST", 126, 130], ["BAL", "TEST", 135, 138], ["disease", "PROBLEM", 185, 192], ["hypoxemic", "OBSERVATION_MODIFIER", 63, 72], ["respiratory failure", "OBSERVATION", 73, 92], ["disease", "OBSERVATION", 185, 192]]], ["HRCT was performed with 1-to 2-mm collimation sections reconstructed by the use of a high spatial frequency algorithm using a (General Electric Medical Systems, Milwaukee, WI).", [["sections", "ANATOMY", 46, 54], ["HRCT", "TEST", 0, 4], ["a high spatial frequency algorithm", "TREATMENT", 83, 117]]], ["The HRCT protocol consisted of thin sections obtained at 10-mm through the chest in a supine position without using intravenous contrast medium.Scoring of HRCT findingsThe HRCT findings, as previously described [9] , were categorized the predominant pattern as: normal attenuation; ground glass opacification (hazy areas of increased attenuation without obscuration of the underlying vessels); consolidation (homogeneous opacification of the parenchyma with obscuration of the underlying vessels); reticular pattern; mixed pattern (combination of consolidation, ground glass opacities and reticular opacities in the presence of architectural distortion); ground-glass attenuation with traction bronchiolectasis or bronchiectasis; and honeycomb pattern.", [["sections", "ANATOMY", 36, 44], ["chest", "ANATOMY", 75, 80], ["intravenous", "ANATOMY", 116, 127], ["vessels", "ANATOMY", 384, 391], ["parenchyma", "ANATOMY", 442, 452], ["vessels", "ANATOMY", 488, 495], ["reticular", "ANATOMY", 498, 507], ["reticular opacities", "ANATOMY", 589, 608], ["opacities", "DISEASE", 599, 608], ["bronchiolectasis", "DISEASE", 694, 710], ["bronchiectasis", "DISEASE", 714, 728], ["sections", "MULTI-TISSUE_STRUCTURE", 36, 44], ["chest", "ORGAN", 75, 80], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 127], ["vessels", "MULTI-TISSUE_STRUCTURE", 384, 391], ["parenchyma", "TISSUE", 442, 452], ["vessels", "MULTI-TISSUE_STRUCTURE", 488, 495], ["The HRCT protocol", "TEST", 0, 17], ["thin sections", "TEST", 31, 44], ["intravenous contrast medium", "TREATMENT", 116, 143], ["HRCT findings", "TEST", 155, 168], ["The HRCT findings", "TEST", 168, 185], ["ground glass opacification", "PROBLEM", 282, 308], ["increased attenuation", "PROBLEM", 324, 345], ["obscuration of the underlying vessels)", "PROBLEM", 354, 392], ["consolidation (homogeneous opacification of the parenchyma", "PROBLEM", 394, 452], ["obscuration of the underlying vessels)", "PROBLEM", 458, 496], ["reticular pattern", "PROBLEM", 498, 515], ["consolidation", "PROBLEM", 547, 560], ["ground glass opacities", "PROBLEM", 562, 584], ["reticular opacities", "PROBLEM", 589, 608], ["architectural distortion)", "PROBLEM", 628, 653], ["ground-glass attenuation", "PROBLEM", 655, 679], ["traction bronchiolectasis", "PROBLEM", 685, 710], ["bronchiectasis", "PROBLEM", 714, 728], ["honeycomb pattern", "PROBLEM", 734, 751], ["chest", "ANATOMY", 75, 80], ["normal", "OBSERVATION", 262, 268], ["attenuation", "OBSERVATION_MODIFIER", 269, 280], ["ground glass opacification", "OBSERVATION", 282, 308], ["hazy", "OBSERVATION_MODIFIER", 310, 314], ["areas", "OBSERVATION_MODIFIER", 315, 320], ["increased", "OBSERVATION_MODIFIER", 324, 333], ["attenuation", "OBSERVATION_MODIFIER", 334, 345], ["without", "UNCERTAINTY", 346, 353], ["obscuration", "OBSERVATION_MODIFIER", 354, 365], ["vessels", "ANATOMY", 384, 391], ["consolidation", "OBSERVATION", 394, 407], ["homogeneous", "OBSERVATION_MODIFIER", 409, 420], ["opacification", "OBSERVATION", 421, 434], ["parenchyma", "ANATOMY_MODIFIER", 442, 452], ["obscuration", "OBSERVATION_MODIFIER", 458, 469], ["vessels", "ANATOMY", 488, 495], ["reticular", "OBSERVATION_MODIFIER", 498, 507], ["pattern", "OBSERVATION_MODIFIER", 508, 515], ["mixed", "OBSERVATION_MODIFIER", 517, 522], ["pattern", "OBSERVATION_MODIFIER", 523, 530], ["consolidation", "OBSERVATION", 547, 560], ["ground glass opacities", "OBSERVATION", 562, 584], ["reticular opacities", "OBSERVATION", 589, 608], ["architectural distortion", "OBSERVATION", 628, 652], ["ground-glass attenuation", "OBSERVATION", 655, 679], ["traction bronchiolectasis", "OBSERVATION", 685, 710], ["bronchiectasis", "OBSERVATION", 714, 728], ["honeycomb pattern", "OBSERVATION", 734, 751]]], ["The extent of involvement of each abnormality was assessed independently for each of three zones: upper (above the carina), middle (below carina up to the inferior pulmonary vein), and lower (below the inferior pulmonary vein).", [["carina", "ANATOMY", 115, 121], ["carina", "ANATOMY", 138, 144], ["inferior pulmonary vein", "ANATOMY", 155, 178], ["inferior pulmonary vein", "ANATOMY", 202, 225], ["upper", "ORGANISM_SUBDIVISION", 98, 103], ["carina", "MULTI-TISSUE_STRUCTURE", 115, 121], ["carina", "MULTI-TISSUE_STRUCTURE", 138, 144], ["pulmonary vein", "MULTI-TISSUE_STRUCTURE", 164, 178], ["inferior pulmonary vein", "MULTI-TISSUE_STRUCTURE", 202, 225], ["each abnormality", "PROBLEM", 29, 45], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["involvement", "OBSERVATION", 14, 25], ["each", "OBSERVATION_MODIFIER", 29, 33], ["abnormality", "OBSERVATION", 34, 45], ["upper", "ANATOMY_MODIFIER", 98, 103], ["carina", "ANATOMY", 115, 121], ["middle", "ANATOMY_MODIFIER", 124, 130], ["inferior pulmonary vein", "ANATOMY", 155, 178], ["lower", "ANATOMY_MODIFIER", 185, 190], ["inferior pulmonary vein", "ANATOMY", 202, 225]]], ["Each lung zone (total of 6 lung zones) was assigned a score, modified from previously described [9] , based on the following: 0 when no involvement, 1 when <25% involvement, 2 when 25 <50% involvement; 3 when 50% <75% involvement and 4 when 75% involvement.", [["lung zone", "ANATOMY", 5, 14], ["lung zones", "ANATOMY", 27, 37], ["lung zone", "MULTI-TISSUE_STRUCTURE", 5, 14], ["lung zones", "MULTI-TISSUE_STRUCTURE", 27, 37], ["lung", "ANATOMY", 5, 9], ["zone", "ANATOMY_MODIFIER", 10, 14], ["total", "OBSERVATION_MODIFIER", 16, 21], ["lung", "ANATOMY", 27, 31], ["zones", "ANATOMY_MODIFIER", 32, 37]]], ["Summation of scores provided overall lung involvement (maximal CT score 24).", [["lung", "ANATOMY", 37, 41], ["lung", "ORGAN", 37, 41], ["overall lung involvement", "PROBLEM", 29, 53], ["maximal CT score", "TEST", 55, 71], ["lung", "ANATOMY", 37, 41]]], ["The grading of the patient's chest radiograph and HRCT was the consensus of two observers who were blind to clinical information of the patients.Fibreoptic bronchoscopy and BALBAL was performed on all the study subjects using six aliquots (50 ml each) of 0.9% saline solution as described previously [15] .", [["patient", "ORGANISM", 19, 26], ["chest", "ORGAN", 29, 34], ["patients", "ORGANISM", 136, 144], ["saline", "SIMPLE_CHEMICAL", 260, 266], ["patient", "SPECIES", 19, 26], ["patients", "SPECIES", 136, 144], ["the patient's chest radiograph", "TEST", 15, 45], ["HRCT", "TEST", 50, 54], ["Fibreoptic bronchoscopy", "TEST", 145, 168], ["BALBAL", "TREATMENT", 173, 179], ["0.9% saline solution", "TREATMENT", 255, 275], ["chest", "ANATOMY", 29, 34]]], ["Briefly, sterile saline solution was introduced into the subsegmental bronchus of the most severely involved lobe.", [["subsegmental bronchus", "ANATOMY", 57, 78], ["lobe", "ANATOMY", 109, 113], ["subsegmental bronchus", "MULTI-TISSUE_STRUCTURE", 57, 78], ["lobe", "ORGAN", 109, 113], ["sterile saline solution", "TREATMENT", 9, 32], ["subsegmental", "ANATOMY_MODIFIER", 57, 69], ["bronchus", "ANATOMY", 70, 78], ["most severely", "OBSERVATION_MODIFIER", 86, 99], ["lobe", "ANATOMY_MODIFIER", 109, 113]]], ["The BAL fluid was retrieved and centrifuged.", [["BAL fluid", "ANATOMY", 4, 13], ["BAL fluid", "ORGANISM_SUBSTANCE", 4, 13], ["The BAL fluid", "TEST", 0, 13], ["BAL", "ANATOMY", 4, 7], ["fluid", "OBSERVATION", 8, 13]]], ["The supernatant was stored at -70\u00b0C until analysis and the cell pellet was washed and resuspended at 10 6 cells per ml.", [["supernatant", "ANATOMY", 4, 15], ["cell pellet", "ANATOMY", 59, 70], ["cells", "ANATOMY", 106, 111], ["cell", "CELL", 59, 63], ["cells", "CELL", 106, 111], ["analysis", "TEST", 42, 50], ["the cell pellet", "TREATMENT", 55, 70]]], ["The cell viability and differential cell counts were determined.", [["cell", "ANATOMY", 4, 8], ["cell", "ANATOMY", 36, 40], ["cell", "CELL", 4, 8], ["cell", "CELL", 36, 40], ["The cell viability", "TEST", 0, 18], ["differential cell counts", "TEST", 23, 47], ["cell viability", "OBSERVATION", 4, 18], ["differential cell counts", "OBSERVATION", 23, 47]]], ["Total RNA and DNA were extracted from nasopharyngeal aspirates and cells retrieved by BAL with the Viral RNA minikit and QIAmp DNA minikit (QIAGEN, Hilden, Germany).", [["nasopharyngeal aspirates", "ANATOMY", 38, 62], ["cells", "ANATOMY", 67, 72], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 38, 62], ["cells", "CELL", 67, 72], ["BAL", "ORGANISM_SUBSTANCE", 86, 89], ["Total RNA and DNA", "PROBLEM", 0, 17], ["nasopharyngeal aspirates", "TEST", 38, 62], ["BAL", "TEST", 86, 89], ["the Viral RNA minikit", "TREATMENT", 95, 116], ["QIAmp DNA minikit", "TREATMENT", 121, 138], ["nasopharyngeal", "ANATOMY", 38, 52], ["aspirates", "OBSERVATION", 53, 62]]], ["Reverse-transcriptase (RT) PCR was done for influenza A, adenovirus, human metapneumovirus, and SARS-CoV as-described previously [16] .Measurement of T cell subpopulations by flow cytometric analysisBAL cells were simultaneously stained with fluorescein isothiocyanate or phycoerythrin-conjugated monoclonal antibodies (anti-IgG1, -IgG2a, -CD3, -CD4, -CD8, -CD19, -CD56) (Beckon Dickinson, Mountain View, CA) according to the manufacturer's protocol to identify the proportions of T lymphocytes, CD4, CD8 T cells, B cells and natural killer (NK) cells subpopulations respectively.", [["T cell", "ANATOMY", 150, 156], ["analysisBAL cells", "ANATOMY", 191, 208], ["T lymphocytes", "ANATOMY", 481, 494], ["CD4", "ANATOMY", 496, 499], ["CD8 T cells", "ANATOMY", 501, 512], ["B cells", "ANATOMY", 514, 521], ["natural killer (NK) cells", "ANATOMY", 526, 551], ["influenza A", "DISEASE", 44, 55], ["human metapneumovirus", "DISEASE", 69, 90], ["fluorescein isothiocyanate", "CHEMICAL", 242, 268], ["fluorescein isothiocyanate", "CHEMICAL", 242, 268], ["influenza A", "ORGANISM", 44, 55], ["adenovirus", "ORGANISM", 57, 67], ["human", "ORGANISM", 69, 74], ["metapneumovirus", "ORGANISM", 75, 90], ["SARS-CoV", "ORGANISM", 96, 104], ["T cell", "CELL", 150, 156], ["analysisBAL cells", "CELL", 191, 208], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 242, 268], ["phycoerythrin", "SIMPLE_CHEMICAL", 272, 285], ["IgG1", "GENE_OR_GENE_PRODUCT", 325, 329], ["IgG2a", "GENE_OR_GENE_PRODUCT", 332, 337], ["CD3", "GENE_OR_GENE_PRODUCT", 340, 343], ["CD4", "GENE_OR_GENE_PRODUCT", 346, 349], ["CD8", "GENE_OR_GENE_PRODUCT", 352, 355], ["CD19", "GENE_OR_GENE_PRODUCT", 358, 362], ["CD56", "GENE_OR_GENE_PRODUCT", 365, 369], ["T lymphocytes", "CELL", 481, 494], ["CD4", "GENE_OR_GENE_PRODUCT", 496, 499], ["CD8", "GENE_OR_GENE_PRODUCT", 501, 504], ["B cells", "CELL", 514, 521], ["natural killer (NK) cells", "CELL", 526, 551], ["Reverse-transcriptase", "PROTEIN", 0, 21], ["T cell subpopulations", "CELL_TYPE", 150, 171], ["analysisBAL cells", "CELL_LINE", 191, 208], ["phycoerythrin-conjugated monoclonal antibodies", "PROTEIN", 272, 318], ["IgG1", "PROTEIN", 325, 329], ["IgG2a", "PROTEIN", 332, 337], ["CD3", "PROTEIN", 340, 343], ["CD4", "PROTEIN", 346, 349], ["CD8", "PROTEIN", 352, 355], ["CD19", "PROTEIN", 358, 362], ["CD56", "PROTEIN", 365, 369], ["T lymphocytes", "CELL_TYPE", 481, 494], ["CD4, CD8 T cells", "CELL_TYPE", 496, 512], ["B cells", "CELL_TYPE", 514, 521], ["natural killer (NK) cells subpopulations", "CELL_TYPE", 526, 566], ["human", "SPECIES", 69, 74], ["metapneumovirus", "SPECIES", 75, 90], ["influenza A", "SPECIES", 44, 55], ["adenovirus", "SPECIES", 57, 67], ["human metapneumovirus", "SPECIES", 69, 90], ["SARS-CoV", "SPECIES", 96, 104], ["transcriptase (RT) PCR", "TEST", 8, 30], ["influenza", "PROBLEM", 44, 53], ["adenovirus", "PROBLEM", 57, 67], ["human metapneumovirus", "PROBLEM", 69, 90], ["SARS", "PROBLEM", 96, 100], ["Measurement of T cell subpopulations", "TEST", 135, 171], ["flow cytometric analysisBAL cells", "TEST", 175, 208], ["fluorescein isothiocyanate", "TEST", 242, 268], ["phycoerythrin", "TEST", 272, 285], ["conjugated monoclonal antibodies", "TEST", 286, 318], ["anti-IgG1", "TEST", 320, 329], ["IgG2a", "TEST", 332, 337], ["CD3", "TEST", 340, 343], ["CD4", "TEST", 346, 349], ["CD8", "TEST", 352, 355], ["CD19", "TEST", 358, 362], ["the manufacturer's protocol", "TREATMENT", 422, 449], ["CD4", "TEST", 496, 499], ["T cell subpopulations", "OBSERVATION", 150, 171], ["lymphocytes", "ANATOMY", 483, 494]]], ["The relative ratio of CD4 or CD8 in CD3-positive cells was assayed by a dual-color analysis.", [["CD3-positive cells", "ANATOMY", 36, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 22, 25], ["CD8", "GENE_OR_GENE_PRODUCT", 29, 32], ["CD3", "GENE_OR_GENE_PRODUCT", 36, 39], ["CD4", "PROTEIN", 22, 25], ["CD8", "PROTEIN", 29, 32], ["CD3", "PROTEIN", 36, 39], ["The relative ratio", "TEST", 0, 18], ["CD4", "TEST", 22, 25], ["CD3", "TEST", 36, 39], ["positive cells", "PROBLEM", 40, 54], ["a dual-color analysis", "TEST", 70, 91], ["positive cells", "OBSERVATION", 40, 54]]], ["Data were acquired and analyzed using Becton Dickinson BD LYSYS II and Cytometric Bead Array (CBA) software (San Jose, CA).Levels of cytokine and chemokine in BAL fluidThe levels of cytokines and chemokines in BAL fluid were assayed using Becton Dickinson (BD) Cytometric Bead Array\u2122 [17] (CBA; BD Biosciences, San Jose, CA) according to manufacturer's instructions with an antibody (PharMoingen, San Diego, CA) against one of five cytokines (Human Chemokine Kit I: CXCL8/IL-8, CCL5/ RANTES, CXCL9/MIG, CCL2/MCP-1, CXCL10/IP-10, BD Biosciences,) or of the six cytokines (Human Inflammation Kit: IL-8, IL-1\u03b2, IL-6, IL-10, TNF-\u03b1, IL-12, BD Biosciences).", [["BAL fluid", "ANATOMY", 159, 168], ["BAL fluid", "ANATOMY", 210, 219], ["BAL fluid", "ORGANISM_SUBSTANCE", 159, 168], ["BAL fluid", "ORGANISM_SUBSTANCE", 210, 219], ["Human", "ORGANISM", 443, 448], ["Kit I", "GENE_OR_GENE_PRODUCT", 459, 464], ["CXCL8", "GENE_OR_GENE_PRODUCT", 466, 471], ["IL-8", "GENE_OR_GENE_PRODUCT", 472, 476], ["CCL5", "GENE_OR_GENE_PRODUCT", 478, 482], ["RANTES", "GENE_OR_GENE_PRODUCT", 484, 490], ["CXCL9", "GENE_OR_GENE_PRODUCT", 492, 497], ["MIG", "GENE_OR_GENE_PRODUCT", 498, 501], ["CCL2", "GENE_OR_GENE_PRODUCT", 503, 507], ["MCP-1", "GENE_OR_GENE_PRODUCT", 508, 513], ["CXCL10", "GENE_OR_GENE_PRODUCT", 515, 521], ["IP-10", "GENE_OR_GENE_PRODUCT", 522, 527], ["BD", "GENE_OR_GENE_PRODUCT", 529, 531], ["Human", "ORGANISM", 571, 576], ["Kit", "GENE_OR_GENE_PRODUCT", 590, 593], ["IL-8", "GENE_OR_GENE_PRODUCT", 595, 599], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 601, 606], ["IL-6", "GENE_OR_GENE_PRODUCT", 608, 612], ["IL-10", "GENE_OR_GENE_PRODUCT", 614, 619], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 621, 626], ["IL-12", "GENE_OR_GENE_PRODUCT", 628, 633], ["BD", "GENE_OR_GENE_PRODUCT", 635, 637], ["cytokine", "PROTEIN", 133, 141], ["chemokine", "PROTEIN", 146, 155], ["cytokines", "PROTEIN", 182, 191], ["chemokines", "PROTEIN", 196, 206], ["cytokines", "PROTEIN", 432, 441], ["Human Chemokine Kit I", "PROTEIN", 443, 464], ["CXCL8", "PROTEIN", 466, 471], ["IL-8", "PROTEIN", 472, 476], ["CCL5", "PROTEIN", 478, 482], ["RANTES", "PROTEIN", 484, 490], ["CXCL9", "PROTEIN", 492, 497], ["MIG", "PROTEIN", 498, 501], ["CCL2", "PROTEIN", 503, 507], ["MCP", "PROTEIN", 508, 511], ["CXCL10", "PROTEIN", 515, 521], ["IP", "PROTEIN", 522, 524], ["BD Biosciences", "PROTEIN", 529, 543], ["cytokines", "PROTEIN", 560, 569], ["Human Inflammation Kit: IL-8, IL-1\u03b2, IL-6, IL-10", "PROTEIN", 571, 619], ["TNF", "PROTEIN", 621, 624], ["IL", "PROTEIN", 628, 630], ["BD Biosciences", "PROTEIN", 635, 649], ["Human", "SPECIES", 443, 448], ["Human", "SPECIES", 571, 576], ["Levels", "TEST", 123, 129], ["cytokine", "TREATMENT", 133, 141], ["chemokine in BAL fluid", "TEST", 146, 168], ["cytokines", "TREATMENT", 182, 191], ["chemokines in BAL fluid", "TEST", 196, 219], ["Cytometric Bead Array\u2122", "TEST", 261, 283], ["CBA", "TEST", 290, 293], ["an antibody", "TEST", 371, 382], ["CXCL8/IL", "TEST", 466, 474], ["CCL5", "TEST", 478, 482], ["RANTES", "TEST", 484, 490], ["CXCL9", "TEST", 492, 497], ["MIG", "TEST", 498, 501], ["CCL2", "TEST", 503, 507], ["MCP", "TEST", 508, 511], ["CXCL10/IP", "TREATMENT", 515, 524], ["the six cytokines", "TEST", 552, 569], ["Human Inflammation Kit", "TEST", 571, 593], ["IL", "TEST", 595, 597], ["IL", "TEST", 601, 603], ["IL", "TEST", 608, 610], ["IL", "TEST", 614, 616], ["TNF", "TEST", 621, 624], ["IL", "TEST", 628, 630]]], ["Commercially available ELISA (R&D Systems, Minneapolis) was used for measurement of the growth factors, TGF-\u03b2, IGF-1 and EGF.Electron microscopic (EM) examinationWe used a previously-described method for virus detection by electron microscopy [18] .", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 104, 109], ["IGF-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["EGF", "GENE_OR_GENE_PRODUCT", 121, 124], ["growth factors", "PROTEIN", 88, 102], ["TGF-\u03b2", "PROTEIN", 104, 109], ["IGF-1", "PROTEIN", 111, 116], ["EGF", "PROTEIN", 121, 124], ["the growth factors", "TEST", 84, 102], ["TGF", "TEST", 104, 107], ["IGF", "TEST", 111, 114], ["virus detection", "TEST", 204, 219], ["electron microscopy", "TEST", 223, 242]]], ["Cells retrieved by BAL from SARS patients and normal subjects were centrifuged.", [["Cells", "ANATOMY", 0, 5], ["BAL", "ANATOMY", 19, 22], ["SARS", "DISEASE", 28, 32], ["Cells", "CELL", 0, 5], ["BAL", "ORGANISM_SUBSTANCE", 19, 22], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Cells", "TEST", 0, 5]]], ["The cell pellets were fixed, embedded and stained with 4% tannic acid and 0.5% uranyl acetate.", [["cell", "ANATOMY", 4, 8], ["tannic acid", "CHEMICAL", 58, 69], ["uranyl acetate", "CHEMICAL", 79, 93], ["tannic acid", "CHEMICAL", 58, 69], ["uranyl acetate", "CHEMICAL", 79, 93], ["cell", "CELL", 4, 8], ["tannic acid", "SIMPLE_CHEMICAL", 58, 69], ["uranyl acetate", "SIMPLE_CHEMICAL", 79, 93], ["4% tannic acid", "TREATMENT", 55, 69], ["0.5% uranyl acetate", "TREATMENT", 74, 93], ["cell pellets", "OBSERVATION", 4, 16]]], ["The ultra-thin sections were cut from Epon-embedded blocks, stained with uranyl acetate and lead citrate, and examined using a transmission electron microscope (TEM) (H-500, Hitachi, Tokyo, Japan).Statistical analysisData are expressed as mean \u00b1 SEM.", [["sections", "ANATOMY", 15, 23], ["uranyl acetate", "CHEMICAL", 73, 87], ["lead citrate", "CHEMICAL", 92, 104], ["uranyl acetate", "CHEMICAL", 73, 87], ["citrate", "CHEMICAL", 97, 104], ["sections", "MULTI-TISSUE_STRUCTURE", 15, 23], ["uranyl acetate", "SIMPLE_CHEMICAL", 73, 87], ["lead citrate", "SIMPLE_CHEMICAL", 92, 104], ["The ultra-thin sections", "TREATMENT", 0, 23], ["Epon-embedded blocks", "TREATMENT", 38, 58], ["uranyl acetate", "TREATMENT", 73, 87], ["lead citrate", "TREATMENT", 92, 104], ["a transmission electron microscope", "TEST", 125, 159]]], ["The baseline characteristics, disease and laboratory variables between groups were compared using the two-tailed Student t-test and chisquare test, respectively.", [["disease", "PROBLEM", 30, 37], ["chisquare test", "TEST", 132, 146], ["disease", "OBSERVATION", 30, 37]]], ["Spearman rank test was used to determine correlations between HRCT scores and T cell numbers, and their subpopulations, as well as CD4/CD8 ratio.", [["T cell", "ANATOMY", 78, 84], ["T cell", "CELL", 78, 84], ["CD4", "GENE_OR_GENE_PRODUCT", 131, 134], ["CD8", "GENE_OR_GENE_PRODUCT", 135, 138], ["CD4", "PROTEIN", 131, 134], ["CD8", "PROTEIN", 135, 138], ["Spearman rank test", "TEST", 0, 18], ["HRCT scores", "TEST", 62, 73], ["T cell numbers", "TEST", 78, 92], ["CD4/CD8 ratio", "TEST", 131, 144]]], ["Univariate analyses to determine the factors responsible for persistence of HRCT abnormalities were primarily used for selection of variables, based on a p value <0.05.", [["Univariate analyses", "TEST", 0, 19], ["HRCT abnormalities", "PROBLEM", 76, 94], ["a p value", "TEST", 152, 161]]], ["The significant variables were entered into a stepwise logistic regression analysis to determine the net effect for each predictor while controlling of the others.", [["a stepwise logistic regression analysis", "TEST", 44, 83], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["A pvalue <0.05 was considered as statistically significant.", [["A pvalue", "TEST", 0, 8]]], ["Analysis was performed using SPSS software version 10.0 (Chicago, IL, USA).Study subjects28 patients with confirmed diagnosis of SARS were admitted during the study period.", [["SARS", "DISEASE", 129, 133], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Analysis", "TEST", 0, 8], ["SPSS software version", "TEST", 29, 50], ["SARS", "PROBLEM", 129, 133]]], ["Sixteen patients received intubation and ventilatory support for respiratory failure.", [["respiratory", "ANATOMY", 65, 76], ["respiratory failure", "DISEASE", 65, 84], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["intubation", "TREATMENT", 26, 36], ["ventilatory support", "TREATMENT", 41, 60], ["respiratory failure", "PROBLEM", 65, 84], ["respiratory failure", "OBSERVATION", 65, 84]]], ["Three died of intractable hypoxemic respiratory failure.", [["respiratory", "ANATOMY", 36, 47], ["hypoxemic respiratory failure", "DISEASE", 26, 55], ["intractable hypoxemic respiratory failure", "PROBLEM", 14, 55], ["intractable", "OBSERVATION_MODIFIER", 14, 25], ["hypoxemic", "OBSERVATION_MODIFIER", 26, 35], ["respiratory failure", "OBSERVATION", 36, 55]]], ["Twenty-five patients recovered subsequently and were discharged from the hospital.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["No patient relapsed with either fever or new pulmonary infiltrates after discharge from the hospital.", [["pulmonary", "ANATOMY", 45, 54], ["fever", "DISEASE", 32, 37], ["patient", "ORGANISM", 3, 10], ["pulmonary", "ORGAN", 45, 54], ["patient", "SPECIES", 3, 10], ["fever", "PROBLEM", 32, 37], ["new pulmonary infiltrates", "PROBLEM", 41, 66], ["relapsed", "OBSERVATION", 11, 19], ["new", "OBSERVATION_MODIFIER", 41, 44], ["pulmonary", "ANATOMY", 45, 54], ["infiltrates", "OBSERVATION", 55, 66]]], ["Twenty of the 25 patients were randomly selected into the protocol and twelve agreed to participate.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["These patients complied with the protocol at 60 days but at 90 days, only 10 of 12 patients agreed to have a repeat HRCT, and 6 of 12 patients had a follow-up bronchoscopy.Clinical manifestationsAt 60 days, the commonest symptoms in SARS patients were general weakness (8 of 12 patients), exertional dyspnea (6 of 12 patients), joint pains (4 of 12 patients) and partial hair loss (11 of 12 patients).", [["joint", "ANATOMY", 328, 333], ["hair", "ANATOMY", 371, 375], ["SARS", "DISEASE", 233, 237], ["weakness", "DISEASE", 260, 268], ["exertional dyspnea", "DISEASE", 289, 307], ["joint pains", "DISEASE", 328, 339], ["hair loss", "DISEASE", 371, 380], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 134, 142], ["patients", "ORGANISM", 238, 246], ["patients", "ORGANISM", 278, 286], ["patients", "ORGANISM", 317, 325], ["patients", "ORGANISM", 349, 357], ["hair", "ORGAN", 371, 375], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 134, 142], ["patients", "SPECIES", 238, 246], ["patients", "SPECIES", 278, 286], ["patients", "SPECIES", 317, 325], ["patients", "SPECIES", 349, 357], ["patients", "SPECIES", 391, 399], ["the protocol", "TREATMENT", 29, 41], ["a repeat HRCT", "TEST", 107, 120], ["a follow-up bronchoscopy", "TEST", 147, 171], ["the commonest symptoms", "PROBLEM", 207, 229], ["SARS", "PROBLEM", 233, 237], ["general weakness", "PROBLEM", 252, 268], ["exertional dyspnea", "PROBLEM", 289, 307], ["joint pains", "PROBLEM", 328, 339], ["partial hair loss", "PROBLEM", 363, 380], ["weakness", "OBSERVATION", 260, 268], ["exertional", "OBSERVATION_MODIFIER", 289, 299], ["dyspnea", "OBSERVATION", 300, 307], ["joint", "ANATOMY", 328, 333], ["pains", "OBSERVATION", 334, 339], ["partial", "OBSERVATION_MODIFIER", 363, 370], ["hair loss", "OBSERVATION", 371, 380]]], ["At 90 days, all the 12 SARS patients were well without any of the abovedescribed symptoms.", [["SARS", "DISEASE", 23, 27], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["the abovedescribed symptoms", "PROBLEM", 62, 89]]], ["There was no detectable SARS-CoV antibody in the sera of close contact relatives of the study patients, even though SARS patients were not isolated after discharge from hospital from their close relatives.HRCT scoreAt 60 days, 5 SARS patients were found with an HRCT abnormality of <10 % of the total lung field.", [["sera", "ANATOMY", 49, 53], ["lung", "ANATOMY", 301, 305], ["SARS", "DISEASE", 116, 120], ["SARS", "DISEASE", 229, 233], ["SARS-CoV antibody", "GENE_OR_GENE_PRODUCT", 24, 41], ["sera", "ORGANISM_SUBSTANCE", 49, 53], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 234, 242], ["lung", "ORGAN", 301, 305], ["SARS-CoV antibody", "PROTEIN", 24, 41], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 234, 242], ["SARS-CoV", "SPECIES", 24, 32], ["detectable SARS", "PROBLEM", 13, 28], ["CoV antibody", "TEST", 29, 41], ["the study", "TEST", 84, 93], ["SARS", "PROBLEM", 116, 120], ["HRCT", "TEST", 205, 209], ["an HRCT abnormality", "PROBLEM", 259, 278], ["no", "UNCERTAINTY", 10, 12], ["detectable", "OBSERVATION_MODIFIER", 13, 23], ["SARS", "OBSERVATION", 24, 28], ["HRCT", "OBSERVATION", 262, 266], ["total", "ANATOMY_MODIFIER", 295, 300], ["lung", "ANATOMY", 301, 305], ["field", "ANATOMY_MODIFIER", 306, 311]]], ["In 3, the score was zero, in one ground glass attenuation was found in 7.5% of total lung field, and in another, there was consolidation in 1.7% of total lung field.", [["lung", "ANATOMY", 85, 89], ["lung", "ANATOMY", 154, 158], ["lung", "ORGAN", 85, 89], ["lung", "ORGAN", 154, 158], ["consolidation", "PROBLEM", 123, 136], ["ground glass attenuation", "OBSERVATION", 33, 57], ["lung", "ANATOMY", 85, 89], ["field", "ANATOMY_MODIFIER", 90, 95], ["consolidation", "OBSERVATION", 123, 136], ["1.7%", "OBSERVATION_MODIFIER", 140, 144], ["total", "OBSERVATION_MODIFIER", 148, 153], ["lung", "ANATOMY", 154, 158], ["field", "ANATOMY_MODIFIER", 159, 164]]], ["The other 7 SARS patients had HRCT abnormality > 10% of each lung field (a mean of 37.5 \u00b1 7.9% involvement of total lung field) ( Table 1 ).", [["lung", "ANATOMY", 61, 65], ["lung", "ANATOMY", 116, 120], ["SARS", "DISEASE", 12, 16], ["patients", "ORGANISM", 17, 25], ["lung", "ORGAN", 61, 65], ["lung", "ORGAN", 116, 120], ["patients", "SPECIES", 17, 25], ["HRCT abnormality", "PROBLEM", 30, 46], ["lung", "ANATOMY", 61, 65], ["lung", "ANATOMY", 116, 120]]], ["The most prominent HRCT findings in these patients were ground-glass attenuation (80.8 \u00b1 12.2% of total abnormality on HRCT) and consolidation (13.6 \u00b1 10.9% of total abnormality on HRCT).", [["HRCT", "CANCER", 19, 23], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["ground-glass attenuation", "PROBLEM", 56, 80], ["total abnormality", "PROBLEM", 98, 115], ["HRCT", "TEST", 119, 123], ["consolidation", "PROBLEM", 129, 142], ["\u00b1", "TEST", 149, 150], ["total abnormality", "PROBLEM", 160, 177], ["HRCT", "TEST", 181, 185], ["most", "OBSERVATION_MODIFIER", 4, 8], ["prominent", "OBSERVATION_MODIFIER", 9, 18], ["HRCT", "OBSERVATION", 19, 23], ["ground", "OBSERVATION_MODIFIER", 56, 62], ["glass attenuation", "OBSERVATION", 63, 80], ["consolidation", "OBSERVATION", 129, 142]]], ["Honeycombing and bronchiectatic changes were found in only 3 SARS patients with high HRCT score (5.5 \u00b1 2.7% of total abnormality on HRCT).", [["SARS", "DISEASE", 61, 65], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["Honeycombing", "PROBLEM", 0, 12], ["bronchiectatic changes", "PROBLEM", 17, 39], ["high HRCT score", "PROBLEM", 80, 95], ["total abnormality", "PROBLEM", 111, 128], ["HRCT", "TEST", 132, 136], ["bronchiectatic", "OBSERVATION", 17, 31]]], ["Seven of 11 patients were found normal on their follow-up HRCT at 90 days (Table 2; Figure 1) .", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["HRCT", "TEST", 58, 62], ["normal", "OBSERVATION", 32, 38]]], ["Two of the patients had persistently high HRCT scores (Table 1) .", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["persistently high HRCT scores", "PROBLEM", 24, 53]]], ["One with very high HRCT score at 60 days refused a follow-up HRCT.Factors associated with residual HRCT abnormalities at day 60The residual abnormality on HRCT at 60 days was related to the clinical course.", [["very high HRCT score", "PROBLEM", 9, 29], ["residual HRCT abnormalities", "PROBLEM", 90, 117], ["The residual abnormality", "PROBLEM", 127, 151], ["HRCT", "TEST", 155, 159], ["residual", "OBSERVATION_MODIFIER", 90, 98], ["HRCT", "OBSERVATION", 99, 103], ["residual", "OBSERVATION_MODIFIER", 131, 139], ["abnormality", "OBSERVATION", 140, 151]]], ["Univariate analysis identified 3 factors associated with the residual abnormality on HRCT.", [["Univariate analysis", "TEST", 0, 19], ["the residual abnormality on HRCT", "PROBLEM", 57, 89], ["residual", "OBSERVATION_MODIFIER", 61, 69], ["abnormality", "OBSERVATION", 70, 81]]], ["There were a greater proportion of patients receiving pulse steroid therapy (4 of 7) in patients with high HRCT score ( Table 2 ).", [["steroid", "CHEMICAL", 60, 67], ["steroid", "CHEMICAL", 60, 67], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 88, 96], ["pulse steroid therapy", "TREATMENT", 54, 75], ["high HRCT score", "PROBLEM", 102, 117], ["greater", "OBSERVATION_MODIFIER", 13, 20]]], ["In contrast, none of the patients with low HRCT score received pulse steroid therapy (Table 2 ).", [["steroid", "CHEMICAL", 69, 76], ["steroid", "CHEMICAL", 69, 76], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["low HRCT score", "PROBLEM", 39, 53], ["pulse steroid therapy", "TREATMENT", 63, 84]]], ["There was no significant difference in other therapy, including maintenance or short course corticosteroid therapy, IVIG or ribavirin, between patients with high HRCT score and those with low HRCT score ( Table 2) .", [["ribavirin", "CHEMICAL", 124, 133], ["ribavirin", "CHEMICAL", 124, 133], ["corticosteroid", "SIMPLE_CHEMICAL", 92, 106], ["IVIG", "SIMPLE_CHEMICAL", 116, 120], ["ribavirin", "SIMPLE_CHEMICAL", 124, 133], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["other therapy", "TREATMENT", 39, 52], ["short course corticosteroid therapy", "TREATMENT", 79, 114], ["IVIG", "TREATMENT", 116, 120], ["ribavirin", "TREATMENT", 124, 133], ["high HRCT score", "PROBLEM", 157, 172], ["low HRCT score", "PROBLEM", 188, 202], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["Patients with high HRCT score had significantly longer course of fever and higher serum SARS-CoV antibody titer when compared to those in patients with low HRCT score ( Table 2) .Inflammatory profiles of BAL fluidAt 60 days, compared to normal subjects, there was a significant increase in total cell counts in BAL fluid from SARS patients (Table 3 ) with a significant increase in alveolar macrophages (AM) and lymphocytes., The proportion of CD8+ T cells was increased to a greater extent than CD4+ T cells, leading to a significant decrease in CD4/CD8 ratio (Table 4 ).", [["serum", "ANATOMY", 82, 87], ["BAL", "ANATOMY", 204, 207], ["cell", "ANATOMY", 296, 300], ["BAL fluid", "ANATOMY", 311, 320], ["alveolar macrophages", "ANATOMY", 382, 402], ["AM", "ANATOMY", 404, 406], ["lymphocytes", "ANATOMY", 412, 423], ["CD8+ T cells", "ANATOMY", 444, 456], ["CD4+", "ANATOMY", 496, 500], ["T cells", "ANATOMY", 501, 508], ["fever", "DISEASE", 65, 70], ["SARS", "DISEASE", 326, 330], ["Patients", "ORGANISM", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["patients", "ORGANISM", 138, 146], ["cell", "CELL", 296, 300], ["BAL fluid", "ORGANISM_SUBSTANCE", 311, 320], ["patients", "ORGANISM", 331, 339], ["alveolar macrophages", "CELL", 382, 402], ["AM", "CELL", 404, 406], ["lymphocytes", "CELL", 412, 423], ["CD8", "GENE_OR_GENE_PRODUCT", 444, 447], ["CD4", "GENE_OR_GENE_PRODUCT", 496, 499], ["T cells", "CELL", 501, 508], ["CD4", "GENE_OR_GENE_PRODUCT", 547, 550], ["CD8", "GENE_OR_GENE_PRODUCT", 551, 554], ["alveolar macrophages", "CELL_TYPE", 382, 402], ["AM", "CELL_TYPE", 404, 406], ["lymphocytes", "CELL_TYPE", 412, 423], ["CD8+ T cells", "CELL_TYPE", 444, 456], ["CD4", "PROTEIN", 496, 499], ["T cells", "CELL_TYPE", 501, 508], ["CD4", "PROTEIN", 547, 550], ["CD8", "PROTEIN", 551, 554], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 331, 339], ["high HRCT score", "PROBLEM", 14, 29], ["fever", "PROBLEM", 65, 70], ["higher serum SARS", "PROBLEM", 75, 92], ["CoV antibody titer", "TEST", 93, 111], ["low HRCT score", "PROBLEM", 152, 166], ["Inflammatory profiles of BAL fluidAt", "PROBLEM", 179, 215], ["a significant increase", "PROBLEM", 264, 286], ["total cell counts", "TEST", 290, 307], ["BAL fluid", "TEST", 311, 320], ["a significant increase in alveolar macrophages", "PROBLEM", 356, 402], ["lymphocytes", "PROBLEM", 412, 423], ["T cells", "PROBLEM", 449, 456], ["T cells", "PROBLEM", 501, 508], ["a significant decrease in CD4/CD8 ratio", "PROBLEM", 521, 560], ["BAL", "ANATOMY", 204, 207], ["significant", "OBSERVATION_MODIFIER", 266, 277], ["increase", "OBSERVATION_MODIFIER", 278, 286], ["total cell counts", "OBSERVATION", 290, 307], ["BAL fluid", "OBSERVATION", 311, 320], ["significant", "OBSERVATION_MODIFIER", 358, 369], ["increase", "OBSERVATION_MODIFIER", 370, 378], ["alveolar macrophages", "OBSERVATION", 382, 402], ["lymphocytes", "ANATOMY", 412, 423], ["greater extent", "OBSERVATION_MODIFIER", 476, 490], ["significant", "OBSERVATION_MODIFIER", 523, 534], ["decrease", "OBSERVATION_MODIFIER", 535, 543]]], ["There was also a significant increase in the proportion of NK cells in SARS patients (Table 4 ).", [["NK cells", "ANATOMY", 59, 67], ["SARS", "DISEASE", 71, 75], ["NK cells", "CELL", 59, 67], ["patients", "ORGANISM", 76, 84], ["NK cells", "CELL_TYPE", 59, 67], ["patients", "SPECIES", 76, 84], ["a significant increase", "PROBLEM", 15, 37], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["NK cells", "OBSERVATION", 59, 67]]], ["There was no significant difference in B lym- phocytes between SARS patients with low or high HRCT scores and normal subjects.", [["SARS", "DISEASE", 63, 67], ["B lym- phocytes", "CANCER", 39, 54], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["significant difference in B lym- phocytes", "PROBLEM", 13, 54], ["SARS", "PROBLEM", 63, 67], ["low or high HRCT scores", "PROBLEM", 82, 105], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["lym", "ANATOMY", 41, 44], ["normal", "OBSERVATION", 110, 116]]], ["HRCT scores were highly correlated with the cell counts of total lymphocyte, CD4+ and CD8+ T cells, and inversely related to the CD4/CD8 ratio (Figure 2 ).", [["cell", "ANATOMY", 44, 48], ["lymphocyte", "ANATOMY", 65, 75], ["CD4+", "ANATOMY", 77, 81], ["T cells", "ANATOMY", 91, 98], ["cell", "CELL", 44, 48], ["lymphocyte", "CELL", 65, 75], ["CD4", "GENE_OR_GENE_PRODUCT", 77, 80], ["CD8", "GENE_OR_GENE_PRODUCT", 86, 89], ["T cells", "CELL", 91, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 129, 132], ["CD8", "GENE_OR_GENE_PRODUCT", 133, 136], ["CD4", "PROTEIN", 77, 80], ["CD8", "PROTEIN", 86, 89], ["T cells", "CELL_TYPE", 91, 98], ["CD4", "PROTEIN", 129, 132], ["CD8", "PROTEIN", 133, 136], ["HRCT scores", "TEST", 0, 11], ["the cell counts", "TEST", 40, 55], ["total lymphocyte", "TEST", 59, 75], ["CD4", "TEST", 77, 80], ["CD8", "TEST", 86, 89], ["T cells", "TEST", 91, 98], ["the CD4", "TEST", 125, 132]]], ["At 90 days, the cellular profiles in BAL fluid of 6 SARS patients were significantly improved compared with those at 60 days, with near normalization (Tables 3, 4) .Cytokine and chemokine level in BAL fluidAt 60 days, SARS patients had a significantly higher level of chemokines, IL-8, MCP-1, and RANTES (Table 5) , and of pro-inflammatory cytokines, TNF-\u03b1 and IL-6.", [["cellular", "ANATOMY", 16, 24], ["BAL fluid", "ANATOMY", 37, 46], ["BAL fluidAt", "ANATOMY", 197, 208], ["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 218, 222], ["cellular", "CELL", 16, 24], ["BAL fluid", "MULTI-TISSUE_STRUCTURE", 37, 46], ["patients", "ORGANISM", 57, 65], ["Cytokine", "GENE_OR_GENE_PRODUCT", 165, 173], ["patients", "ORGANISM", 223, 231], ["IL-8", "GENE_OR_GENE_PRODUCT", 280, 284], ["MCP-1", "GENE_OR_GENE_PRODUCT", 286, 291], ["RANTES", "GENE_OR_GENE_PRODUCT", 297, 303], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 351, 356], ["IL-6", "GENE_OR_GENE_PRODUCT", 361, 365], ["Cytokine", "PROTEIN", 165, 173], ["chemokine", "PROTEIN", 178, 187], ["chemokines", "PROTEIN", 268, 278], ["IL-8", "PROTEIN", 280, 284], ["MCP-1", "PROTEIN", 286, 291], ["RANTES", "PROTEIN", 297, 303], ["pro-inflammatory cytokines", "PROTEIN", 323, 349], ["TNF-\u03b1 and IL-6", "PROTEIN", 351, 365], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 223, 231], ["the cellular profiles", "TEST", 12, 33], ["BAL fluid", "TEST", 37, 46], ["Cytokine", "TREATMENT", 165, 173], ["chemokine level", "TEST", 178, 193], ["BAL fluidAt", "TEST", 197, 208], ["IL", "TEST", 280, 282], ["MCP", "TEST", 286, 289], ["pro-inflammatory cytokines", "TEST", 323, 349], ["TNF", "TEST", 351, 354], ["IL", "TEST", 361, 363], ["BAL fluid", "OBSERVATION", 37, 46], ["significantly", "OBSERVATION_MODIFIER", 71, 84], ["improved", "OBSERVATION_MODIFIER", 85, 93], ["pro-inflammatory cytokines", "ANATOMY", 323, 349]]], ["However, the growth factors, transforming growth factor-\u03b2 (TGF-\u03b2), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), were not increased (Table 5 ).Virus detectionThe 12 enrolled patients had serological evidence of recent infection with the SARS-CoV and in seven, viral RNA was detected in samples taken from nasopharyngeal aspirate or stool.", [["samples", "ANATOMY", 309, 316], ["nasopharyngeal aspirate", "ANATOMY", 328, 351], ["stool", "ANATOMY", 355, 360], ["infection", "DISEASE", 241, 250], ["SARS", "DISEASE", 260, 264], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 29, 57], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 59, 64], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 67, 90], ["EGF", "GENE_OR_GENE_PRODUCT", 92, 95], ["insulin-like growth factor-1", "GENE_OR_GENE_PRODUCT", 98, 126], ["IGF-1", "GENE_OR_GENE_PRODUCT", 128, 133], ["Virus", "ORGANISM", 166, 171], ["patients", "ORGANISM", 197, 205], ["SARS-CoV", "ORGANISM", 260, 268], ["samples", "CANCER", 309, 316], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 328, 351], ["stool", "ORGANISM_SUBSTANCE", 355, 360], ["growth factors", "PROTEIN", 13, 27], ["transforming growth factor-\u03b2", "PROTEIN", 29, 57], ["TGF-\u03b2", "PROTEIN", 59, 64], ["epidermal growth factor", "PROTEIN", 67, 90], ["EGF", "PROTEIN", 92, 95], ["insulin-like growth factor-1", "PROTEIN", 98, 126], ["IGF", "PROTEIN", 128, 131], ["viral RNA", "RNA", 283, 292], ["patients", "SPECIES", 197, 205], ["SARS-CoV", "SPECIES", 260, 268], ["the growth factors", "PROBLEM", 9, 27], ["transforming growth factor", "TEST", 29, 55], ["TGF", "TEST", 59, 62], ["epidermal growth factor", "TEST", 67, 90], ["EGF", "TEST", 92, 95], ["insulin", "TEST", 98, 105], ["growth factor", "TEST", 111, 124], ["IGF", "TEST", 128, 131], ["Virus detection", "TEST", 166, 181], ["recent infection", "PROBLEM", 234, 250], ["the SARS-CoV", "PROBLEM", 256, 268], ["viral RNA", "PROBLEM", 283, 292], ["nasopharyngeal aspirate", "TEST", 328, 351], ["infection", "OBSERVATION", 241, 250], ["viral RNA", "OBSERVATION", 283, 292], ["nasopharyngeal", "ANATOMY", 328, 342], ["aspirate", "OBSERVATION", 343, 351], ["stool", "OBSERVATION", 355, 360]]], ["However, viral RNA was not detectable in the stool or nasopharyngeal aspirate of any of the SARS patients at 60 days.", [["stool", "ANATOMY", 45, 50], ["nasopharyngeal aspirate", "ANATOMY", 54, 77], ["SARS", "DISEASE", 92, 96], ["stool", "ORGANISM_SUBSTANCE", 45, 50], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 54, 77], ["patients", "ORGANISM", 97, 105], ["viral RNA", "RNA", 9, 18], ["patients", "SPECIES", 97, 105], ["viral RNA", "TEST", 9, 18], ["nasopharyngeal aspirate", "TEST", 54, 77], ["viral RNA", "OBSERVATION", 9, 18], ["stool", "OBSERVATION", 45, 50], ["nasopharyngeal", "ANATOMY", 54, 68], ["aspirate", "OBSERVATION", 69, 77]]], ["Healthy controls had no evidence of SARS-CoV antibody or RNA in the serum or the respiratory tract.", [["serum", "ANATOMY", 68, 73], ["respiratory tract", "ANATOMY", 81, 98], ["SARS", "DISEASE", 36, 40], ["SARS-CoV antibody", "GENE_OR_GENE_PRODUCT", 36, 53], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["respiratory tract", "ORGANISM_SUBDIVISION", 81, 98], ["SARS-CoV antibody", "PROTEIN", 36, 53], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["CoV antibody", "TEST", 41, 53], ["RNA in the serum or the respiratory tract", "PROBLEM", 57, 98], ["no evidence of", "UNCERTAINTY", 21, 35], ["SARS", "OBSERVATION", 36, 40], ["respiratory tract", "ANATOMY", 81, 98]]], ["There were no detectable common viruses including influenza viruses A and B, RSV virus, adenovirus, human metapneumovirus, and parainfluenzavirus types 1, 2, and 3, using IFA for nasopharyngeal aspirates or using RT-PCR assay for cells retrieved by BAL at 60 or 90 days.", [["nasopharyngeal aspirates", "ANATOMY", 179, 203], ["cells", "ANATOMY", 230, 235], ["influenza viruses", "DISEASE", 50, 67], ["human metapneumovirus", "DISEASE", 100, 121], ["influenza viruses A", "ORGANISM", 50, 69], ["B", "GENE_OR_GENE_PRODUCT", 74, 75], ["RSV virus", "ORGANISM", 77, 86], ["adenovirus", "ORGANISM", 88, 98], ["human", "ORGANISM", 100, 105], ["metapneumovirus", "ORGANISM", 106, 121], ["3", "GENE_OR_GENE_PRODUCT", 162, 163], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 179, 203], ["cells", "CELL", 230, 235], ["RSV virus", "SPECIES", 77, 86], ["human", "SPECIES", 100, 105], ["metapneumovirus", "SPECIES", 106, 121], ["RSV virus", "SPECIES", 77, 86], ["adenovirus", "SPECIES", 88, 98], ["human metapneumovirus", "SPECIES", 100, 121], ["detectable common viruses", "PROBLEM", 14, 39], ["influenza viruses A and B, RSV virus", "PROBLEM", 50, 86], ["adenovirus", "PROBLEM", 88, 98], ["human metapneumovirus", "PROBLEM", 100, 121], ["parainfluenzavirus types", "TEST", 127, 151], ["IFA", "TEST", 171, 174], ["nasopharyngeal aspirates", "PROBLEM", 179, 203], ["RT-PCR assay", "TEST", 213, 225], ["cells", "PROBLEM", 230, 235], ["BAL", "TEST", 249, 252], ["no detectable", "UNCERTAINTY", 11, 24], ["common", "OBSERVATION_MODIFIER", 25, 31], ["viruses", "OBSERVATION", 32, 39], ["influenza viruses", "OBSERVATION", 50, 67], ["metapneumovirus", "OBSERVATION", 106, 121], ["nasopharyngeal", "ANATOMY", 179, 193], ["aspirates", "OBSERVATION", 194, 203]]], ["Serological studies for Clamydia, Mycoplasma or Legionella were negative in all subjects.Virus detectionAt 60 days, EM examination of BAL fluid revealed many coronavirus-infected alveolar macrophages with intracellular viral particles in 7 of 12 patients ( Figure 3 ; Table 1 ).", [["BAL fluid", "ANATOMY", 134, 143], ["alveolar macrophages", "ANATOMY", 179, 199], ["intracellular", "ANATOMY", 205, 218], ["Mycoplasma", "ORGANISM", 34, 44], ["Legionella", "ORGANISM_SUBSTANCE", 48, 58], ["Virus", "ORGANISM", 89, 94], ["coronavirus", "ORGANISM", 158, 169], ["alveolar macrophages", "CELL", 179, 199], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 205, 218], ["patients", "ORGANISM", 246, 254], ["coronavirus-infected alveolar macrophages", "CELL_TYPE", 158, 199], ["patients", "SPECIES", 246, 254], ["Serological studies", "TEST", 0, 19], ["Clamydia", "TEST", 24, 32], ["Mycoplasma", "PROBLEM", 34, 44], ["Legionella", "PROBLEM", 48, 58], ["EM examination of BAL fluid", "TEST", 116, 143], ["many coronavirus", "PROBLEM", 153, 169], ["infected alveolar macrophages", "PROBLEM", 170, 199], ["intracellular viral particles", "PROBLEM", 205, 234], ["BAL", "ANATOMY", 134, 137], ["coronavirus", "OBSERVATION", 158, 169], ["infected", "OBSERVATION_MODIFIER", 170, 178], ["alveolar macrophages", "OBSERVATION", 179, 199], ["viral particles", "OBSERVATION", 219, 234]]], ["These patients had the high HRCT scan scores.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["the high HRCT scan scores", "PROBLEM", 19, 44]]], ["Coronavirus infected cells were not detected in any of SARS patients with low HRCT score or in normal subjects (Table 1) .", [["cells", "ANATOMY", 21, 26], ["SARS", "DISEASE", 55, 59], ["cells", "CELL", 21, 26], ["patients", "ORGANISM", 60, 68], ["Coronavirus infected cells", "CELL_TYPE", 0, 26], ["patients", "SPECIES", 60, 68], ["Coronavirus infected cells", "PROBLEM", 0, 26], ["low HRCT score", "PROBLEM", 74, 88], ["infected cells", "OBSERVATION", 12, 26]]], ["RT-PCR amplification of coronavirus nucleic acids was positive in 3 of 7 patients with high HRCT score, but in none of patients with low HRCT score or normal subjects.", [["nucleic acids", "CHEMICAL", 36, 49], ["coronavirus", "ORGANISM", 24, 35], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 119, 127], ["RT-PCR amplification", "TEST", 0, 20], ["coronavirus nucleic acids", "TEST", 24, 49], ["high HRCT score", "PROBLEM", 87, 102], ["low HRCT score", "PROBLEM", 133, 147], ["normal", "OBSERVATION", 151, 157]]], ["At 90 days, EM examination did not detect any coronavirusinfected cells in 6 SARS patients, in 5 of the 6, viral inclusions were found in AM at day 60 (Table 1) .", [["coronavirusinfected cells", "ANATOMY", 46, 71], ["SARS", "DISEASE", 77, 81], ["cells", "CELL", 66, 71], ["patients", "ORGANISM", 82, 90], ["coronavirusinfected cells", "CELL_TYPE", 46, 71], ["patients", "SPECIES", 82, 90], ["EM examination", "TEST", 12, 26], ["any coronavirusinfected cells", "PROBLEM", 42, 71], ["viral inclusions", "PROBLEM", 107, 123]]], ["One patient with persistent high HRCT score (case 12) refused follow-up BAL study at 90 days.DiscussionThis study was performed during the last epidemic of SARS in Taiwan, and the number of patients recruited has been limited.", [["SARS", "DISEASE", 156, 160], ["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 190, 198], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 190, 198], ["persistent high HRCT score", "PROBLEM", 17, 43], ["follow-up BAL study", "TEST", 62, 81], ["This study", "TEST", 103, 113], ["SARS", "PROBLEM", 156, 160], ["persistent", "OBSERVATION_MODIFIER", 17, 27], ["high", "OBSERVATION_MODIFIER", 28, 32]]], ["The epidemic did not recur during 2004, and there have been no further cases of SARS in Taiwan, such that we were not able to increase the number of patients in this study.", [["SARS", "DISEASE", 80, 84], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["SARS", "PROBLEM", 80, 84], ["this study", "TEST", 161, 171], ["no", "UNCERTAINTY", 60, 62]]], ["Despite the relatively low numbers, our observations indicate that there are persistent important inflammatory and radiological abnormalities in some patients who have recovered from acute SARS at 60 Residual abnormality on HRCT of a SARS patient with high HRCT score at 60 days (A) Figure 1 Residual abnormality on HRCT of a SARS patient with high HRCT score at 60 days (A).", [["SARS", "DISEASE", 189, 193], ["SARS", "DISEASE", 234, 238], ["SARS", "DISEASE", 326, 330], ["patients", "ORGANISM", 150, 158], ["patient", "ORGANISM", 239, 246], ["patient", "ORGANISM", 331, 338], ["patients", "SPECIES", 150, 158], ["patient", "SPECIES", 239, 246], ["patient", "SPECIES", 331, 338], ["persistent important inflammatory and radiological abnormalities", "PROBLEM", 77, 141], ["acute SARS", "PROBLEM", 183, 193], ["Residual abnormality", "PROBLEM", 200, 220], ["HRCT", "TEST", 224, 228], ["a SARS", "PROBLEM", 232, 238], ["high HRCT score", "PROBLEM", 252, 267], ["Residual abnormality", "PROBLEM", 292, 312], ["HRCT", "TEST", 316, 320], ["a SARS", "PROBLEM", 324, 330], ["high HRCT score", "PROBLEM", 344, 359], ["persistent", "OBSERVATION_MODIFIER", 77, 87], ["important", "OBSERVATION_MODIFIER", 88, 97], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["acute", "OBSERVATION_MODIFIER", 183, 188], ["SARS", "OBSERVATION", 189, 193]]], ["HRCT became almost normal at 90 days (B).Discussiondays after the illness.", [["HRCT", "TEST", 0, 4], ["the illness", "PROBLEM", 62, 73], ["almost", "OBSERVATION_MODIFIER", 12, 18], ["normal", "OBSERVATION", 19, 25]]], ["These changes were those of groundglass or/and consolidation abnormalities which may be overlooked on examination of plain chest radiographs.", [["chest", "ANATOMY", 123, 128], ["chest", "ORGANISM_SUBDIVISION", 123, 128], ["groundglass", "PROBLEM", 28, 39], ["consolidation abnormalities", "PROBLEM", 47, 74], ["examination", "TEST", 102, 113], ["plain chest radiographs", "TEST", 117, 140], ["consolidation", "OBSERVATION", 47, 60], ["may be", "UNCERTAINTY", 81, 87]]], ["The BAL fluid examination performed for the first time in recovering SARS patients confirmed the presence of an ongoing active inflammatory process in most patients with increased macrophages, NK cells and T cells, and augmented levels of chemokines and pro-inflammatory cytokines.", [["BAL fluid", "ANATOMY", 4, 13], ["macrophages", "ANATOMY", 180, 191], ["NK cells", "ANATOMY", 193, 201], ["T cells", "ANATOMY", 206, 213], ["SARS", "DISEASE", 69, 73], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 156, 164], ["macrophages", "CELL", 180, 191], ["NK cells", "CELL", 193, 201], ["T cells", "CELL", 206, 213], ["macrophages", "CELL_TYPE", 180, 191], ["NK cells", "CELL_TYPE", 193, 201], ["T cells", "CELL_TYPE", 206, 213], ["chemokines", "PROTEIN", 239, 249], ["pro-inflammatory cytokines", "PROTEIN", 254, 280], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 156, 164], ["The BAL fluid examination", "TEST", 0, 25], ["an ongoing active inflammatory process", "PROBLEM", 109, 147], ["increased macrophages", "PROBLEM", 170, 191], ["NK cells", "PROBLEM", 193, 201], ["T cells", "TEST", 206, 213], ["augmented levels of chemokines", "PROBLEM", 219, 249], ["pro-inflammatory cytokines", "PROBLEM", 254, 280], ["active", "OBSERVATION_MODIFIER", 120, 126], ["inflammatory", "OBSERVATION", 127, 139], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["macrophages", "OBSERVATION", 180, 191], ["NK cells", "OBSERVATION", 193, 201], ["pro-inflammatory cytokines", "OBSERVATION", 254, 280]]], ["These inflammatory responses may be elicited by the persistent presence of coronavirus in alveolar macrophages, since the patients with the highest HRCT changes had coronaviruses present and there was no evidence of bacterial or other viral infection in these patients.DiscussionMost viral diseases are characterized by the development of a specific infiltration consisting predominantly of Correlation of the cell counts of (A) total lymphocytes, (B) CD4 and (C) CD8 T cells, or the (D) CD4/CD8 ratio with HRCT scores in SARS patients mononuclear leukocytes while neutrophils are absent [19] .", [["alveolar macrophages", "ANATOMY", 90, 110], ["cell", "ANATOMY", 410, 414], ["lymphocytes", "ANATOMY", 435, 446], ["B) CD4 and (C) CD8 T cells", "ANATOMY", 449, 475], ["mononuclear leukocytes", "ANATOMY", 536, 558], ["neutrophils", "ANATOMY", 565, 576], ["viral infection", "DISEASE", 235, 250], ["viral diseases", "DISEASE", 284, 298], ["SARS", "DISEASE", 522, 526], ["coronavirus", "ORGANISM", 75, 86], ["alveolar macrophages", "CELL", 90, 110], ["patients", "ORGANISM", 122, 130], ["coronaviruses", "ORGANISM", 165, 178], ["patients", "ORGANISM", 260, 268], ["cell", "CELL", 410, 414], ["lymphocytes", "CELL", 435, 446], ["(B) CD4", "GENE_OR_GENE_PRODUCT", 448, 455], ["CD4", "GENE_OR_GENE_PRODUCT", 488, 491], ["CD8", "GENE_OR_GENE_PRODUCT", 492, 495], ["patients", "ORGANISM", 527, 535], ["mononuclear leukocytes", "CELL", 536, 558], ["neutrophils", "CELL", 565, 576], ["alveolar macrophages", "CELL_TYPE", 90, 110], ["lymphocytes", "CELL_TYPE", 435, 446], ["B) CD4 and (C) CD8 T cells", "CELL_TYPE", 449, 475], ["CD4", "PROTEIN", 488, 491], ["CD8", "PROTEIN", 492, 495], ["mononuclear leukocytes", "CELL_TYPE", 536, 558], ["neutrophils", "CELL_TYPE", 565, 576], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 260, 268], ["patients", "SPECIES", 527, 535], ["coronavirus in alveolar macrophages", "PROBLEM", 75, 110], ["the highest HRCT changes", "PROBLEM", 136, 160], ["coronaviruses", "PROBLEM", 165, 178], ["bacterial or other viral infection", "PROBLEM", 216, 250], ["Most viral diseases", "PROBLEM", 279, 298], ["a specific infiltration", "PROBLEM", 339, 362], ["the cell counts", "TEST", 406, 421], ["total lymphocytes", "TEST", 429, 446], ["CD4", "TEST", 452, 455], ["CD8 T cells", "TEST", 464, 475], ["the (D) CD4/CD8 ratio", "TEST", 480, 501], ["HRCT scores", "TEST", 507, 518], ["SARS", "PROBLEM", 522, 526], ["mononuclear leukocytes", "TEST", 536, 558], ["neutrophils", "TEST", 565, 576], ["inflammatory", "OBSERVATION", 6, 18], ["persistent", "OBSERVATION_MODIFIER", 52, 62], ["coronavirus", "OBSERVATION", 75, 86], ["alveolar macrophages", "OBSERVATION", 90, 110], ["no evidence of", "UNCERTAINTY", 201, 215], ["bacterial", "OBSERVATION_MODIFIER", 216, 225], ["viral", "OBSERVATION_MODIFIER", 235, 240], ["infection", "OBSERVATION", 241, 250], ["viral diseases", "OBSERVATION", 284, 298], ["specific", "OBSERVATION_MODIFIER", 341, 349], ["infiltration", "OBSERVATION", 350, 362], ["cell counts", "OBSERVATION", 410, 421], ["mononuclear leukocytes", "OBSERVATION", 536, 558]]], ["The most striking features of alveolar inflammation in patients were increased numbers of alveolar macrophages, T lymphocytes and NK cells, with a striking decrease in CD4/CD8 ratio.", [["alveolar", "ANATOMY", 30, 38], ["alveolar macrophages", "ANATOMY", 90, 110], ["T lymphocytes", "ANATOMY", 112, 125], ["NK cells", "ANATOMY", 130, 138], ["alveolar inflammation", "DISEASE", 30, 51], ["alveolar", "MULTI-TISSUE_STRUCTURE", 30, 38], ["patients", "ORGANISM", 55, 63], ["alveolar macrophages", "CELL", 90, 110], ["T lymphocytes", "CELL", 112, 125], ["NK cells", "CELL", 130, 138], ["CD4", "GENE_OR_GENE_PRODUCT", 168, 171], ["CD8", "GENE_OR_GENE_PRODUCT", 172, 175], ["alveolar macrophages", "CELL_TYPE", 90, 110], ["T lymphocytes", "CELL_TYPE", 112, 125], ["NK cells", "CELL_TYPE", 130, 138], ["CD4", "PROTEIN", 168, 171], ["CD8", "PROTEIN", 172, 175], ["patients", "SPECIES", 55, 63], ["alveolar inflammation", "PROBLEM", 30, 51], ["alveolar macrophages", "PROBLEM", 90, 110], ["T lymphocytes and NK cells", "PROBLEM", 112, 138], ["a striking decrease in CD4/CD8 ratio", "PROBLEM", 145, 181], ["most striking", "OBSERVATION_MODIFIER", 4, 17], ["alveolar", "ANATOMY_MODIFIER", 30, 38], ["inflammation", "OBSERVATION", 39, 51], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["numbers", "OBSERVATION_MODIFIER", 79, 86], ["alveolar macrophages", "OBSERVATION", 90, 110], ["lymphocytes", "OBSERVATION", 114, 125], ["NK cells", "OBSERVATION", 130, 138], ["striking", "OBSERVATION_MODIFIER", 147, 155], ["decrease", "OBSERVATION_MODIFIER", 156, 164], ["CD8 ratio", "OBSERVATION", 172, 181]]], ["The HRCT score was highly correlated with T lymphocyte numbers and their subpopulations, and was inversely related to CD4/CD8 ratio.", [["T lymphocyte", "ANATOMY", 42, 54], ["T lymphocyte", "CELL", 42, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD8", "GENE_OR_GENE_PRODUCT", 122, 125], ["CD4", "PROTEIN", 118, 121], ["CD8", "PROTEIN", 122, 125], ["The HRCT score", "TEST", 0, 14], ["T lymphocyte numbers", "TEST", 42, 62], ["CD4/CD8 ratio", "TEST", 118, 131], ["subpopulations", "OBSERVATION_MODIFIER", 73, 87]]], ["CD8+ T cells may act as cytotoxic cells and are key effectors of virus clearance [20] .", [["CD8+ T cells", "ANATOMY", 0, 12], ["cells", "ANATOMY", 34, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytotoxic cells", "CELL", 24, 39], ["CD8", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["cytotoxic cells", "CELL_TYPE", 24, 39], ["CD8", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["cytotoxic cells", "PROBLEM", 24, 39], ["virus clearance", "PROBLEM", 65, 80]]], ["The concurrent increase in CD4+ T cells may promote the clonal expansion of virusspecific CD8+ T cells and is essential for maintaining continued CD8+ T cells surveillance and effector capacity [19] .DiscussionExposure of monocytes or macrophages to viruses causes the release of proinflammatory cytokines, such as TNF-\u03b1, IL-1, and IL-6, and chemokines [20] [21] [22] as well as members of the CC-chemokine subfamily such as MIP-l\u03b1, MCP-1, and RANTES which preferentially attract monocytes and lymphocytes [22] .", [["CD4+ T cells", "ANATOMY", 27, 39], ["virusspecific CD8+ T cells", "ANATOMY", 76, 102], ["CD8+ T cells", "ANATOMY", 146, 158], ["monocytes", "ANATOMY", 222, 231], ["macrophages", "ANATOMY", 235, 246], ["monocytes", "ANATOMY", 480, 489], ["lymphocytes", "ANATOMY", 494, 505], ["CD4", "GENE_OR_GENE_PRODUCT", 27, 30], ["CD8", "GENE_OR_GENE_PRODUCT", 90, 93], ["CD8", "GENE_OR_GENE_PRODUCT", 146, 149], ["monocytes", "CELL", 222, 231], ["macrophages", "CELL", 235, 246], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 315, 320], ["IL-1", "GENE_OR_GENE_PRODUCT", 322, 326], ["IL-6", "GENE_OR_GENE_PRODUCT", 332, 336], ["chemokines [20] [21] [22]", "SIMPLE_CHEMICAL", 342, 367], ["MIP-l\u03b1", "GENE_OR_GENE_PRODUCT", 425, 431], ["MCP-1", "GENE_OR_GENE_PRODUCT", 433, 438], ["RANTES", "GENE_OR_GENE_PRODUCT", 444, 450], ["monocytes", "CELL", 480, 489], ["lymphocytes", "CELL", 494, 505], ["CD4", "PROTEIN", 27, 30], ["T cells", "CELL_TYPE", 32, 39], ["virusspecific CD8+ T cells", "CELL_TYPE", 76, 102], ["CD8+ T cells", "CELL_TYPE", 146, 158], ["monocytes", "CELL_TYPE", 222, 231], ["macrophages", "CELL_TYPE", 235, 246], ["proinflammatory cytokines", "PROTEIN", 280, 305], ["TNF", "PROTEIN", 315, 318], ["IL-6", "PROTEIN", 332, 336], ["chemokines", "PROTEIN", 342, 352], ["CC-chemokine subfamily", "PROTEIN", 394, 416], ["MIP", "PROTEIN", 425, 428], ["l\u03b1", "PROTEIN", 429, 431], ["MCP-1", "PROTEIN", 433, 438], ["RANTES", "PROTEIN", 444, 450], ["monocytes", "CELL_TYPE", 480, 489], ["lymphocytes", "CELL_TYPE", 494, 505], ["CD4+ T cells", "PROBLEM", 27, 39], ["T cells", "PROBLEM", 95, 102], ["monocytes", "PROBLEM", 222, 231], ["macrophages", "PROBLEM", 235, 246], ["viruses", "PROBLEM", 250, 257], ["proinflammatory cytokines", "TEST", 280, 305], ["TNF", "TEST", 315, 318], ["IL", "TEST", 322, 324], ["the CC", "TEST", 390, 396], ["chemokine subfamily", "TEST", 397, 416], ["MIP", "TEST", 425, 428], ["MCP", "TEST", 433, 436], ["RANTES", "TEST", 444, 450], ["monocytes", "TEST", 480, 489], ["lymphocytes", "TEST", 494, 505], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["monocytes", "OBSERVATION", 222, 231], ["macrophages", "OBSERVATION", 235, 246]]], ["The CXC-chemokines, such as IL-8 or GRO-\u03b1, are major neutrophil chemoattractants [23] .", [["neutrophil", "ANATOMY", 53, 63], ["CXC", "GENE_OR_GENE_PRODUCT", 4, 7], ["IL-8", "GENE_OR_GENE_PRODUCT", 28, 32], ["GRO-\u03b1", "GENE_OR_GENE_PRODUCT", 36, 41], ["neutrophil", "CELL", 53, 63], ["CXC", "PROTEIN", 4, 7], ["chemokines", "PROTEIN", 8, 18], ["IL-8", "PROTEIN", 28, 32], ["GRO", "PROTEIN", 36, 39], ["\u03b1", "PROTEIN", 40, 41], ["neutrophil chemoattractants", "PROTEIN", 53, 80], ["The CXC", "TEST", 0, 7], ["chemokines", "TEST", 8, 18], ["IL", "TEST", 28, 30], ["GRO-\u03b1", "TEST", 36, 41], ["major neutrophil chemoattractants", "PROBLEM", 47, 80], ["neutrophil chemoattractants", "OBSERVATION", 53, 80]]], ["MIG/CXC chemokine ligand (CXCL) 9 and IP-10/ CXCL10, both inducible by interferon-\u03b3, are ELR-negative CXC chemokines and are potent chemoattractants for mononuclear cells, specifically activated T lymphocytes and NK cells [24] .", [["mononuclear cells", "ANATOMY", 153, 170], ["T lymphocytes", "ANATOMY", 195, 208], ["NK cells", "ANATOMY", 213, 221], ["MIG", "GENE_OR_GENE_PRODUCT", 0, 3], ["CXC chemokine ligand (CXCL) 9", "GENE_OR_GENE_PRODUCT", 4, 33], ["IP-10", "GENE_OR_GENE_PRODUCT", 38, 43], ["CXCL10", "GENE_OR_GENE_PRODUCT", 45, 51], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 71, 83], ["ELR", "GENE_OR_GENE_PRODUCT", 89, 92], ["CXC", "GENE_OR_GENE_PRODUCT", 102, 105], ["mononuclear cells", "CELL", 153, 170], ["T lymphocytes", "CELL", 195, 208], ["NK cells", "CELL", 213, 221], ["MIG", "PROTEIN", 0, 3], ["CXC chemokine ligand (CXCL) 9", "PROTEIN", 4, 33], ["IP-10", "PROTEIN", 38, 43], ["CXCL10", "PROTEIN", 45, 51], ["interferon-\u03b3", "PROTEIN", 71, 83], ["ELR", "PROTEIN", 89, 92], ["CXC chemokines", "PROTEIN", 102, 116], ["mononuclear cells", "CELL_TYPE", 153, 170], ["activated T lymphocytes", "CELL_TYPE", 185, 208], ["NK cells", "CELL_TYPE", 213, 221], ["MIG/CXC chemokine ligand", "TEST", 0, 24], ["CXCL", "TEST", 26, 30], ["IP", "TEST", 38, 40], ["CXCL10", "TEST", 45, 51], ["interferon", "TEST", 71, 81], ["ELR", "TEST", 89, 92], ["CXC chemokines", "TEST", 102, 116], ["mononuclear cells", "PROBLEM", 153, 170], ["activated T lymphocytes", "PROBLEM", 185, 208], ["NK cells", "TEST", 213, 221]]], ["In this report, we demonstrated elevated levels of TNF-\u03b1, IL-6, MCP-1, RANTES and IL-8 in BAL fluid in SARS patients compared to those of normal subjects.", [["BAL fluid", "ANATOMY", 90, 99], ["SARS", "DISEASE", 103, 107], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["MCP-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["RANTES", "GENE_OR_GENE_PRODUCT", 71, 77], ["IL-8", "GENE_OR_GENE_PRODUCT", 82, 86], ["BAL fluid", "ORGANISM_SUBSTANCE", 90, 99], ["patients", "ORGANISM", 108, 116], ["TNF", "PROTEIN", 51, 54], ["IL-6", "PROTEIN", 58, 62], ["MCP", "PROTEIN", 64, 67], ["RANTES", "PROTEIN", 71, 77], ["IL-8", "PROTEIN", 82, 86], ["patients", "SPECIES", 108, 116], ["elevated levels", "PROBLEM", 32, 47], ["TNF", "TEST", 51, 54], ["IL", "TEST", 58, 60], ["MCP", "TEST", 64, 67], ["RANTES", "TEST", 71, 77], ["IL", "TEST", 82, 84], ["BAL fluid", "TEST", 90, 99], ["SARS", "PROBLEM", 103, 107], ["elevated", "OBSERVATION", 32, 40], ["BAL", "ANATOMY", 90, 93], ["fluid", "OBSERVATION", 94, 99]]], ["Increased secretion of TNF-\u03b1 and IL-6 may be derived from virus-infected macrophages or from CD4+ or CD8+ T cells, and these cytokines may promote T-lymphocyte extravasation and macrophage activation [19] , but such processes may not be sufficient on their own to recruit and activate mononuclear cells in virus-infected lungs.", [["macrophages", "ANATOMY", 73, 84], ["CD4+", "ANATOMY", 93, 97], ["CD8+ T cells", "ANATOMY", 101, 113], ["T-lymphocyte", "ANATOMY", 147, 159], ["macrophage", "ANATOMY", 178, 188], ["mononuclear cells", "ANATOMY", 285, 302], ["lungs", "ANATOMY", 321, 326], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 33, 37], ["macrophages", "CELL", 73, 84], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["CD8", "GENE_OR_GENE_PRODUCT", 101, 104], ["T-lymphocyte", "CELL", 147, 159], ["macrophage", "CELL", 178, 188], ["mononuclear cells", "CELL", 285, 302], ["lungs", "ORGAN", 321, 326], ["TNF", "PROTEIN", 23, 26], ["IL-6", "PROTEIN", 33, 37], ["virus-infected macrophages", "CELL_TYPE", 58, 84], ["CD4+ or CD8+ T cells", "CELL_TYPE", 93, 113], ["cytokines", "PROTEIN", 125, 134], ["mononuclear cells", "CELL_TYPE", 285, 302], ["Increased secretion of TNF", "PROBLEM", 0, 26], ["IL", "TREATMENT", 33, 35], ["virus", "PROBLEM", 58, 63], ["infected macrophages", "PROBLEM", 64, 84], ["CD4", "TEST", 93, 96], ["CD8+ T cells", "PROBLEM", 101, 113], ["these cytokines", "TEST", 119, 134], ["T-lymphocyte extravasation", "PROBLEM", 147, 173], ["macrophage activation", "TEST", 178, 199], ["mononuclear cells in virus", "PROBLEM", 285, 311], ["infected lungs", "PROBLEM", 312, 326], ["infected", "OBSERVATION_MODIFIER", 64, 72], ["macrophages", "OBSERVATION", 73, 84], ["lymphocyte extravasation", "OBSERVATION", 149, 173], ["mononuclear cells", "OBSERVATION", 285, 302], ["infected", "OBSERVATION", 312, 320], ["lungs", "ANATOMY", 321, 326]]], ["The increased levels of MCP-1 and RANTES in BAL fluid of all SARS patients may be responsible for the generation of mononuclear infiltrates observed after coronavirus infection.", [["BAL fluid", "ANATOMY", 44, 53], ["mononuclear infiltrates", "ANATOMY", 116, 139], ["SARS", "DISEASE", 61, 65], ["coronavirus infection", "DISEASE", 155, 176], ["MCP-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["RANTES", "GENE_OR_GENE_PRODUCT", 34, 40], ["BAL fluid", "ORGANISM_SUBSTANCE", 44, 53], ["patients", "ORGANISM", 66, 74], ["mononuclear infiltrates", "CELL", 116, 139], ["coronavirus", "ORGANISM", 155, 166], ["MCP-1", "PROTEIN", 24, 29], ["RANTES", "PROTEIN", 34, 40], ["mononuclear infiltrates", "CELL_TYPE", 116, 139], ["patients", "SPECIES", 66, 74], ["MCP", "TEST", 24, 27], ["RANTES in BAL fluid", "TEST", 34, 53], ["mononuclear infiltrates", "PROBLEM", 116, 139], ["coronavirus infection", "PROBLEM", 155, 176], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["mononuclear", "OBSERVATION_MODIFIER", 116, 127], ["infiltrates", "OBSERVATION", 128, 139], ["coronavirus", "OBSERVATION_MODIFIER", 155, 166], ["infection", "OBSERVATION", 167, 176]]], ["IP-10 and MIG, whose levels are also increase in SARS patients, recruit monocytes and macrophages, NK cells and activated, but not resting T lymphocytes [25, 26] .DiscussionAlthough there were increased levels of IL-8 in BAL fluid in SARS patients, the number of neutrophils in BALF were sparse.", [["monocytes", "ANATOMY", 72, 81], ["macrophages", "ANATOMY", 86, 97], ["NK cells", "ANATOMY", 99, 107], ["T lymphocytes", "ANATOMY", 139, 152], ["BAL fluid", "ANATOMY", 221, 230], ["neutrophils", "ANATOMY", 263, 274], ["BALF", "ANATOMY", 278, 282], ["SARS", "DISEASE", 49, 53], ["SARS", "DISEASE", 234, 238], ["IP-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["MIG", "GENE_OR_GENE_PRODUCT", 10, 13], ["patients", "ORGANISM", 54, 62], ["monocytes", "CELL", 72, 81], ["macrophages", "CELL", 86, 97], ["NK cells", "CELL", 99, 107], ["T lymphocytes", "CELL", 139, 152], ["IL-8", "GENE_OR_GENE_PRODUCT", 213, 217], ["BAL fluid", "ORGANISM_SUBSTANCE", 221, 230], ["patients", "ORGANISM", 239, 247], ["neutrophils", "CELL", 263, 274], ["BALF", "CELL", 278, 282], ["MIG", "PROTEIN", 10, 13], ["monocytes", "CELL_TYPE", 72, 81], ["macrophages", "CELL_TYPE", 86, 97], ["NK cells", "CELL_TYPE", 99, 107], ["resting T lymphocytes", "CELL_TYPE", 131, 152], ["IL-8", "PROTEIN", 213, 217], ["neutrophils", "CELL_TYPE", 263, 274], ["BALF", "CELL_TYPE", 278, 282], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 239, 247], ["IP", "TEST", 0, 2], ["whose levels", "TEST", 15, 27], ["SARS", "PROBLEM", 49, 53], ["monocytes", "TEST", 72, 81], ["macrophages", "TEST", 86, 97], ["NK cells", "TEST", 99, 107], ["resting T lymphocytes", "TEST", 131, 152], ["IL", "TEST", 213, 215], ["BAL fluid", "TEST", 221, 230], ["neutrophils in BALF", "TEST", 263, 282], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["macrophages", "ANATOMY", 86, 97], ["NK cells", "OBSERVATION", 99, 107], ["increased", "OBSERVATION_MODIFIER", 193, 202], ["BAL", "ANATOMY", 221, 224], ["fluid", "OBSERVATION", 225, 230], ["neutrophils", "OBSERVATION", 263, 274], ["BALF", "ANATOMY", 278, 282]]], ["The absence of neutrophil infiltration in influenza A virus or respiratory syncytial viruses (RSV) infection is attributed to the suppression of neutrophil attracting CXC-chemokines or by induction of IL-10 [27] .", [["neutrophil", "ANATOMY", 15, 25], ["neutrophil", "ANATOMY", 145, 155], ["influenza A", "DISEASE", 42, 53], ["respiratory syncytial viruses", "DISEASE", 63, 92], ["infection", "DISEASE", 99, 108], ["neutrophil", "CELL", 15, 25], ["influenza A virus", "ORGANISM", 42, 59], ["respiratory syncytial viruses", "ORGANISM", 63, 92], ["RSV", "ORGANISM", 94, 97], ["neutrophil", "CELL", 145, 155], ["CXC", "GENE_OR_GENE_PRODUCT", 167, 170], ["IL-10", "GENE_OR_GENE_PRODUCT", 201, 206], ["neutrophil", "CELL_TYPE", 145, 155], ["CXC", "PROTEIN", 167, 170], ["chemokines", "PROTEIN", 171, 181], ["IL", "PROTEIN", 201, 203], ["influenza A virus", "SPECIES", 42, 59], ["respiratory syncytial viruses", "SPECIES", 63, 92], ["influenza A virus", "SPECIES", 42, 59], ["respiratory syncytial viruses", "SPECIES", 63, 92], ["RSV", "SPECIES", 94, 97], ["neutrophil infiltration", "PROBLEM", 15, 38], ["influenza", "PROBLEM", 42, 51], ["A virus", "PROBLEM", 52, 59], ["respiratory syncytial viruses (RSV) infection", "PROBLEM", 63, 108], ["neutrophil attracting CXC", "TREATMENT", 145, 170], ["IL", "TEST", 201, 203], ["absence of", "UNCERTAINTY", 4, 14], ["neutrophil infiltration", "OBSERVATION", 15, 38], ["respiratory syncytial viruses", "OBSERVATION", 63, 92]]], ["However, IL-8 production can be induced by measles virus infection of fibroblasts [28] and by influenza A virus, RSV and rhinovirus in pulmonary epithelial cells or AM [28] [29] [30] [31] .", [["fibroblasts", "ANATOMY", 70, 81], ["pulmonary epithelial cells", "ANATOMY", 135, 161], ["measles virus infection", "DISEASE", 43, 66], ["IL-8", "GENE_OR_GENE_PRODUCT", 9, 13], ["measles virus", "ORGANISM", 43, 56], ["fibroblasts", "CELL", 70, 81], ["influenza A virus", "ORGANISM", 94, 111], ["RSV", "ORGANISM", 113, 116], ["rhinovirus", "ORGANISM", 121, 131], ["pulmonary epithelial cells", "CELL", 135, 161], ["IL-8", "PROTEIN", 9, 13], ["fibroblasts", "CELL_TYPE", 70, 81], ["pulmonary epithelial cells", "CELL_TYPE", 135, 161], ["influenza A virus", "SPECIES", 94, 111], ["RSV", "SPECIES", 113, 116], ["measles virus", "SPECIES", 43, 56], ["influenza A virus", "SPECIES", 94, 111], ["RSV", "SPECIES", 113, 116], ["IL-8 production", "TREATMENT", 9, 24], ["measles virus infection of fibroblasts", "PROBLEM", 43, 81], ["influenza A virus", "PROBLEM", 94, 111], ["RSV", "PROBLEM", 113, 116], ["rhinovirus", "PROBLEM", 121, 131], ["pulmonary epithelial cells", "TEST", 135, 161], ["pulmonary epithelial", "ANATOMY", 135, 155]]], ["The reasons for the lack of neutrophil recruitment in response to elevated IL-8 levels in SARS patients are not known and this deserves further investigation.DiscussionDespite the presence of virus in AM at 60 days when patients had already been discharged from hospital, these patients were not infectious, because none of their close contact relatives developed any detectable SARS-CoV antibody in their sera.", [["neutrophil", "ANATOMY", 28, 38], ["sera", "ANATOMY", 406, 410], ["SARS", "DISEASE", 90, 94], ["neutrophil", "CELL", 28, 38], ["IL-8", "GENE_OR_GENE_PRODUCT", 75, 79], ["patients", "ORGANISM", 95, 103], ["AM", "CELL", 201, 203], ["patients", "ORGANISM", 220, 228], ["patients", "ORGANISM", 278, 286], ["SARS-CoV antibody", "GENE_OR_GENE_PRODUCT", 379, 396], ["sera", "ORGANISM_SUBSTANCE", 406, 410], ["IL-8", "PROTEIN", 75, 79], ["SARS-CoV antibody", "PROTEIN", 379, 396], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 220, 228], ["patients", "SPECIES", 278, 286], ["SARS-CoV", "SPECIES", 379, 387], ["neutrophil recruitment", "PROBLEM", 28, 50], ["elevated IL", "TEST", 66, 77], ["SARS", "PROBLEM", 90, 94], ["further investigation", "TEST", 136, 157], ["virus", "PROBLEM", 192, 197], ["infectious", "PROBLEM", 296, 306], ["any detectable SARS", "PROBLEM", 364, 383], ["CoV antibody", "TEST", 384, 396], ["neutrophil recruitment", "OBSERVATION", 28, 50], ["virus", "OBSERVATION", 192, 197]]], ["The HRCT and the clinical course until the 90th day of illness did not suggest any evidence of pulmonary fibrosis in SARS patients.", [["pulmonary", "ANATOMY", 95, 104], ["pulmonary fibrosis", "DISEASE", 95, 113], ["SARS", "DISEASE", 117, 121], ["pulmonary", "ORGAN", 95, 104], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["The HRCT", "TEST", 0, 8], ["illness", "PROBLEM", 55, 62], ["pulmonary fibrosis", "PROBLEM", 95, 113], ["not suggest any evidence of", "UNCERTAINTY", 67, 94], ["pulmonary", "ANATOMY", 95, 104], ["fibrosis", "OBSERVATION", 105, 113]]], ["This was in accord with the low level of cytokines and growth factors responsible for tissue repairing and fibrosis [32] , such as IL-1\u03b2, TGF-\u03b2, IGF-1, and EGF detected in BAL fluid.", [["tissue", "ANATOMY", 86, 92], ["BAL fluid", "ANATOMY", 172, 181], ["fibrosis", "DISEASE", 107, 115], ["tissue", "TISSUE", 86, 92], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 131, 136], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 138, 143], ["IGF-1", "GENE_OR_GENE_PRODUCT", 145, 150], ["EGF", "GENE_OR_GENE_PRODUCT", 156, 159], ["BAL fluid", "ORGANISM_SUBSTANCE", 172, 181], ["cytokines", "PROTEIN", 41, 50], ["growth factors", "PROTEIN", 55, 69], ["IL", "PROTEIN", 131, 133], ["TGF-\u03b2", "PROTEIN", 138, 143], ["IGF", "PROTEIN", 145, 148], ["EGF", "PROTEIN", 156, 159], ["growth factors", "PROBLEM", 55, 69], ["tissue repairing", "TREATMENT", 86, 102], ["fibrosis", "PROBLEM", 107, 115], ["IL", "TEST", 131, 133], ["TGF", "TEST", 138, 141], ["IGF", "TEST", 145, 148], ["EGF", "TEST", 156, 159], ["BAL fluid", "TEST", 172, 181], ["fibrosis", "OBSERVATION", 107, 115], ["BAL fluid", "OBSERVATION", 172, 181]]], ["However, evidence of fibrosis on HRCT has been obtained on HRCT scans particularly in patients with very severe disease during the acute phase of SARS [33] .", [["fibrosis", "DISEASE", 21, 29], ["SARS", "DISEASE", 146, 150], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["fibrosis", "PROBLEM", 21, 29], ["HRCT", "TEST", 33, 37], ["HRCT scans", "TEST", 59, 69], ["very severe disease", "PROBLEM", 100, 119], ["evidence of", "UNCERTAINTY", 9, 20], ["fibrosis", "OBSERVATION", 21, 29], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["disease", "OBSERVATION", 112, 119]]], ["Ultrastructural characteristics of a coronavirus-infected cell in BAL fluid from a SARS patient at 60 days, with several intracel-lular particles The use of corticosteroids together with ribavirin has been reported to confer clinical benefit, although randomized clinical trials to support its clinical efficacy are not available.", [["cell", "ANATOMY", 58, 62], ["BAL fluid", "ANATOMY", 66, 75], ["coronavirus-infected", "DISEASE", 37, 57], ["SARS", "DISEASE", 83, 87], ["ribavirin", "CHEMICAL", 187, 196], ["corticosteroids", "CHEMICAL", 157, 172], ["ribavirin", "CHEMICAL", 187, 196], ["coronavirus", "ORGANISM", 37, 48], ["cell", "CELL", 58, 62], ["BAL fluid", "ORGANISM_SUBSTANCE", 66, 75], ["patient", "ORGANISM", 88, 95], ["ribavirin", "SIMPLE_CHEMICAL", 187, 196], ["coronavirus", "SPECIES", 37, 48], ["patient", "SPECIES", 88, 95], ["a coronavirus-infected cell in BAL fluid", "PROBLEM", 35, 75], ["several intracel-lular particles", "PROBLEM", 113, 145], ["corticosteroids", "TREATMENT", 157, 172], ["ribavirin", "TREATMENT", 187, 196], ["randomized clinical trials", "TREATMENT", 252, 278], ["coronavirus", "OBSERVATION_MODIFIER", 37, 48], ["infected", "OBSERVATION_MODIFIER", 49, 57], ["cell", "OBSERVATION", 58, 62], ["BAL fluid", "OBSERVATION", 66, 75]]], ["Pulse steroid therapy was reported to lead to less oxygen requirement, better radiographic outcome, and less likelihood to require rescue pulse steroid therapy than their counterparts [34] .", [["steroid", "CHEMICAL", 6, 13], ["oxygen", "CHEMICAL", 51, 57], ["steroid", "CHEMICAL", 144, 151], ["steroid", "CHEMICAL", 6, 13], ["oxygen", "CHEMICAL", 51, 57], ["steroid", "CHEMICAL", 144, 151], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["steroid", "SIMPLE_CHEMICAL", 144, 151], ["Pulse steroid therapy", "TREATMENT", 0, 21], ["less oxygen requirement", "PROBLEM", 46, 69], ["rescue pulse steroid therapy", "TREATMENT", 131, 159]]], ["However, corticosteroids have been shown to increase mortality of pneumovirusinfected mice by accelerating replication of virus [35] .DiscussionPulse steroid therapy was also reported to be associated with residual abnormality on HRCT in SARS patients after discharge from hospital [10] .", [["corticosteroids", "CHEMICAL", 9, 24], ["steroid", "CHEMICAL", 150, 157], ["SARS", "DISEASE", 238, 242], ["corticosteroids", "CHEMICAL", 9, 24], ["steroid", "CHEMICAL", 150, 157], ["corticosteroids", "SIMPLE_CHEMICAL", 9, 24], ["mice", "ORGANISM", 86, 90], ["DiscussionPulse steroid", "SIMPLE_CHEMICAL", 134, 157], ["patients", "ORGANISM", 243, 251], ["mice", "SPECIES", 86, 90], ["patients", "SPECIES", 243, 251], ["mice", "SPECIES", 86, 90], ["corticosteroids", "TREATMENT", 9, 24], ["accelerating replication of virus", "TREATMENT", 94, 127], ["DiscussionPulse steroid therapy", "TREATMENT", 134, 165], ["residual abnormality", "PROBLEM", 206, 226]]], ["In the current retrospective, non-randomized series, pulse steroid therapy appeared to be associated with delayed resolution of pneumonitis.", [["steroid", "CHEMICAL", 59, 66], ["pneumonitis", "DISEASE", 128, 139], ["steroid", "CHEMICAL", 59, 66], ["non-randomized series", "TEST", 30, 51], ["pulse steroid therapy", "TREATMENT", 53, 74], ["pneumonitis", "PROBLEM", 128, 139], ["pneumonitis", "OBSERVATION", 128, 139]]], ["We have planned a prospective future study on investigating the effect of pulse steroid therapy in case of future outbreaks of SARS.", [["steroid", "CHEMICAL", 80, 87], ["SARS", "DISEASE", 127, 131], ["steroid", "CHEMICAL", 80, 87], ["steroid", "SIMPLE_CHEMICAL", 80, 87], ["a prospective future study", "TEST", 16, 42], ["pulse steroid therapy", "TREATMENT", 74, 95], ["SARS", "PROBLEM", 127, 131]]], ["This is because this issue is extremely important in outcome from SARS.DiscussionIn conclusion, a proportion of recovered SARS patients have delayed resolution of pneumonitis and delayed clearance of coronavirus in the alveolar space at day 60.", [["alveolar space", "ANATOMY", 219, 233], ["SARS", "DISEASE", 66, 70], ["SARS", "DISEASE", 122, 126], ["pneumonitis", "DISEASE", 163, 174], ["coronavirus", "DISEASE", 200, 211], ["patients", "ORGANISM", 127, 135], ["coronavirus", "ORGANISM", 200, 211], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 219, 233], ["patients", "SPECIES", 127, 135], ["pneumonitis", "PROBLEM", 163, 174], ["delayed clearance of coronavirus in the alveolar space", "PROBLEM", 179, 233], ["pneumonitis", "OBSERVATION", 163, 174], ["coronavirus", "OBSERVATION", 200, 211], ["alveolar", "ANATOMY_MODIFIER", 219, 227]]], ["This was associated with persistent inflammatory response characterized by macrophages, T cells particularly CD8+ T cells, and NK cells, and by increase in cytokines and chemokines.", [["macrophages", "ANATOMY", 75, 86], ["T cells", "ANATOMY", 88, 95], ["CD8+ T cells", "ANATOMY", 109, 121], ["NK cells", "ANATOMY", 127, 135], ["macrophages", "CELL", 75, 86], ["T cells", "CELL", 88, 95], ["CD8", "GENE_OR_GENE_PRODUCT", 109, 112], ["NK cells", "CELL", 127, 135], ["macrophages", "CELL_TYPE", 75, 86], ["T cells", "CELL_TYPE", 88, 95], ["CD8+ T cells", "CELL_TYPE", 109, 121], ["NK cells", "CELL_TYPE", 127, 135], ["cytokines", "PROTEIN", 156, 165], ["chemokines", "PROTEIN", 170, 180], ["persistent inflammatory response", "PROBLEM", 25, 57], ["macrophages", "PROBLEM", 75, 86], ["T cells", "PROBLEM", 88, 95], ["CD8+ T cells", "PROBLEM", 109, 121], ["NK cells", "PROBLEM", 127, 135], ["cytokines and chemokines", "TREATMENT", 156, 180], ["associated with", "UNCERTAINTY", 9, 24], ["persistent", "OBSERVATION_MODIFIER", 25, 35], ["inflammatory response", "OBSERVATION", 36, 57], ["macrophages", "OBSERVATION", 75, 86], ["T cells", "OBSERVATION", 114, 121], ["NK cells", "OBSERVATION", 127, 135], ["increase", "OBSERVATION_MODIFIER", 144, 152], ["cytokines", "OBSERVATION", 156, 165]]], ["This host inflammatory response against SARS-CoV infection may contribute to persistent HRCT abnormalities during recovery phase of SARS.", [["SARS-CoV infection", "DISEASE", 40, 58], ["SARS", "DISEASE", 132, 136], ["SARS-CoV", "ORGANISM", 40, 48], ["SARS-CoV", "SPECIES", 40, 48], ["This host inflammatory response", "PROBLEM", 0, 31], ["SARS", "PROBLEM", 40, 44], ["CoV infection", "PROBLEM", 45, 58], ["persistent HRCT abnormalities", "PROBLEM", 77, 106], ["SARS", "PROBLEM", 132, 136], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["CoV", "OBSERVATION_MODIFIER", 45, 48], ["infection", "OBSERVATION", 49, 58], ["persistent", "OBSERVATION_MODIFIER", 77, 87], ["HRCT", "OBSERVATION", 88, 92]]], ["On the other hand, we found no evidence of pulmonary fibrosis in SARS patients during recovery.", [["pulmonary", "ANATOMY", 43, 52], ["pulmonary fibrosis", "DISEASE", 43, 61], ["SARS", "DISEASE", 65, 69], ["pulmonary", "ORGAN", 43, 52], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["pulmonary fibrosis", "PROBLEM", 43, 61], ["no evidence of", "UNCERTAINTY", 28, 42], ["pulmonary", "ANATOMY", 43, 52], ["fibrosis", "OBSERVATION", 53, 61]]], ["At day 90, many of the abnormalities have disappeared.", [["the abnormalities", "PROBLEM", 19, 36], ["abnormalities", "OBSERVATION", 23, 36]]], ["Patients recovering from SARS need to be followed up for at least 3 months after the infection.", [["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 85, 94], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["SARS", "PROBLEM", 25, 29], ["the infection", "PROBLEM", 81, 94], ["infection", "OBSERVATION", 85, 94]]]], "6a8ff224950e96259d7b41df77752756a19862a8": [["IntroductionMedical care in low-income countries (LIC) differs a from western medical standards [1] .", [["IntroductionMedical care", "TREATMENT", 0, 24]]], ["Compared with civilian trauma in LIC, which is mainly caused by road traffic accidents, the injuries in war zones present different patterns with numerous wounds caused by bullets, mines, and bombs [2, 3] .IntroductionIn high-income countries (HIC), the surgical training focuses early on a specialty.", [["wounds", "ANATOMY", 155, 161], ["trauma", "DISEASE", 23, 29], ["traffic accidents", "DISEASE", 69, 86], ["injuries", "DISEASE", 92, 100], ["wounds", "DISEASE", 155, 161], ["wounds", "PATHOLOGICAL_FORMATION", 155, 161], ["the injuries in war zones", "PROBLEM", 88, 113], ["numerous wounds", "PROBLEM", 146, 161], ["the surgical training", "TREATMENT", 250, 271], ["mainly caused", "UNCERTAINTY", 47, 60], ["numerous", "OBSERVATION_MODIFIER", 146, 154], ["wounds", "OBSERVATION", 155, 161], ["bullets", "OBSERVATION", 172, 179]]], ["This leads to high knowledge in a very narrow surgical field but a lack of broad general surgical experience [4] [5] [6] .IntroductionThe lack of surgical experience might not be relevant as long as a hospital provides a specialist for every probable pathology, but in cases of a sudden high volume of causalities like in a terror attack or train accident, adequate treatment of the injured could get difficult [7, 8] .", [["causalities", "DISEASE", 302, 313], ["[4] [5] [6]", "SIMPLE_CHEMICAL", 109, 120], ["a very narrow surgical field", "PROBLEM", 32, 60], ["a sudden high volume of causalities", "PROBLEM", 278, 313], ["high", "OBSERVATION_MODIFIER", 14, 18]]], ["In this setting, a specialist for every injured region in one patient would deplete human resources.IntroductionBesides fast surgery in mass casualties, patients' flow needs to be efficient, both in speed and direction.", [["patient", "ORGANISM", 62, 69], ["human", "ORGANISM", 84, 89], ["patients", "ORGANISM", 153, 161], ["patient", "SPECIES", 62, 69], ["human", "SPECIES", 84, 89], ["patients", "SPECIES", 153, 161], ["human", "SPECIES", 84, 89], ["fast surgery", "TREATMENT", 120, 132]]], ["The in-hospital pathways must be clear for the personnel from the moment the patient enters the hospital to the final destination [9] .IntroductionAs much as medical standards in LIC and war zones lag behind, there might be a potential knowledge of primary injury treatment and basic surgical techniques, expectable injury patterns, and experience in dealing with mass causalities by fast decision-making.", [["primary injury", "DISEASE", 249, 263], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["primary injury treatment", "TREATMENT", 249, 273], ["basic surgical techniques", "TREATMENT", 278, 303], ["expectable injury patterns", "PROBLEM", 305, 331], ["mass causalities", "PROBLEM", 364, 380]]], ["A hospital in a war region has limited resources and needs to cope with a high constant and sudden patient inflow.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["a high constant and sudden patient inflow", "TREATMENT", 72, 113]]], ["The surgeons in these hospitals would have an incomparable amount of experience in treating war injuries.", [["injuries", "DISEASE", 96, 104], ["war injuries", "PROBLEM", 92, 104]]], ["The question is, if this knowledge can be helpful when an unexpected incident like a terror attack happens in a \"developed HIC\" country.IntroductionThe aim of the study was to identify possible solution strategies from a non-governmental (NGO) hospital in a war region, in Lashkar Gah, Afghanistan.", [["a terror attack", "PROBLEM", 83, 98], ["the study", "TEST", 159, 168], ["solution strategies", "TREATMENT", 194, 213]]], ["For this purpose, we analyzed the hospital resources, its management strategies, and the epidemiology of war injuries and their treatments.", [["injuries", "DISEASE", 109, 117], ["its management strategies", "TREATMENT", 54, 79], ["war injuries", "PROBLEM", 105, 117], ["their treatments", "TREATMENT", 122, 138]]], ["Useful pathways and surgical skills for HIC should be determined to help cope with mass casualties and terror injuries.", [["terror injuries", "DISEASE", 103, 118], ["surgical skills", "TREATMENT", 20, 35], ["HIC", "TREATMENT", 40, 43], ["mass casualties", "PROBLEM", 83, 98], ["terror injuries", "PROBLEM", 103, 118]]], ["The hypothesis was that, when a hospital with limited resources could treat a high amount of war injuries, the important factors must lie somewhere else than on the resources.IntroductionA solution strategy for HIC might be to develop a guideline for fast decision-making with the simplest diagnostic means in order to treat first what kills first with the quickest and safest treatment option available.SettingThe NGO hospital is equipped with 92 beds, six intensive care unit (ICU) beds without ventilator, two operation theatres (OT), and one outpatient department (OPD).", [["injuries", "DISEASE", 97, 105], ["war injuries", "PROBLEM", 93, 105], ["IntroductionA solution strategy", "TREATMENT", 175, 206], ["safest treatment option", "TREATMENT", 370, 393], ["ventilator", "TREATMENT", 497, 507]]], ["Besides the six wards, there was a room for physiotherapy and casting.", [["physiotherapy and casting", "TREATMENT", 44, 69]]], ["Although the OT is clean, the hygienic level is very basic compared with western standards.", [["clean", "OBSERVATION", 19, 24], ["very", "OBSERVATION_MODIFIER", 48, 52]]], ["Intra-operative X-ray control is difficult but feasible.", [["Intra-operative X-ray control", "TREATMENT", 0, 29]]], ["The hospitals X-ray machine is analogue and no CT is available.SettingIn total, four junior and four trauma senior surgeons were in charge; during on calls one junior and one senior surgeon were present.", [["trauma", "DISEASE", 101, 107], ["The hospitals X-ray machine", "TREATMENT", 0, 27], ["CT", "TEST", 47, 49]]], ["Anaesthesia is performed by \"anesthiologic technicians\" trained by international aestheticians, they are not anaesthetists.SettingThe international team was a general surgeon, an orthopaedic/trauma surgeon (the author), and an anesthesiologist.", [["trauma", "DISEASE", 191, 197]]], ["Logistics and teaching nurses were provided by the NGO.SettingAmong admitted patients were war victims, civilian trauma victims younger than 14 years old, and patients in lifethreatening condition of any sort.", [["trauma", "DISEASE", 113, 119], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 159, 167]]], ["Patients with chronic posttraumatic deformities were not admitted [10].Management and hospital pathwaysThe triage and management of injured patients were done by OPD nurses.", [["chronic posttraumatic deformities", "DISEASE", 14, 47], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 140, 148], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 140, 148], ["chronic posttraumatic deformities", "PROBLEM", 14, 47], ["The triage", "TEST", 103, 113], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["posttraumatic", "OBSERVATION_MODIFIER", 22, 35], ["deformities", "OBSERVATION", 36, 47]]], ["The standardized procedure consisted of the measurement of heart rate, blood pressure, oxygen saturation, and the clinical examination after undressing and cleaning the patient.", [["heart", "ANATOMY", 59, 64], ["blood", "ANATOMY", 71, 76], ["oxygen", "CHEMICAL", 87, 93], ["oxygen", "CHEMICAL", 87, 93], ["heart", "ORGAN", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["oxygen", "SIMPLE_CHEMICAL", 87, 93], ["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["The standardized procedure", "TREATMENT", 0, 26], ["heart rate", "TEST", 59, 69], ["blood pressure", "TEST", 71, 85], ["oxygen saturation", "TEST", 87, 104], ["the clinical examination", "TEST", 110, 134], ["heart", "ANATOMY", 59, 64], ["oxygen saturation", "OBSERVATION", 87, 104]]], ["Two intravenous lines were inserted, and blood samples for laboratory analysis were taken.", [["intravenous lines", "ANATOMY", 4, 21], ["blood samples", "ANATOMY", 41, 54], ["intravenous lines", "CELL", 4, 21], ["blood samples", "ORGANISM_SUBSTANCE", 41, 54], ["Two intravenous lines", "TREATMENT", 0, 21], ["blood samples", "TEST", 41, 54], ["laboratory analysis", "TEST", 59, 78], ["intravenous lines", "OBSERVATION", 4, 21]]], ["Fluid resuscitation was usually done with 2 l Ringer's lactate.", [["lactate", "CHEMICAL", 55, 62], ["lactate", "CHEMICAL", 55, 62], ["lactate", "SIMPLE_CHEMICAL", 55, 62], ["Fluid resuscitation", "TREATMENT", 0, 19], ["Ringer's lactate", "TEST", 46, 62]]], ["Packed red blood cells were available.Management and hospital pathwaysThe national surgeon completed diagnostics by clinical examination, auscultation of chest and abdomen, and seldom ordering an X-ray.", [["red blood cells", "ANATOMY", 7, 22], ["chest", "ANATOMY", 154, 159], ["abdomen", "ANATOMY", 164, 171], ["red blood cells", "CELL", 7, 22], ["chest", "ORGANISM_SUBDIVISION", 154, 159], ["abdomen", "ORGAN", 164, 171], ["Packed red blood cells", "CELL_TYPE", 0, 22], ["Packed red blood cells", "TEST", 0, 22], ["clinical examination", "TEST", 116, 136], ["auscultation of chest and abdomen", "TEST", 138, 171], ["an X-ray", "TEST", 193, 201], ["blood cells", "OBSERVATION", 11, 22], ["chest", "ANATOMY", 154, 159], ["abdomen", "ANATOMY", 164, 171]]], ["Subsequently the patients went for operation without any delay.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["operation", "TREATMENT", 35, 44], ["any delay", "PROBLEM", 53, 62]]], ["In the OT, the patient was draped and intubated for surgery by the local staff before the surgeon could even scrub entirely.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["intubated", "TREATMENT", 38, 47], ["surgery", "TREATMENT", 52, 59]]], ["The patients flow was clearly defined from OPD to OT and then to the ward or ICU for minor and life-threatening injuries.", [["injuries", "DISEASE", 112, 120], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["minor and life-threatening injuries", "PROBLEM", 85, 120]]], ["It was performed very fast by the local staff for both.War surgerySurgery and treatment of war wounded was performed according war surgery guidelines 10 [11] .EpidemiologyData for evaluation was collected from 26.02.2016 to 11.05.2016.", [["EpidemiologyData", "TEST", 159, 175], ["evaluation", "TEST", 180, 190]]], ["In this 76 days period, 577 patients were admitted to the hospital, 484 (83.88%) war victims, 77 (13.35%) children that had sustained falls or road traffic accidents, and 16 (2.77%) patients of miscellaneous, life-threatening injuries.", [["falls", "DISEASE", 134, 139], ["traffic accidents", "DISEASE", 148, 165], ["injuries", "DISEASE", 226, 234], ["patients", "ORGANISM", 28, 36], ["children", "ORGANISM", 106, 114], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 28, 36], ["children", "SPECIES", 106, 114], ["patients", "SPECIES", 182, 190], ["life-threatening injuries", "PROBLEM", 209, 234]]], ["Patients mean age was 21.84 years, most of them were male (Table 1) .EpidemiologyFor this study, only war victims were evaluated (n = 484).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["this study", "TEST", 85, 95]]], ["The mean age of war casualties was 23.5 years; 434 (89.9%) were male, and 50 (10.1%) were female.EpidemiologyThe injuries were analyzed for the cause of injury, the region injured, for the surgical procedures performed, and the death rate.EpidemiologyOf all patients, 233 were readmitted for planned surgery, and four were readmitted twice.", [["death", "DISEASE", 228, 233], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 258, 266], ["The injuries", "PROBLEM", 109, 121], ["injury", "PROBLEM", 153, 159], ["the surgical procedures", "TEST", 185, 208], ["the death rate", "TEST", 224, 238], ["surgery", "TREATMENT", 300, 307], ["injury", "OBSERVATION", 153, 159]]], ["Planned suregry was mostly delayed primary closures.Cause of injury and affected body region of war victimsAll regions of the body were affected: skull, face, eye, neck, chest, abdomen, back, flank, buttock, pelvis, genitourinary, spine, upper extremities (UE), and lower extremities (LE).Cause of injury and affected body region of war victimsThe most common cause of injuries were bullet injuries (BI) n = 282 (58.3%) followed by shell injuries (SI) n = 137 (28.3%), mine injuries (MI) n = 44 (9.1%), and stab wounds (SW) n = 21 (4.3%).Cause of injury and affected body region of war victimsThe most common injured body region was the LE followed by the UE and the chest or the face.Cause of injury and affected body region of war victimsAn overview dealing with the cause and the affected body region can be seen in Fig. 1 and Table 2 .Performed proceduresA surgical wound debridement was performed on every patient that got operated upon.", [["body", "ANATOMY", 81, 85], ["body", "ANATOMY", 126, 130], ["skull", "ANATOMY", 146, 151], ["face", "ANATOMY", 153, 157], ["eye", "ANATOMY", 159, 162], ["neck", "ANATOMY", 164, 168], ["chest", "ANATOMY", 170, 175], ["abdomen", "ANATOMY", 177, 184], ["back", "ANATOMY", 186, 190], ["flank", "ANATOMY", 192, 197], ["buttock", "ANATOMY", 199, 206], ["pelvis", "ANATOMY", 208, 214], ["genitourinary", "ANATOMY", 216, 229], ["spine", "ANATOMY", 231, 236], ["upper extremities", "ANATOMY", 238, 255], ["UE", "ANATOMY", 257, 259], ["lower extremities", "ANATOMY", 266, 283], ["body", "ANATOMY", 318, 322], ["wounds", "ANATOMY", 512, 518], ["body", "ANATOMY", 567, 571], ["body region", "ANATOMY", 617, 628], ["UE", "ANATOMY", 656, 658], ["chest", "ANATOMY", 667, 672], ["face", "ANATOMY", 680, 684], ["body", "ANATOMY", 714, 718], ["body", "ANATOMY", 792, 796], ["wound", "ANATOMY", 870, 875], ["injuries", "DISEASE", 369, 377], ["bullet injuries", "DISEASE", 383, 398], ["shell injuries", "DISEASE", 432, 446], ["injuries", "DISEASE", 474, 482], ["MI", "DISEASE", 484, 486], ["stab wounds", "DISEASE", 507, 518], ["body", "ORGANISM_SUBDIVISION", 81, 85], ["body", "ORGANISM_SUBDIVISION", 126, 130], ["skull", "ORGAN", 146, 151], ["eye", "ORGAN", 159, 162], ["neck", "ORGAN", 164, 168], ["chest", "ORGAN", 170, 175], ["abdomen", "ORGAN", 177, 184], ["flank", "ORGANISM_SUBDIVISION", 192, 197], ["buttock", "ORGANISM_SUBDIVISION", 199, 206], ["pelvis", "ORGAN", 208, 214], ["genitourinary", "ORGAN", 216, 229], ["spine", "MULTI-TISSUE_STRUCTURE", 231, 236], ["upper extremities", "ORGANISM_SUBDIVISION", 238, 255], ["lower extremities", "ORGANISM_SUBDIVISION", 266, 283], ["body", "ORGANISM_SUBDIVISION", 318, 322], ["wounds", "PATHOLOGICAL_FORMATION", 512, 518], ["body", "ORGANISM_SUBDIVISION", 567, 571], ["body", "ORGANISM_SUBDIVISION", 617, 621], ["chest", "ORGAN", 667, 672], ["body", "ORGANISM_SUBDIVISION", 714, 718], ["body", "ORGANISM_SUBDIVISION", 792, 796], ["wound", "PATHOLOGICAL_FORMATION", 870, 875], ["patient", "ORGANISM", 911, 918], ["patient", "SPECIES", 911, 918], ["suregry", "TREATMENT", 8, 15], ["injury", "PROBLEM", 61, 67], ["affected body region", "PROBLEM", 72, 92], ["war victims", "PROBLEM", 96, 107], ["skull, face, eye, neck, chest, abdomen, back, flank, buttock, pelvis, genitourinary, spine", "TEST", 146, 236], ["injury", "PROBLEM", 298, 304], ["affected body region", "PROBLEM", 309, 329], ["war victims", "PROBLEM", 333, 344], ["injuries", "PROBLEM", 369, 377], ["bullet injuries", "PROBLEM", 383, 398], ["shell injuries", "PROBLEM", 432, 446], ["mine injuries (MI) n", "PROBLEM", 469, 489], ["stab wounds", "PROBLEM", 507, 518], ["injury", "PROBLEM", 547, 553], ["affected body region", "PROBLEM", 558, 578], ["war victims", "PROBLEM", 582, 593], ["injury", "PROBLEM", 694, 700], ["affected body region", "PROBLEM", 705, 725], ["war victims", "PROBLEM", 729, 740], ["the affected body region", "PROBLEM", 779, 803], ["A surgical wound debridement", "TREATMENT", 859, 887], ["delayed", "OBSERVATION_MODIFIER", 27, 34], ["primary closures", "OBSERVATION", 35, 51], ["injury", "OBSERVATION", 61, 67], ["war victims", "OBSERVATION", 96, 107], ["regions", "ANATOMY_MODIFIER", 111, 118], ["body", "ANATOMY", 126, 130], ["skull", "ANATOMY", 146, 151], ["face", "ANATOMY", 153, 157], ["eye", "ANATOMY", 159, 162], ["neck", "ANATOMY", 164, 168], ["chest", "ANATOMY", 170, 175], ["abdomen", "ANATOMY", 177, 184], ["back", "ANATOMY", 186, 190], ["flank", "ANATOMY", 192, 197], ["buttock", "ANATOMY", 199, 206], ["pelvis", "ANATOMY", 208, 214], ["genitourinary", "ANATOMY", 216, 229], ["spine", "ANATOMY", 231, 236], ["upper extremities", "ANATOMY", 238, 255], ["UE", "ANATOMY", 257, 259], ["lower extremities", "ANATOMY", 266, 283], ["LE", "ANATOMY", 285, 287], ["injury", "OBSERVATION", 298, 304], ["war victims", "OBSERVATION", 333, 344], ["injuries", "OBSERVATION", 369, 377], ["stab", "ANATOMY", 507, 511], ["wounds", "OBSERVATION", 512, 518], ["injury", "OBSERVATION", 547, 553], ["war victims", "OBSERVATION", 582, 593], ["most", "OBSERVATION_MODIFIER", 597, 601], ["common", "OBSERVATION_MODIFIER", 602, 608], ["injured", "OBSERVATION", 609, 616], ["body", "ANATOMY_MODIFIER", 617, 621], ["region", "ANATOMY_MODIFIER", 622, 628], ["LE", "ANATOMY_MODIFIER", 637, 639], ["UE", "ANATOMY", 656, 658], ["chest", "ANATOMY", 667, 672], ["face", "ANATOMY", 680, 684], ["injury", "OBSERVATION", 694, 700], ["war victims", "OBSERVATION", 729, 740], ["debridement", "OBSERVATION", 876, 887]]], ["All war wounds were left open at the primary operation and planned for delayed primary closure five days later [11] .", [["wounds", "ANATOMY", 8, 14], ["wounds", "PATHOLOGICAL_FORMATION", 8, 14], ["All war wounds", "PROBLEM", 0, 14], ["the primary operation", "TREATMENT", 33, 54], ["delayed primary closure", "TREATMENT", 71, 94], ["war", "OBSERVATION_MODIFIER", 4, 7], ["wounds", "OBSERVATION", 8, 14], ["left", "ANATOMY_MODIFIER", 20, 24]]], ["No wound dressing was made before that fifth day in the operation room, except there was a high suspicion for infection.", [["wound", "ANATOMY", 3, 8], ["infection", "DISEASE", 110, 119], ["wound", "PATHOLOGICAL_FORMATION", 3, 8], ["wound dressing", "TREATMENT", 3, 17], ["infection", "PROBLEM", 110, 119], ["wound", "ANATOMY", 3, 8], ["dressing", "OBSERVATION", 9, 17], ["infection", "OBSERVATION", 110, 119]]], ["If the health condition allowed, the patient was discharged and readmitted for delayed primary closure.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["delayed primary closure", "TREATMENT", 79, 102], ["closure", "OBSERVATION", 95, 102]]], ["In case of clean stab wounds, they were closed primarily after debridement.Performed proceduresThe second most common specific surgical procedure performed was the laparotomy n = 66 (30.70%) (additional 4 revision operations) followed by installation of a chest drainage n = 40 (18.60%) and amputation n = 29 (13.48%).", [["wounds", "ANATOMY", 22, 28], ["chest", "ANATOMY", 256, 261], ["wounds", "PATHOLOGICAL_FORMATION", 22, 28], ["clean stab wounds", "PROBLEM", 11, 28], ["debridement", "TREATMENT", 63, 74], ["the laparotomy n", "TEST", 160, 176], ["4 revision operations", "TREATMENT", 203, 224], ["a chest drainage n", "TEST", 254, 272], ["amputation n", "TEST", 291, 303], ["clean", "OBSERVATION_MODIFIER", 11, 16], ["stab", "OBSERVATION_MODIFIER", 17, 21], ["wounds", "OBSERVATION", 22, 28], ["debridement", "OBSERVATION", 63, 74], ["chest", "ANATOMY", 256, 261]]], ["Two hundred fifteen war injuries underwent further surgical procedures.", [["injuries", "DISEASE", 24, 32], ["further surgical procedures", "TREATMENT", 43, 70], ["surgical procedures", "OBSERVATION", 51, 70]]], ["Taking into account the fact that all wounds have been debrided in the operation theatre, the average number of surgical procedures increases to 6.37 per day.Performed proceduresBroken down into injured body regions: After BI the most common operation was the laparotomy n = 40 (34.48%) followed by installation of a chest drainage n = 25 (21.55%) and vascular reconstruction/craniotomy n = 9 (7.76%).", [["wounds", "ANATOMY", 38, 44], ["body", "ANATOMY", 203, 207], ["chest", "ANATOMY", 317, 322], ["vascular", "ANATOMY", 352, 360], ["wounds", "PATHOLOGICAL_FORMATION", 38, 44], ["body", "ORGANISM_SUBDIVISION", 203, 207], ["vascular", "MULTI-TISSUE_STRUCTURE", 352, 360], ["all wounds", "PROBLEM", 34, 44], ["surgical procedures", "TREATMENT", 112, 131], ["the laparotomy n", "TREATMENT", 256, 272], ["a chest drainage n", "TREATMENT", 315, 333], ["vascular reconstruction/craniotomy n", "TREATMENT", 352, 388], ["all", "OBSERVATION_MODIFIER", 34, 37], ["wounds", "OBSERVATION", 38, 44], ["debrided", "OBSERVATION", 55, 63], ["average", "OBSERVATION_MODIFIER", 94, 101], ["number", "OBSERVATION_MODIFIER", 102, 108], ["surgical", "OBSERVATION", 112, 120], ["injured body", "ANATOMY_MODIFIER", 195, 207], ["laparotomy", "OBSERVATION", 260, 270], ["chest", "ANATOMY", 317, 322], ["vascular", "ANATOMY", 352, 360], ["craniotomy", "OBSERVATION", 376, 386]]], ["After SI the most common operation was the laparotomy n = 20 (35.71%) followed by installation of a chest drainage n = 9 (16.07%) and vascular reconstruction n = 6 (10.71%).", [["chest", "ANATOMY", 100, 105], ["vascular", "ANATOMY", 134, 142], ["vascular", "MULTI-TISSUE_STRUCTURE", 134, 142], ["the laparotomy n", "TEST", 39, 55], ["a chest drainage n", "TREATMENT", 98, 116], ["vascular reconstruction n", "TEST", 134, 159], ["laparotomy", "OBSERVATION", 43, 53], ["chest", "ANATOMY", 100, 105], ["vascular", "ANATOMY", 134, 142]]], ["After MI the most common operation was the amputation n = 19 (51.35%) followed by installation of a chest drainage n = 5 (13.51%) and laparotomy n = 3 (8.11%).", [["chest", "ANATOMY", 100, 105], ["MI", "DISEASE", 6, 8], ["MI", "PROBLEM", 6, 8], ["the amputation n", "TEST", 39, 55], ["a chest drainage n", "TREATMENT", 98, 116], ["laparotomy n", "TEST", 134, 146], ["chest", "ANATOMY", 100, 105], ["laparotomy", "OBSERVATION", 134, 144]]], ["After SW the most common operation was the laparotomy n = 3 (50.00%) followed by chest drainage/amputation/vascular reconstruction n = 1 (16.67%).Performed proceduresAn overview over the cause of injury and the surgical procedures performed can be seen in Fig. 2 and Table 3 .Performed proceduresIn 60 cases (12.40%), the injuries were located on both sides of the body.", [["chest", "ANATOMY", 81, 86], ["vascular", "ANATOMY", 107, 115], ["body", "ANATOMY", 365, 369], ["injuries", "DISEASE", 322, 330], ["vascular", "MULTI-TISSUE_STRUCTURE", 107, 115], ["body", "ORGANISM_SUBDIVISION", 365, 369], ["the laparotomy n", "TREATMENT", 39, 55], ["chest drainage/amputation/vascular reconstruction n", "TREATMENT", 81, 132], ["injury", "PROBLEM", 196, 202], ["the surgical procedures", "TEST", 207, 230], ["the injuries", "PROBLEM", 318, 330], ["laparotomy", "OBSERVATION", 43, 53], ["chest", "ANATOMY", 81, 86], ["amputation", "OBSERVATION", 96, 106], ["vascular", "ANATOMY", 107, 115], ["injury", "OBSERVATION", 196, 202], ["injuries", "OBSERVATION", 322, 330], ["body", "ANATOMY", 365, 369]]], ["The percentage was maximal for MI (50.00%), followed by SI (18.98%) and BI (4.26%).LaparotomiesAnalyzing the 66 primary laparotomies, the most often injured intra-abdominal organ found was the bowel (47.41%) followed by the liver (11.20%) and the diaphragm (8.62%).", [["intra-abdominal organ", "ANATOMY", 157, 178], ["bowel", "ANATOMY", 193, 198], ["liver", "ANATOMY", 224, 229], ["diaphragm", "ANATOMY", 247, 256], ["MI", "DISEASE", 31, 33], ["intra-abdominal", "ORGAN", 157, 172], ["organ", "ORGAN", 173, 178], ["bowel", "ORGAN", 193, 198], ["liver", "ORGAN", 224, 229], ["diaphragm", "ORGAN", 247, 256], ["MI", "PROBLEM", 31, 33], ["SI", "TEST", 56, 58], ["BI", "TEST", 72, 74], ["Laparotomies", "TREATMENT", 83, 95], ["the 66 primary laparotomies", "TREATMENT", 105, 132], ["primary laparotomies", "OBSERVATION", 112, 132], ["injured", "OBSERVATION", 149, 156], ["intra-abdominal organ", "ANATOMY", 157, 178], ["bowel", "ANATOMY", 193, 198], ["liver", "ANATOMY", 224, 229], ["diaphragm", "ANATOMY", 247, 256]]], ["A laparotomy was performed on all perforating abdominal injuries.", [["abdominal", "ANATOMY", 46, 55], ["abdominal injuries", "DISEASE", 46, 64], ["abdominal", "ORGANISM_SUBDIVISION", 46, 55], ["A laparotomy", "TREATMENT", 0, 12], ["all perforating abdominal injuries", "PROBLEM", 30, 64], ["laparotomy", "OBSERVATION", 2, 12], ["perforating", "OBSERVATION_MODIFIER", 34, 45], ["abdominal", "ANATOMY", 46, 55], ["injuries", "OBSERVATION", 56, 64]]], ["Seven of these diagnostic laparotomies were negative.LaparotomiesIn BI and SI, the bowel was injured the most, followed by the diaphragm.", [["bowel", "ANATOMY", 83, 88], ["diaphragm", "ANATOMY", 127, 136], ["bowel", "ORGAN", 83, 88], ["diaphragm", "ORGAN", 127, 136], ["these diagnostic laparotomies", "TEST", 9, 38], ["laparotomies", "OBSERVATION", 26, 38], ["bowel", "ANATOMY", 83, 88], ["injured", "OBSERVATION", 93, 100], ["diaphragm", "ANATOMY", 127, 136]]], ["Third most common injured organs were the liver and kidney for BI and liver and spleen for SI.", [["organs", "ANATOMY", 26, 32], ["liver", "ANATOMY", 42, 47], ["kidney", "ANATOMY", 52, 58], ["liver", "ANATOMY", 70, 75], ["spleen", "ANATOMY", 80, 86], ["organs", "ORGAN", 26, 32], ["liver", "ORGAN", 42, 47], ["kidney", "ORGAN", 52, 58], ["liver", "ORGAN", 70, 75], ["spleen", "ORGAN", 80, 86], ["SI", "PROBLEM", 91, 93], ["liver", "ANATOMY", 42, 47], ["kidney", "ANATOMY", 52, 58], ["liver", "ANATOMY", 70, 75], ["spleen", "ANATOMY", 80, 86]]], ["Concerning the abdomen, mines injured the bowel only.LaparotomiesAccordingly, the most frequently performed procedures were bowel-related (direct repairs 44.33%, anastomosisDeath ratesIn total, n = 14 (2.89%) patients died in the hospital; these were 11 out of 282 BI patients (3.90%), one out of 138 SI patients (0.73%), one out of 44 MI patients (2.72%), and one out of 21 SW patients (4.76%).DiscussionTrauma surgery in a war zone such as Lashkar Gah differs from trauma surgery in a HIC.", [["abdomen", "ANATOMY", 15, 22], ["bowel", "ANATOMY", 42, 47], ["bowel", "ANATOMY", 124, 129], ["MI", "DISEASE", 336, 338], ["Trauma", "DISEASE", 405, 411], ["trauma", "DISEASE", 467, 473], ["abdomen", "ORGAN", 15, 22], ["bowel", "ORGAN", 42, 47], ["bowel", "ORGAN", 124, 129], ["patients", "ORGANISM", 209, 217], ["patients", "ORGANISM", 268, 276], ["patients", "ORGANISM", 304, 312], ["patients", "ORGANISM", 339, 347], ["patients", "ORGANISM", 378, 386], ["patients", "SPECIES", 209, 217], ["patients", "SPECIES", 268, 276], ["patients", "SPECIES", 304, 312], ["patients", "SPECIES", 339, 347], ["patients", "SPECIES", 378, 386], ["LaparotomiesAccordingly", "TREATMENT", 53, 76], ["direct repairs", "TREATMENT", 139, 153], ["anastomosisDeath", "TEST", 162, 178], ["Trauma surgery", "TREATMENT", 405, 419], ["trauma surgery", "TREATMENT", 467, 481], ["abdomen", "ANATOMY", 15, 22], ["mines", "OBSERVATION", 24, 29], ["bowel", "ANATOMY", 42, 47], ["bowel", "ANATOMY", 124, 129]]], ["Thus, there is a lot of knowledge to benefit from, especially when dealing with uncommon injuries and mass causalities [12] .", [["injuries", "DISEASE", 89, 97], ["uncommon injuries", "PROBLEM", 80, 97], ["mass causalities", "PROBLEM", 102, 118], ["mass", "OBSERVATION", 102, 106]]], ["This becomes even more impressive, regarding the fact that with exception of the surgeons, the medical personnel was trained in the hospital only, with no pre-existing medical education.", [["more impressive", "OBSERVATION_MODIFIER", 18, 33]]], ["It seems that standardized pathways can compensate the lack of medical education and are crucial in the treatment of high patient's inflow.", [["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["medical education", "TREATMENT", 63, 80], ["high patient's inflow", "TREATMENT", 117, 138]]], ["During the Paris Terror in 2015, 495 wounded and 130 dead victims were counted.", [["dead victims", "TEST", 53, 65]]], ["In case of a terror attack, the severely injured patient may not reach a level 1 trauma centre, but a primary health care institution.", [["trauma", "DISEASE", 81, 87], ["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["a terror attack", "PROBLEM", 11, 26]]], ["This fact underlines the need of a profound training in life-saving skills of every doctor in charge [9] .", [["a profound training", "TREATMENT", 33, 52]]], ["In those cases, necessary diagnostic procedures should be kept simple and focused on life-threatening injuries to assure a quick life-saving treatment.", [["injuries", "DISEASE", 102, 110], ["diagnostic procedures", "TREATMENT", 26, 47], ["saving treatment", "TREATMENT", 134, 150]]], ["They include a fast but thorough clinical examination of the undressed patient, measurement of heart rate, blood pressure, and oxygen saturation, insertion of two large bore intravenous lines, taking blood samples, and radiography only if necessary.", [["heart", "ANATOMY", 95, 100], ["blood", "ANATOMY", 107, 112], ["intravenous lines", "ANATOMY", 174, 191], ["blood samples", "ANATOMY", 200, 213], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "CHEMICAL", 127, 133], ["patient", "ORGANISM", 71, 78], ["heart", "ORGAN", 95, 100], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["patient", "SPECIES", 71, 78], ["thorough clinical examination", "TEST", 24, 53], ["heart rate", "TEST", 95, 105], ["blood pressure", "TEST", 107, 121], ["oxygen saturation", "TEST", 127, 144], ["two large bore intravenous lines", "TREATMENT", 159, 191], ["blood samples", "TEST", 200, 213], ["radiography", "TEST", 219, 230], ["heart", "ANATOMY", 95, 100], ["oxygen saturation", "OBSERVATION", 127, 144], ["large", "OBSERVATION_MODIFIER", 163, 168], ["bore", "OBSERVATION_MODIFIER", 169, 173], ["intravenous lines", "OBSERVATION", 174, 191]]], ["All these steps stick to a well-defined simple pathway.DiscussionAfter diagnosing, a fast treatment without delay is essential.", [["a fast treatment", "TREATMENT", 83, 99]]], ["Besides fast and thorough wound debridement, this means mostly performing laparotomies, inserting chest tubes and amputations.", [["wound", "ANATOMY", 26, 31], ["chest tubes", "ANATOMY", 98, 109], ["amputations", "DISEASE", 114, 125], ["wound", "PATHOLOGICAL_FORMATION", 26, 31], ["thorough wound debridement", "TREATMENT", 17, 43], ["laparotomies", "TREATMENT", 74, 86], ["inserting chest tubes", "TREATMENT", 88, 109], ["amputations", "TREATMENT", 114, 125], ["wound", "ANATOMY", 26, 31], ["debridement", "OBSERVATION", 32, 43], ["laparotomies", "OBSERVATION", 74, 86], ["chest", "ANATOMY", 98, 103], ["tubes", "OBSERVATION", 104, 109], ["amputations", "OBSERVATION", 114, 125]]], ["These skills are crucial to save the patient's life [9, 13] .", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44]]], ["They are also providing the basis for western surgeons dealing with an enormous number of casualties by a terror attack or a mass catastrophe [14, 15] .", [["a mass catastrophe", "PROBLEM", 123, 141], ["mass", "OBSERVATION", 125, 129]]], ["The speed factor is essential, not only for the patient treated momentarily, but for the next severely injured patients waiting for treatment.DiscussionSurgical skills needed include vessel repairs, craniotomies, and thoracotomies.DiscussionThe war surgeon needs to combine techniques from different surgical fields such as maxilla-facial, plastic, abdominal, orthopedic, and neurosurgery [4, 16] .", [["vessel", "ANATOMY", 183, 189], ["facial", "ANATOMY", 332, 338], ["abdominal", "ANATOMY", 349, 358], ["patient", "ORGANISM", 48, 55], ["patients", "ORGANISM", 111, 119], ["vessel", "MULTI-TISSUE_STRUCTURE", 183, 189], ["abdominal", "ORGANISM_SUBDIVISION", 349, 358], ["patient", "SPECIES", 48, 55], ["patients", "SPECIES", 111, 119], ["treatment", "TREATMENT", 132, 141], ["vessel repairs", "TREATMENT", 183, 197], ["craniotomies", "TREATMENT", 199, 211], ["thoracotomies", "TREATMENT", 217, 230], ["different surgical fields", "TREATMENT", 290, 315], ["vessel", "ANATOMY", 183, 189], ["repairs", "OBSERVATION", 190, 197], ["craniotomies", "OBSERVATION", 199, 211], ["thoracotomies", "OBSERVATION", 217, 230], ["maxilla", "ANATOMY", 324, 331], ["facial", "ANATOMY", 332, 338], ["abdominal", "ANATOMY", 349, 358]]], ["In Lashkar Gah, specialist surgical care was needed for eye related procedures.", [["eye", "ANATOMY", 56, 59], ["eye", "ORGAN", 56, 59], ["specialist surgical care", "TREATMENT", 16, 40], ["eye related procedures", "TREATMENT", 56, 78]]], ["These patients were sent to Kabul.DiscussionAlthough war surgery's spectrum is broad, surgeons have to deal with two main trauma mechanisms.", [["trauma", "DISEASE", 122, 128], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["war surgery", "TREATMENT", 53, 64]]], ["Most of the injuries are caused by penetrating high velocity projectiles of any sort (BI and SI) or by blasts and burns from explosives like bombs or mines (SI and MI) [2] .DiscussionEven though resources in western countries might be superior to NGO hospitals in LIC, critical incidents like terror attacks will overwhelm local resources [17] .", [["blasts", "ANATOMY", 103, 109], ["injuries", "DISEASE", 12, 20], ["burns", "DISEASE", 114, 119], ["blasts", "CELL_TYPE", 103, 109], ["the injuries", "PROBLEM", 8, 20], ["penetrating high velocity projectiles", "PROBLEM", 35, 72], ["blasts", "PROBLEM", 103, 109], ["burns", "PROBLEM", 114, 119], ["explosives", "PROBLEM", 125, 135], ["mines (SI and MI)", "PROBLEM", 150, 167], ["injuries", "OBSERVATION", 12, 20], ["penetrating", "OBSERVATION_MODIFIER", 35, 46], ["high velocity", "OBSERVATION", 47, 60], ["blasts", "OBSERVATION", 103, 109]]], ["As a solution, mass casualty protocols have been created to assure a proper medical health care even in situations with more than 500 severely injured [9, 18] .SkillsBesides these in-hospital pathways, surgical skills need to be trained as well.", [["a solution, mass casualty protocols", "TREATMENT", 3, 38], ["surgical skills", "TREATMENT", 202, 217]]], ["Teaching of life-saving procedures, compulsory for every surgeon in training might be helpful [19, 20] , Table 3 but they hardly match the surgeons expertise gained through high patient turnover.", [["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185]]], ["But not every patient is \"in extremis.\"", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["Wound debridements, simple laparotomies, insertion of chest tubes, and vessel repairs are probably the majority of cases and need to be achieved as fast as possible.SkillsTreatment pathways and surgical skills are the main characteristics of the Lashkar Gah hospital for civilian war victims.", [["Wound", "ANATOMY", 0, 5], ["chest tubes", "ANATOMY", 54, 65], ["vessel", "ANATOMY", 71, 77], ["Wound", "PATHOLOGICAL_FORMATION", 0, 5], ["chest tubes", "MULTI-TISSUE_STRUCTURE", 54, 65], ["vessel", "MULTI-TISSUE_STRUCTURE", 71, 77], ["Wound debridements", "TREATMENT", 0, 18], ["simple laparotomies", "TREATMENT", 20, 39], ["insertion of chest tubes", "TREATMENT", 41, 65], ["vessel repairs", "TREATMENT", 71, 85], ["surgical skills", "TREATMENT", 194, 209], ["debridements", "OBSERVATION", 6, 18], ["simple", "OBSERVATION_MODIFIER", 20, 26], ["laparotomies", "OBSERVATION", 27, 39], ["chest", "ANATOMY", 54, 59], ["tubes", "OBSERVATION", 60, 65], ["vessel", "ANATOMY", 71, 77], ["repairs", "OBSERVATION", 78, 85]]], ["Although medical education was not available for most of the personnel and the hospital is very basic, it could cope with a high number of patients.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147]]], ["Training, surgical skills, and clear pathways did lead to reliable, appropriate, and rapid treatment of the seriously injured, even with a large proportion of staff who have not received any official medical training.LimitationsThe mission period was restricted to three months, and the data collected only reflect this period.", [["the data", "TEST", 283, 291]]], ["Due to the limited documentation in a war zone, a further evaluation of long-term follow-up was not possible.", [["a further evaluation", "TEST", 48, 68]]], ["Although medial impact is increasing, death due to terrorism has decreased over the last 40 years [21] .", [["death", "DISEASE", 38, 43], ["terrorism", "DISEASE", 51, 60], ["death", "PROBLEM", 38, 43], ["terrorism", "PROBLEM", 51, 60], ["medial", "OBSERVATION_MODIFIER", 9, 15], ["increasing", "OBSERVATION_MODIFIER", 26, 36], ["terrorism", "OBSERVATION", 51, 60], ["decreased", "OBSERVATION_MODIFIER", 65, 74]]], ["Further, the data published from these incidents showed good coping strategies of the treating hospitals, even without specific preparation [22] .", [["the data", "TEST", 9, 17]]], ["Nevertheless, the determined characteristics could be useful for polytraumatized patients.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["polytraumatized patients", "PROBLEM", 65, 89]]], ["In these cases, fast treating algorithms and surgical manoeuvres are essential [9] .LimitationsSummarizing, the knowledge of any anatomic region and the ability to perform fast surgery make the war surgeon unique.", [["fast treating algorithms", "TREATMENT", 16, 40], ["surgical manoeuvres", "TREATMENT", 45, 64], ["any anatomic region", "PROBLEM", 125, 144], ["fast surgery", "TREATMENT", 172, 184]]], ["Speed is essential in surgery and treatment pathways.", [["surgery", "TREATMENT", 22, 29], ["treatment pathways", "TREATMENT", 34, 52]]], ["Those special abilities can provide a basis for surgeons working in HIC who are confronted with a mass casualty incident like a terror attack.LimitationsThe lesson learned from Lashkar Gah for terror surgery in Europe:Limitations& Surgeons must be trained in war surgery performing thorough debridements, laparotomies, chest tube insertions, vessel repair, and craniotomies. & Treatment pathways must be trained by the hospitals' staff. & The hospitals\u00b4resources are of minor importance.LimitationsAuthors' contributions All authors have contributed substantially and sufficiently in the conception, design, acquisition, analysis, and interpretation of the data.LimitationsFunding Open access funding provided by Paracelsus Medical University.Compliance with ethical standardsConflict of interest Nothing to declare.Compliance with ethical standardsEthics approval Due to the study setting in a war zone, no ethics approval was obtained because of a lack of ethical committee in Afghanistan.Consent for publication N/AAvailability of data and material All data gathered including X-rays can be requested from the authors.Conflicts of interest of all authors none.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["chest tube", "ANATOMY", 319, 329], ["vessel", "ANATOMY", 342, 348], ["chest tube", "MULTI-TISSUE_STRUCTURE", 319, 329], ["vessel", "MULTI-TISSUE_STRUCTURE", 342, 348], ["a terror attack", "PROBLEM", 126, 141], ["terror surgery", "TREATMENT", 193, 207], ["war surgery", "TREATMENT", 259, 270], ["thorough debridements", "TREATMENT", 282, 303], ["laparotomies", "TREATMENT", 305, 317], ["chest tube insertions", "TREATMENT", 319, 340], ["vessel repair", "TREATMENT", 342, 355], ["craniotomies", "TREATMENT", 361, 373], ["Treatment pathways", "TREATMENT", 377, 395], ["analysis", "TEST", 621, 629], ["the data", "TEST", 653, 661], ["ethical standards", "TREATMENT", 759, 776], ["ethical standards", "TREATMENT", 832, 849], ["the study", "TEST", 872, 881], ["All data", "TEST", 1052, 1060], ["Open Access", "TREATMENT", 1163, 1174], ["debridements", "OBSERVATION", 291, 303], ["laparotomies", "OBSERVATION", 305, 317], ["chest", "ANATOMY", 319, 324], ["tube insertions", "OBSERVATION", 325, 340], ["vessel", "ANATOMY", 342, 348], ["repair", "OBSERVATION", 349, 355], ["craniotomies", "OBSERVATION", 361, 373]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "889f49db646cf0f46662822cfc14dde90cec6168": [["Most early reports classified cases as SARS on the basis of clinical case definitions, although the recognition of the SARS-CoV as the causative agent allowed specific laboratory confirmation to be made.", [["SARS", "DISEASE", 39, 43], ["SARS", "DISEASE", 119, 123], ["SARS-CoV", "ORGANISM", 119, 127], ["SARS-CoV", "SPECIES", 119, 127], ["specific laboratory confirmation", "TEST", 159, 191]]], ["[2] [3] [4] [5] [6] [7] [8] [9] [10] Approximately 75% of patients presenting with SARS have a laboratory-confirmed SARS-CoV infection, 5 with the remainder either having other infectious causes of severe atypical pneumonia or undetected SARS-CoV infection.", [["[2] [3] [4] [5] [6", "CHEMICAL", 0, 18], ["SARS", "DISEASE", 83, 87], ["SARS-CoV infection", "DISEASE", 116, 134], ["pneumonia", "DISEASE", 214, 223], ["SARS-CoV infection", "DISEASE", 238, 256], ["[2] [3] [4] [5] [6] [7] [8] [9] [10", "SIMPLE_CHEMICAL", 0, 35], ["patients", "ORGANISM", 58, 66], ["SARS-CoV", "ORGANISM", 116, 124], ["patients", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 116, 124], ["SARS-CoV", "SPECIES", 238, 246], ["SARS", "PROBLEM", 83, 87], ["a laboratory", "TEST", 93, 105], ["SARS", "PROBLEM", 116, 120], ["CoV infection", "PROBLEM", 121, 134], ["severe atypical pneumonia", "PROBLEM", 198, 223], ["undetected SARS", "PROBLEM", 227, 242], ["CoV infection", "PROBLEM", 243, 256], ["CoV", "ANATOMY", 121, 124], ["infection", "OBSERVATION", 125, 134], ["infectious", "OBSERVATION", 177, 187], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["atypical", "OBSERVATION_MODIFIER", 205, 213], ["pneumonia", "OBSERVATION", 214, 223], ["CoV infection", "OBSERVATION", 243, 256]]], ["Among the clinical and laboratory features of SARS, a number of hematological abnormalities have been described.", [["hematological", "ANATOMY", 64, 77], ["SARS", "DISEASE", 46, 50], ["hematological abnormalities", "DISEASE", 64, 91], ["SARS", "PROBLEM", 46, 50], ["hematological abnormalities", "PROBLEM", 64, 91]]], ["Prominent amongst these is a total lymphopenia, although in most studies lymphocyte subset analyses were not reported.", [["lymphocyte", "ANATOMY", 73, 83], ["lymphopenia", "DISEASE", 35, 46], ["lymphocyte", "CELL", 73, 83], ["a total lymphopenia", "PROBLEM", 27, 46], ["total", "OBSERVATION_MODIFIER", 29, 34], ["lymphopenia", "OBSERVATION", 35, 46]]], ["4, 6, [8] [9] [10] [11] In this study, an examination of lymphocyte subsets was undertaken in a cohort of 271 laboratoryconfirmed cases of SARS.MethodsThe daily clinical and laboratory findings of 304 SARS patients at the Ditan Hospital in Beijing were entered on a pre-designed database.", [["lymphocyte", "ANATOMY", 57, 67], ["SARS", "DISEASE", 139, 143], ["SARS", "DISEASE", 201, 205], ["4, 6, [8] [9] [10] [11", "SIMPLE_CHEMICAL", 0, 22], ["lymphocyte", "CELL", 57, 67], ["patients", "ORGANISM", 206, 214], ["lymphocyte subsets", "CELL_TYPE", 57, 75], ["patients", "SPECIES", 206, 214], ["this study", "TEST", 27, 37], ["an examination of lymphocyte subsets", "TEST", 39, 75], ["SARS", "PROBLEM", 139, 143], ["Methods", "TREATMENT", 144, 151]]], ["The clinical case definition of probable SARS included a fever of 38 8C or higher, cough or shortness of breath, new pulmonary infiltrates on chest radiography, and close contact with a person who is a suspected or probable case of SARS.", [["pulmonary", "ANATOMY", 117, 126], ["chest", "ANATOMY", 142, 147], ["SARS", "DISEASE", 41, 45], ["fever", "DISEASE", 57, 62], ["cough", "DISEASE", 83, 88], ["shortness of breath", "DISEASE", 92, 111], ["SARS", "DISEASE", 232, 236], ["pulmonary", "ORGAN", 117, 126], ["person", "SPECIES", 186, 192], ["SARS", "PROBLEM", 41, 45], ["a fever of 38 8C", "PROBLEM", 55, 71], ["cough", "PROBLEM", 83, 88], ["shortness of breath", "PROBLEM", 92, 111], ["new pulmonary infiltrates", "PROBLEM", 113, 138], ["chest radiography", "TEST", 142, 159], ["SARS", "PROBLEM", 232, 236], ["probable", "UNCERTAINTY", 32, 40], ["new", "OBSERVATION_MODIFIER", 113, 116], ["pulmonary", "ANATOMY", 117, 126], ["infiltrates", "OBSERVATION", 127, 138], ["chest", "ANATOMY", 142, 147]]], ["Day 1 of illness was defined as the day of onset of fever.", [["fever", "DISEASE", 52, 57], ["illness", "PROBLEM", 9, 16], ["fever", "PROBLEM", 52, 57], ["fever", "OBSERVATION", 52, 57]]], ["Blood was collected for SARS-CoV specific antibody testing from all patients during hospitalization.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["SARS-CoV", "SPECIES", 24, 32], ["Blood", "TEST", 0, 5], ["SARS", "PROBLEM", 24, 28], ["CoV specific antibody testing", "TEST", 29, 58]]], ["SARS-CoV specific IgM and IgG were detected using an indirect immunofluorescence assay (IFA, Euroimmun AG, Lubeck, Ger-many), SARS-CoV RNA was detected in throat washes, stools and blood using a SARS-CoV RNA fluorescence quantitative RT-PCR assay (ShenZhen PJ Company, Shenzhen, Guangdong Province, China).", [["throat", "ANATOMY", 155, 161], ["stools", "ANATOMY", 170, 176], ["blood", "ANATOMY", 181, 186], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["IgM", "GENE_OR_GENE_PRODUCT", 18, 21], ["IgG", "GENE_OR_GENE_PRODUCT", 26, 29], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 126, 134], ["throat", "ORGANISM_SUBDIVISION", 155, 161], ["stools", "ORGANISM_SUBSTANCE", 170, 176], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["SARS-CoV specific IgM", "PROTEIN", 0, 21], ["IgG", "PROTEIN", 26, 29], ["SARS-CoV RNA", "RNA", 126, 138], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 126, 134], ["SARS-CoV", "SPECIES", 195, 203], ["SARS", "TEST", 0, 4], ["CoV specific IgM", "TEST", 5, 21], ["IgG", "TEST", 26, 29], ["an indirect immunofluorescence assay", "TEST", 50, 86], ["IFA", "TEST", 88, 91], ["Euroimmun", "TEST", 93, 102], ["AG", "TEST", 103, 105], ["Lubeck", "TEST", 107, 113], ["SARS", "PROBLEM", 126, 130], ["CoV RNA", "PROBLEM", 131, 138], ["throat washes", "TEST", 155, 168], ["blood", "TEST", 181, 186], ["a SARS", "TEST", 193, 199], ["throat", "ANATOMY", 155, 161]]], ["Immunological tests included T, NK and B lymphocyte cell counts by flow cytometry (MultiT-EST CD45Percp/CD3FITC/CD4APC/CD8PE TruCount Four-Color kit, MultiTEST CD45Percp/CD3FITC/ CD16+56PE/CD19APC TruCount Four-Color kit, BD Biosciences, San Jose, CA, USA).", [["NK", "ANATOMY", 32, 34], ["B lymphocyte cell", "ANATOMY", 39, 56], ["T", "CELL", 29, 30], ["NK", "CELL", 32, 34], ["B lymphocyte cell", "CELL", 39, 56], ["CD16", "GENE_OR_GENE_PRODUCT", 179, 183], ["MultiT", "PROTEIN", 83, 89], ["CD45Percp", "PROTEIN", 94, 103], ["CD3FITC", "PROTEIN", 104, 111], ["CD4APC", "PROTEIN", 112, 118], ["CD8PE", "PROTEIN", 119, 124], ["CD45Percp", "PROTEIN", 160, 169], ["CD3FITC", "PROTEIN", 170, 177], ["CD16", "PROTEIN", 179, 183], ["56PE", "PROTEIN", 184, 188], ["Immunological tests", "TEST", 0, 19], ["T", "TEST", 29, 30], ["NK", "TEST", 32, 34], ["B lymphocyte cell counts", "TEST", 39, 63], ["flow cytometry", "TEST", 67, 81], ["MultiT", "TEST", 83, 89], ["EST", "TEST", 90, 93], ["CD45Percp", "TEST", 94, 103], ["CD3FITC", "TEST", 104, 111], ["CD4APC", "TEST", 112, 118], ["MultiTEST", "TEST", 150, 159], ["CD3FITC", "TEST", 170, 177], ["CD16", "TEST", 179, 183], ["lymphocyte cell", "OBSERVATION", 41, 56]]], ["Lymphocyte counts were performed as controls on 51 non-SARSaffected and otherwise healthy individuals.", [["Lymphocyte", "ANATOMY", 0, 10], ["Lymphocyte", "CELL", 0, 10], ["Lymphocyte counts", "TEST", 0, 17]]], ["All analyses were performed at a single laboratory.", [["All analyses", "TEST", 0, 12]]], ["The study was approved by the Ethics Committee of Ditan Hospital, Beijing, China.MethodsPatients satisfying the case definition of probable SARS were retrospectively classified after discharge into non-severe (122) and severe (149) cases.", [["SARS", "DISEASE", 140, 144], ["The study", "TEST", 0, 9], ["SARS", "PROBLEM", 140, 144], ["severe (149) cases", "PROBLEM", 219, 237]]], ["The non-severe and severe groups were defined according to 'The standard of clinical diagnosis for atypical pneumonia' guidelines listed by the Chinese Public Health Ministry on 4 May 2003.", [["pneumonia", "DISEASE", 108, 117], ["The non-severe and severe groups", "PROBLEM", 0, 32], ["atypical pneumonia", "PROBLEM", 99, 117], ["non-severe", "OBSERVATION_MODIFIER", 4, 14], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["atypical", "OBSERVATION_MODIFIER", 99, 107], ["pneumonia", "OBSERVATION", 108, 117]]], ["The patients in the non-severe group had a fever of 38 8C or higher, a cough or shortness of breath, and new pulmonary infiltrates on chest radiography.", [["pulmonary", "ANATOMY", 109, 118], ["chest", "ANATOMY", 134, 139], ["fever", "DISEASE", 43, 48], ["cough", "DISEASE", 71, 76], ["shortness of breath", "DISEASE", 80, 99], ["patients", "ORGANISM", 4, 12], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 109, 130], ["patients", "SPECIES", 4, 12], ["a fever", "PROBLEM", 41, 48], ["a cough", "PROBLEM", 69, 76], ["shortness of breath", "PROBLEM", 80, 99], ["new pulmonary infiltrates", "PROBLEM", 105, 130], ["chest radiography", "TEST", 134, 151], ["cough", "OBSERVATION", 71, 76], ["new", "OBSERVATION_MODIFIER", 105, 108], ["pulmonary", "ANATOMY", 109, 118], ["infiltrates", "OBSERVATION", 119, 130], ["chest", "ANATOMY", 134, 139]]], ["The patients in the severe group had in addition at least one of the following features: dyspnea (respiratory rate >30/ minute), hypoxemia (PaO 2 <70 mmHg or SpO 2 <93% whilst on oxygen at a rate of 3-5 L/minute), acute lung injury/acute respiratory distress syndrome, a chest radiograph showing multifocal involvement over one third of the lung fields (or that developed to 50% in 48 hours), and shock or multiple organ dysfunction syndrome (MODS).", [["lung", "ANATOMY", 220, 224], ["respiratory", "ANATOMY", 238, 249], ["chest", "ANATOMY", 271, 276], ["lung", "ANATOMY", 341, 345], ["organ", "ANATOMY", 415, 420], ["dyspnea", "DISEASE", 89, 96], ["hypoxemia", "DISEASE", 129, 138], ["oxygen", "CHEMICAL", 179, 185], ["lung injury", "DISEASE", 220, 231], ["respiratory distress syndrome", "DISEASE", 238, 267], ["shock", "DISEASE", 397, 402], ["multiple organ dysfunction syndrome", "DISEASE", 406, 441], ["MODS", "DISEASE", 443, 447], ["oxygen", "CHEMICAL", 179, 185], ["patients", "ORGANISM", 4, 12], ["oxygen", "SIMPLE_CHEMICAL", 179, 185], ["lung", "ORGAN", 220, 224], ["lung", "ORGAN", 341, 345], ["organ", "ORGAN", 415, 420], ["patients", "SPECIES", 4, 12], ["dyspnea", "PROBLEM", 89, 96], ["respiratory rate", "TEST", 98, 114], ["hypoxemia", "PROBLEM", 129, 138], ["PaO", "TEST", 140, 143], ["SpO", "TEST", 158, 161], ["oxygen", "TREATMENT", 179, 185], ["acute lung injury", "PROBLEM", 214, 231], ["acute respiratory distress syndrome", "PROBLEM", 232, 267], ["a chest radiograph", "TEST", 269, 287], ["multifocal involvement", "PROBLEM", 296, 318], ["shock", "PROBLEM", 397, 402], ["multiple organ dysfunction syndrome", "PROBLEM", 406, 441], ["MODS", "PROBLEM", 443, 447], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["dyspnea", "OBSERVATION", 89, 96], ["hypoxemia", "OBSERVATION", 129, 138], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["lung", "ANATOMY", 220, 224], ["injury", "OBSERVATION", 225, 231], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["respiratory distress", "OBSERVATION", 238, 258], ["chest", "ANATOMY", 271, 276], ["multifocal", "OBSERVATION_MODIFIER", 296, 306], ["involvement", "OBSERVATION", 307, 318], ["lung", "ANATOMY", 341, 345], ["fields", "ANATOMY_MODIFIER", 346, 352], ["shock", "OBSERVATION", 397, 402], ["multiple", "OBSERVATION_MODIFIER", 406, 414], ["organ", "ANATOMY", 415, 420], ["dysfunction", "OBSERVATION", 421, 432]]], ["They also had other underlying diseases, developed a secondary infection or were over 50 years old.", [["infection", "DISEASE", 63, 72], ["other underlying diseases", "PROBLEM", 14, 39], ["a secondary infection", "PROBLEM", 51, 72], ["diseases", "OBSERVATION", 31, 39], ["secondary", "OBSERVATION_MODIFIER", 53, 62], ["infection", "OBSERVATION", 63, 72]]], ["Patients satisfying the case definition of probable SARS were retrospectively classified after discharge into those who recovered (246 cases) and those who died from SARS (25).ResultsProbable SARS patients were regarded as laboratory confirmed if they had at least one of the following: SARS-CoV IgG and/or IgM antibody detected by IFA three or more weeks after the onset of the illness, and/or SARS-CoV RNA detected by RT-PCR during the first two weeks of illness.ResultsIn this study, 271/304 (89.1%) patients were laboratory confirmed as having SARS, including 148 (55%) with SARS-CoV detected by RT-PCR on respiratory tract or fecal samples.", [["respiratory tract", "ANATOMY", 610, 627], ["fecal samples", "ANATOMY", 631, 644], ["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 166, 170], ["SARS", "DISEASE", 192, 196], ["SARS", "DISEASE", 548, 552], ["SARS", "DISEASE", 579, 583], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 197, 205], ["SARS-CoV IgG", "GENE_OR_GENE_PRODUCT", 287, 299], ["IgM", "GENE_OR_GENE_PRODUCT", 307, 310], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 395, 403], ["patients", "ORGANISM", 503, 511], ["tract", "ORGANISM_SUBDIVISION", 622, 627], ["fecal samples", "ORGANISM_SUBSTANCE", 631, 644], ["SARS-CoV IgG", "PROTEIN", 287, 299], ["IgM antibody", "PROTEIN", 307, 319], ["SARS-CoV RNA", "RNA", 395, 407], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 503, 511], ["SARS-CoV", "SPECIES", 287, 295], ["SARS-CoV", "SPECIES", 395, 403], ["SARS-CoV", "SPECIES", 579, 587], ["SARS", "PROBLEM", 52, 56], ["SARS", "PROBLEM", 166, 170], ["SARS", "PROBLEM", 192, 196], ["SARS", "PROBLEM", 287, 291], ["CoV IgG", "TEST", 292, 299], ["IgM antibody", "PROBLEM", 307, 319], ["IFA", "TEST", 332, 335], ["the illness", "PROBLEM", 375, 386], ["SARS", "PROBLEM", 395, 399], ["CoV RNA", "PROBLEM", 400, 407], ["RT-PCR", "TEST", 420, 426], ["illness", "PROBLEM", 457, 464], ["this study", "TEST", 475, 485], ["SARS", "PROBLEM", 548, 552], ["SARS", "PROBLEM", 579, 583], ["CoV", "TEST", 584, 587], ["RT", "TEST", 600, 602], ["PCR", "TEST", 603, 606], ["respiratory tract", "PROBLEM", 610, 627], ["fecal samples", "TEST", 631, 644], ["respiratory tract", "ANATOMY", 610, 627], ["fecal", "ANATOMY", 631, 636]]], ["Of the 148 SARS-CoV RT-PCR positive samples, SARS-CoV IgG was detected in 145 (98%) and SARS-CoV IgM in 117 (79%) using IFA.", [["samples", "ANATOMY", 36, 43], ["SARS-CoV IgG", "GENE_OR_GENE_PRODUCT", 45, 57], ["SARS-CoV IgG", "PROTEIN", 45, 57], ["CoV IgM", "PROTEIN", 93, 100], ["SARS-CoV", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 88, 96], ["SARS", "TEST", 11, 15], ["CoV RT", "TEST", 16, 22], ["PCR", "TEST", 23, 26], ["SARS", "TEST", 45, 49], ["CoV IgG", "TEST", 50, 57], ["SARS", "TEST", 88, 92], ["CoV IgM", "TEST", 93, 100], ["IFA", "TEST", 120, 123]]], ["12 There were 33/304 (10.9%) that were negative on SARS testing.", [["SARS", "DISEASE", 51, 55], ["SARS testing", "TEST", 51, 63]]], ["An alternative laboratory diagnosis was made in 27/33, of which the most common were acute influenza B (13 cases) and Klebsiella pneumoniae infection (nine cases).", [["influenza B", "DISEASE", 91, 102], ["Klebsiella pneumoniae infection", "DISEASE", 118, 149], ["Klebsiella pneumoniae", "ORGANISM", 118, 139], ["Klebsiella pneumoniae", "SPECIES", 118, 139], ["Klebsiella pneumoniae", "SPECIES", 118, 139], ["acute influenza B", "PROBLEM", 85, 102], ["Klebsiella pneumoniae infection", "PROBLEM", 118, 149], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["influenza", "OBSERVATION", 91, 100], ["Klebsiella", "OBSERVATION_MODIFIER", 118, 128], ["pneumoniae", "OBSERVATION_MODIFIER", 129, 139], ["infection", "OBSERVATION", 140, 149]]], ["The mean age of the 271 laboratory-confirmed SARS cases was 36 AE 16 years, with 51 (18.8%) over 50 years of age and nine (3.3%) under 18 years.", [["SARS", "DISEASE", 45, 49], ["SARS cases", "TEST", 45, 55]]], ["There were 157 (57.9%) females and 114 (42.1%) males.", [["females", "TEST", 23, 30]]], ["Thirty-two patients had underlying health problems, including diabetes (18 cases), cardiac disease (eight cases), malignancy (four cases), chronic airways disease (one case) and chronic renal failure (one case).", [["cardiac", "ANATOMY", 83, 90], ["malignancy", "ANATOMY", 114, 124], ["airways", "ANATOMY", 147, 154], ["renal", "ANATOMY", 186, 191], ["diabetes", "DISEASE", 62, 70], ["cardiac disease", "DISEASE", 83, 98], ["malignancy", "DISEASE", 114, 124], ["chronic airways disease", "DISEASE", 139, 162], ["chronic renal failure", "DISEASE", 178, 199], ["patients", "ORGANISM", 11, 19], ["cardiac", "ORGAN", 83, 90], ["airways", "MULTI-TISSUE_STRUCTURE", 147, 154], ["renal", "ORGAN", 186, 191], ["patients", "SPECIES", 11, 19], ["underlying health problems", "PROBLEM", 24, 50], ["diabetes (18 cases)", "PROBLEM", 62, 81], ["cardiac disease (eight cases)", "PROBLEM", 83, 112], ["malignancy", "PROBLEM", 114, 124], ["chronic airways disease", "PROBLEM", 139, 162], ["chronic renal failure", "PROBLEM", 178, 199], ["cardiac", "ANATOMY", 83, 90], ["disease", "OBSERVATION", 91, 98], ["malignancy", "OBSERVATION", 114, 124], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["airways", "ANATOMY", 147, 154], ["disease", "OBSERVATION", 155, 162], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["renal", "ANATOMY", 186, 191], ["failure", "OBSERVATION", 192, 199]]], ["One hundred and twelve individuals (41.3%) acquired SARS in the hospital setting as health care workers, inpatients, or visitors, mostly in the wards of the hospital.", [["SARS", "DISEASE", 52, 56]]], ["A further 62 cases were infected following home exposure, when family members or friends of hospital-associated cases had come into close contact with affected individuals.Lymphocyte subsetsThe lymphocyte subpopulation counts were compared between 696 samples collected from 271 cases of laboratory-confirmed SARS patients and 51 controls ( Table 1 ).", [["Lymphocyte", "ANATOMY", 172, 182], ["lymphocyte", "ANATOMY", 194, 204], ["samples", "ANATOMY", 252, 259], ["SARS", "DISEASE", 309, 313], ["Lymphocyte", "CELL", 172, 182], ["lymphocyte", "CELL", 194, 204], ["patients", "ORGANISM", 314, 322], ["Lymphocyte subsets", "CELL_TYPE", 172, 190], ["patients", "SPECIES", 314, 322], ["Lymphocyte subsets", "TEST", 172, 190], ["The lymphocyte subpopulation counts", "TEST", 190, 225], ["SARS patients", "TEST", 309, 322], ["lymphocyte subpopulation", "OBSERVATION", 194, 218]]], ["The total lymphocyte counts from SARS patients were compared with those from normal individuals, and the lymphocyte counts at each week after the onset of the illness were compared with other weeks of illness and with those from normal individuals.", [["lymphocyte", "ANATOMY", 10, 20], ["lymphocyte", "ANATOMY", 105, 115], ["SARS", "DISEASE", 33, 37], ["lymphocyte", "CELL", 10, 20], ["patients", "ORGANISM", 38, 46], ["lymphocyte", "CELL", 105, 115], ["patients", "SPECIES", 38, 46], ["The total lymphocyte counts", "TEST", 0, 27], ["SARS", "PROBLEM", 33, 37], ["the lymphocyte counts", "TEST", 101, 122], ["the illness", "PROBLEM", 155, 166], ["illness", "PROBLEM", 201, 208], ["total", "OBSERVATION_MODIFIER", 4, 9], ["lymphocyte counts", "OBSERVATION", 10, 27], ["illness", "OBSERVATION", 159, 166]]], ["Using nonparametric tests there were significant decreases in the CD45+, CD3+, CD4+, CD8+, CD19+ and CD16/56+ counts over each of the five weeks of the SARS illness compared to healthy controls, although the CD4+/CD8+ ratio did not change significantly over the course of the illness.", [["CD45+, CD3+, CD4+, CD8+, CD19+", "ANATOMY", 66, 96], ["CD4+/CD8+", "ANATOMY", 208, 217], ["SARS illness", "DISEASE", 152, 164], ["CD45", "GENE_OR_GENE_PRODUCT", 66, 70], ["CD3", "GENE_OR_GENE_PRODUCT", 73, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 79, 82], ["CD8", "GENE_OR_GENE_PRODUCT", 85, 88], ["CD19", "GENE_OR_GENE_PRODUCT", 91, 95], ["CD16", "GENE_OR_GENE_PRODUCT", 101, 105], ["CD4", "GENE_OR_GENE_PRODUCT", 208, 211], ["CD8", "GENE_OR_GENE_PRODUCT", 213, 216], ["CD45", "PROTEIN", 66, 70], ["CD3", "PROTEIN", 73, 76], ["CD4", "PROTEIN", 79, 82], ["CD8", "PROTEIN", 85, 88], ["CD19", "PROTEIN", 91, 95], ["CD16", "PROTEIN", 101, 105], ["/56", "PROTEIN", 105, 108], ["CD4", "PROTEIN", 208, 211], ["CD8", "PROTEIN", 213, 216], ["nonparametric tests", "TEST", 6, 25], ["significant decreases", "PROBLEM", 37, 58], ["the CD45", "TEST", 62, 70], ["CD3", "TEST", 73, 76], ["CD4", "TEST", 79, 82], ["CD8", "TEST", 85, 88], ["CD19", "TEST", 91, 95], ["CD16", "TEST", 101, 105], ["counts", "TEST", 110, 116], ["the SARS illness", "PROBLEM", 148, 164], ["the CD4", "TEST", 204, 211], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["decreases", "OBSERVATION_MODIFIER", 49, 58]]], ["The various lymphocyte populations (CD45+, CD3+, CD4+ and CD8+) were below the normal ranges in the first week of the clinical illness, reaching a nadir during the second week before returning towards normal levels.", [["lymphocyte", "ANATOMY", 12, 22], ["CD45+, CD3+, CD4+", "ANATOMY", 36, 53], ["lymphocyte populations", "CELL", 12, 34], ["CD45", "GENE_OR_GENE_PRODUCT", 36, 40], ["CD3", "GENE_OR_GENE_PRODUCT", 43, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 49, 52], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["lymphocyte populations", "CELL_TYPE", 12, 34], ["CD45", "PROTEIN", 36, 40], ["CD3", "PROTEIN", 43, 46], ["CD4", "PROTEIN", 49, 52], ["CD8", "PROTEIN", 58, 61], ["The various lymphocyte populations", "TEST", 0, 34], ["CD45", "TEST", 36, 40], ["CD3", "TEST", 43, 46], ["CD4", "TEST", 49, 52], ["CD8", "TEST", 58, 61], ["various", "OBSERVATION_MODIFIER", 4, 11], ["lymphocyte populations", "OBSERVATION", 12, 34], ["normal ranges", "OBSERVATION", 79, 92]]], ["There were significant differences in lymphocyte subset counts between weeks 1 and 2, weeks 2 and 3, weeks 4 and 5, and weeks 1 and 5 (Table 1) (Figures 1-3) .", [["lymphocyte", "ANATOMY", 38, 48], ["lymphocyte", "CELL", 38, 48], ["lymphocyte subset", "CELL_TYPE", 38, 55], ["lymphocyte subset counts", "TEST", 38, 62], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["lymphocyte subset counts", "OBSERVATION", 38, 62]]], ["These observations are further defined in Table 2 where the CD45+, CD3+, CD4+, CD8+, CD19+ and CD16/56+ counts on samples collected daily during the first 21 days of SARS are listed.", [["CD45+, CD3+, CD4+, CD8+", "ANATOMY", 60, 83], ["samples", "ANATOMY", 114, 121], ["SARS", "DISEASE", 166, 170], ["CD45", "GENE_OR_GENE_PRODUCT", 60, 64], ["CD3", "GENE_OR_GENE_PRODUCT", 67, 70], ["CD4", "GENE_OR_GENE_PRODUCT", 73, 76], ["CD8", "GENE_OR_GENE_PRODUCT", 79, 82], ["CD19", "GENE_OR_GENE_PRODUCT", 85, 89], ["CD16", "GENE_OR_GENE_PRODUCT", 95, 99], ["56", "GENE_OR_GENE_PRODUCT", 100, 102], ["CD45", "PROTEIN", 60, 64], ["CD3", "PROTEIN", 67, 70], ["CD4", "PROTEIN", 73, 76], ["CD8", "PROTEIN", 79, 82], ["CD19", "PROTEIN", 85, 89], ["CD16", "PROTEIN", 95, 99], ["the CD45", "TEST", 56, 64], ["CD3", "TEST", 67, 70], ["CD4", "TEST", 73, 76], ["CD8", "TEST", 79, 82], ["CD19", "TEST", 85, 89], ["CD16", "TEST", 95, 99], ["counts", "TEST", 104, 110], ["samples", "TEST", 114, 121], ["SARS", "PROBLEM", 166, 170]]], ["The total, CD4+ and CD8+ lymphopenia was most marked at days 7-9 in the second week of the illness.", [["CD4+", "ANATOMY", 11, 15], ["lymphopenia", "DISEASE", 25, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 11, 14], ["CD8", "GENE_OR_GENE_PRODUCT", 20, 23], ["CD4", "PROTEIN", 11, 14], ["CD8", "PROTEIN", 20, 23], ["CD4", "TEST", 11, 14], ["CD8", "TEST", 20, 23], ["lymphopenia", "PROBLEM", 25, 36], ["the illness", "PROBLEM", 87, 98], ["total", "OBSERVATION_MODIFIER", 4, 9], ["lymphopenia", "OBSERVATION", 25, 36], ["marked", "OBSERVATION_MODIFIER", 46, 52], ["illness", "OBSERVATION", 91, 98]]], ["In Table 3 the lymphocyte subpopulation counts were compared between those with severe SARS (260 samples from 149 patients), non-severe SARS (436 samples from 122 patients), and those that recovered (613 samples from 246 cases) or died (48 samples from 25 patients) from SARS.", [["lymphocyte", "ANATOMY", 15, 25], ["samples", "ANATOMY", 97, 104], ["samples", "ANATOMY", 146, 153], ["samples", "ANATOMY", 204, 211], ["samples", "ANATOMY", 240, 247], ["SARS", "DISEASE", 87, 91], ["SARS", "DISEASE", 136, 140], ["SARS", "DISEASE", 271, 275], ["lymphocyte", "CELL", 15, 25], ["patients", "ORGANISM", 114, 122], ["samples", "CANCER", 146, 153], ["patients", "ORGANISM", 163, 171], ["samples", "CANCER", 204, 211], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 256, 264], ["the lymphocyte subpopulation counts", "TEST", 11, 46], ["severe SARS", "PROBLEM", 80, 91], ["non-severe SARS", "PROBLEM", 125, 140], ["SARS", "PROBLEM", 271, 275], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["SARS", "OBSERVATION", 87, 91]]], ["The CD45+, CD3+, CD4+, CD8+, CD19+ and CD16/56+ counts were significantly lower (using nonparametric tests) in those patients that died compared to those who recovered, and in those with severe disease compared to those with nonsevere disease.DiscussionThe interaction between the SARS-CoV and the immune system is complex.", [["CD45+, CD3+, CD4+, CD8+, CD19+", "ANATOMY", 4, 34], ["SARS", "DISEASE", 281, 285], ["CD45", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD3", "GENE_OR_GENE_PRODUCT", 11, 14], ["CD4", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD19", "GENE_OR_GENE_PRODUCT", 29, 33], ["CD16", "GENE_OR_GENE_PRODUCT", 39, 43], ["patients", "ORGANISM", 117, 125], ["SARS-CoV", "ORGANISM", 281, 289], ["CD45", "PROTEIN", 4, 8], ["CD3", "PROTEIN", 11, 14], ["CD4", "PROTEIN", 17, 20], ["CD8", "PROTEIN", 23, 26], ["CD19", "PROTEIN", 29, 33], ["CD16", "PROTEIN", 39, 43], ["/56", "PROTEIN", 43, 46], ["patients", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 281, 289], ["The CD45", "TEST", 0, 8], ["CD3", "TEST", 11, 14], ["CD4", "TEST", 17, 20], ["CD8", "TEST", 23, 26], ["CD19", "TEST", 29, 33], ["CD16", "TEST", 39, 43], ["counts", "TEST", 48, 54], ["nonparametric tests", "TEST", 87, 106], ["severe disease", "PROBLEM", 187, 201], ["nonsevere disease", "PROBLEM", 225, 242], ["the SARS", "TEST", 277, 285], ["CD45", "OBSERVATION", 4, 8], ["CD19", "ANATOMY", 29, 33], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["disease", "OBSERVATION", 194, 201]]], ["In this study, lymphocyte subsets were measured over five weeks in 271DiscussionEffects of severe acute respiratory syndrome (SARS) coronavirus infection 327 Figure 3 Kinetics of lymphocyte subsets (expressed as mean number of cells \u00c2 10 6 /L) measured over the first five weeks of illness in non-severe and severe laboratory-confirmed SARS patients, and in otherwise healthy controls.Discussionlaboratory-proven non-severe and severe cases of SARS, where patients either recovered or died.", [["lymphocyte", "ANATOMY", 15, 25], ["lymphocyte", "ANATOMY", 179, 189], ["cells", "ANATOMY", 227, 232], ["acute respiratory syndrome", "DISEASE", 98, 124], ["SARS", "DISEASE", 126, 130], ["coronavirus infection", "DISEASE", 132, 153], ["illness", "DISEASE", 282, 289], ["SARS", "DISEASE", 336, 340], ["SARS", "DISEASE", 444, 448], ["lymphocyte", "CELL", 15, 25], ["lymphocyte", "CELL", 179, 189], ["cells", "CELL", 227, 232], ["patients", "ORGANISM", 341, 349], ["patients", "ORGANISM", 456, 464], ["lymphocyte subsets", "CELL_TYPE", 15, 33], ["lymphocyte subsets", "CELL_TYPE", 179, 197], ["patients", "SPECIES", 341, 349], ["patients", "SPECIES", 456, 464], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 91, 143], ["this study", "TEST", 3, 13], ["lymphocyte subsets", "TEST", 15, 33], ["severe acute respiratory syndrome", "PROBLEM", 91, 124], ["SARS) coronavirus infection", "PROBLEM", 126, 153], ["lymphocyte subsets", "TEST", 179, 197], ["cells", "TEST", 227, 232], ["illness in non-severe and severe laboratory", "PROBLEM", 282, 325], ["SARS", "PROBLEM", 444, 448], ["lymphocyte subsets", "OBSERVATION", 15, 33], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["respiratory syndrome", "OBSERVATION", 104, 124], ["lymphocyte subsets", "OBSERVATION", 179, 197], ["severe", "OBSERVATION_MODIFIER", 428, 434]]], ["Total lymphocyte counts decreased in the first two weeks of illness (the nadir was in week 2) before increasing in the third week and returning to normal levels by the fifth week.", [["lymphocyte", "ANATOMY", 6, 16], ["illness", "DISEASE", 60, 67], ["lymphocyte", "CELL", 6, 16], ["Total lymphocyte counts", "TEST", 0, 23], ["illness", "PROBLEM", 60, 67], ["the nadir", "TEST", 69, 78], ["lymphocyte counts", "OBSERVATION", 6, 23], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["normal", "OBSERVATION", 147, 153]]], ["Peripheral blood lymphocyte subsets (CD45+, CD3+, CD4+, CD8+) were quantitated by dynamic methods in a large cohort of 271 laboratory-proven cases of SARS.", [["Peripheral blood lymphocyte", "ANATOMY", 0, 27], ["CD45+, CD3+, CD4+, CD8+", "ANATOMY", 37, 60], ["SARS", "DISEASE", 150, 154], ["Peripheral blood lymphocyte", "CELL", 0, 27], ["CD45", "GENE_OR_GENE_PRODUCT", 37, 41], ["CD3", "GENE_OR_GENE_PRODUCT", 44, 47], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 56, 59], ["Peripheral blood lymphocyte subsets", "CELL_TYPE", 0, 35], ["CD45", "PROTEIN", 37, 41], ["CD3", "PROTEIN", 44, 47], ["CD4", "PROTEIN", 50, 53], ["CD8", "PROTEIN", 56, 59], ["Peripheral blood lymphocyte subsets", "TEST", 0, 35], ["CD45", "TEST", 37, 41], ["CD3", "TEST", 44, 47], ["CD4", "TEST", 50, 53], ["CD8", "TEST", 56, 59], ["SARS", "PROBLEM", 150, 154], ["blood", "ANATOMY", 11, 16], ["lymphocyte subsets", "OBSERVATION", 17, 35]]], ["This study confirms observations of lymphopenia noted in most other series of SARS cases.", [["lymphopenia", "DISEASE", 36, 47], ["SARS", "DISEASE", 78, 82], ["This study", "TEST", 0, 10], ["lymphopenia", "PROBLEM", 36, 47], ["SARS cases", "TEST", 78, 88], ["lymphopenia", "OBSERVATION", 36, 47]]], ["4, 6, [8] [9] [10] [11] A study in Hong Kong reported an absolute lymphopenia (<1000 \u00c2 10 6 /L) in 98% of patients during the course of their illness, most marked in the second week.", [["lymphopenia", "DISEASE", 66, 77], ["illness", "DISEASE", 142, 149], ["[8] [9] [10] [11] A", "SIMPLE_CHEMICAL", 6, 25], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["A study", "TEST", 24, 31], ["an absolute lymphopenia", "PROBLEM", 54, 77], ["their illness", "PROBLEM", 136, 149], ["absolute", "OBSERVATION_MODIFIER", 57, 65], ["lymphopenia", "OBSERVATION", 66, 77], ["illness", "OBSERVATION", 142, 149], ["marked", "OBSERVATION_MODIFIER", 156, 162]]], ["11 The data discussed here extend these observations (and provide the first data from mainland China), showing that the total lymphocyte counts of SARS patients were lower than those of normal individuals throughout the clinical course, and that this was more marked in severe disease compared to less severe illness, and in those who died compared to the survivors.", [["lymphocyte", "ANATOMY", 126, 136], ["SARS", "DISEASE", 147, 151], ["illness", "DISEASE", 309, 316], ["lymphocyte", "CELL", 126, 136], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["the total lymphocyte counts", "TEST", 116, 143], ["SARS", "PROBLEM", 147, 151], ["severe disease", "PROBLEM", 270, 284], ["marked", "OBSERVATION_MODIFIER", 260, 266], ["severe", "OBSERVATION_MODIFIER", 270, 276], ["disease", "OBSERVATION", 277, 284], ["less severe", "OBSERVATION_MODIFIER", 297, 308]]], ["A study of 75 patients from the Amoy Gardens outbreak in Hong Kong did not find an association of total lymphocyte counts and progression to ventilatory support and intensive care, 10 although there are differences in the progression to acute respiratory distress syndrome (ARDS), oxygen saturation and gastrointestinal symptoms in these two cohorts.", [["lymphocyte", "ANATOMY", 104, 114], ["respiratory", "ANATOMY", 243, 254], ["gastrointestinal", "ANATOMY", 303, 319], ["acute respiratory distress syndrome", "DISEASE", 237, 272], ["ARDS", "DISEASE", 274, 278], ["oxygen", "CHEMICAL", 281, 287], ["gastrointestinal symptoms", "DISEASE", 303, 328], ["oxygen", "CHEMICAL", 281, 287], ["patients", "ORGANISM", 14, 22], ["lymphocyte", "CELL", 104, 114], ["oxygen", "SIMPLE_CHEMICAL", 281, 287], ["gastrointestinal", "ORGAN", 303, 319], ["patients", "SPECIES", 14, 22], ["A study", "TEST", 0, 7], ["total lymphocyte counts", "TEST", 98, 121], ["ventilatory support", "TREATMENT", 141, 160], ["intensive care", "TREATMENT", 165, 179], ["acute respiratory distress syndrome", "PROBLEM", 237, 272], ["ARDS)", "PROBLEM", 274, 279], ["oxygen saturation", "TEST", 281, 298], ["gastrointestinal symptoms", "PROBLEM", 303, 328], ["ventilatory support", "OBSERVATION", 141, 160], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["respiratory distress syndrome", "OBSERVATION", 243, 272], ["gastrointestinal", "ANATOMY", 303, 319]]], ["However, an association of lymphopenia with more severe disease was seen in another cohort of SARS cases from Hong Kong.", [["lymphopenia", "DISEASE", 27, 38], ["SARS", "DISEASE", 94, 98], ["lymphopenia", "PROBLEM", 27, 38], ["more severe disease", "PROBLEM", 44, 63], ["lymphopenia", "OBSERVATION", 27, 38], ["more severe", "OBSERVATION_MODIFIER", 44, 55], ["disease", "OBSERVATION", 56, 63]]], ["6 In contrast with other series of adult SARS cases, in the study reported here all patients had laboratory evidence of SARS-CoV infection.", [["SARS", "DISEASE", 41, 45], ["SARS-CoV infection", "DISEASE", 120, 138], ["patients", "ORGANISM", 84, 92], ["SARS-CoV", "ORGANISM", 120, 128], ["patients", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 120, 128], ["adult SARS cases", "PROBLEM", 35, 51], ["the study", "TEST", 56, 65], ["SARS", "PROBLEM", 120, 124], ["CoV infection", "PROBLEM", 125, 138], ["SARS", "OBSERVATION", 120, 124], ["CoV", "OBSERVATION_MODIFIER", 125, 128], ["infection", "OBSERVATION", 129, 138]]], ["In two series totalling 25 children with probable or suspect SARS (although only four children had laboratory-proven SARS), total lymphopenia was common and more prominent in older children with more severe disease.", [["SARS", "DISEASE", 61, 65], ["SARS", "DISEASE", 117, 121], ["lymphopenia", "DISEASE", 130, 141], ["children", "ORGANISM", 27, 35], ["children", "ORGANISM", 86, 94], ["children", "ORGANISM", 181, 189], ["children", "SPECIES", 27, 35], ["children", "SPECIES", 86, 94], ["children", "SPECIES", 181, 189], ["SARS", "PROBLEM", 61, 65], ["SARS", "PROBLEM", 117, 121], ["total lymphopenia", "PROBLEM", 124, 141], ["more severe disease", "PROBLEM", 195, 214], ["lymphopenia", "OBSERVATION", 130, 141], ["more prominent", "OBSERVATION_MODIFIER", 157, 171], ["more severe", "OBSERVATION_MODIFIER", 195, 206], ["disease", "OBSERVATION", 207, 214]]], ["13, 14 Lymphocyte subsets (CD4+, CD8+, CD19+ and CD16/56+) were also counted in all patients.", [["Lymphocyte", "ANATOMY", 7, 17], ["CD4+, CD8+, CD19+", "ANATOMY", 27, 44], ["Lymphocyte subsets", "CELL", 7, 25], ["CD4", "GENE_OR_GENE_PRODUCT", 27, 30], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["CD19", "GENE_OR_GENE_PRODUCT", 39, 43], ["CD16", "GENE_OR_GENE_PRODUCT", 49, 53], ["56", "GENE_OR_GENE_PRODUCT", 54, 56], ["patients", "ORGANISM", 84, 92], ["Lymphocyte subsets", "CELL_TYPE", 7, 25], ["CD4", "PROTEIN", 27, 30], ["CD8", "PROTEIN", 33, 36], ["CD19", "PROTEIN", 39, 43], ["CD16", "PROTEIN", 49, 53], ["patients", "SPECIES", 84, 92], ["Lymphocyte subsets", "TEST", 7, 25], ["CD4", "TEST", 27, 30], ["CD8", "TEST", 33, 36], ["CD19", "TEST", 39, 43], ["CD16", "TEST", 49, 53]]], ["A significant CD4+ and CD8+ T cell lymphopenia has been observed in the first two weeks of the SARS illness in 31 patients, 11 but in this study, a more prolonged CD4+ and CD8+ lymphopenia was noted.", [["CD4+", "ANATOMY", 14, 18], ["T cell", "ANATOMY", 28, 34], ["CD4+", "ANATOMY", 163, 167], ["lymphopenia", "DISEASE", 35, 46], ["SARS illness", "DISEASE", 95, 107], ["lymphopenia", "DISEASE", 177, 188], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["T cell", "CELL", 28, 34], ["patients", "ORGANISM", 114, 122], ["CD4", "GENE_OR_GENE_PRODUCT", 163, 166], ["CD8", "GENE_OR_GENE_PRODUCT", 172, 175], ["CD4", "PROTEIN", 14, 17], ["CD8", "PROTEIN", 23, 26], ["CD4", "PROTEIN", 163, 166], ["CD8", "PROTEIN", 172, 175], ["patients", "SPECIES", 114, 122], ["A significant CD4", "TEST", 0, 17], ["T cell lymphopenia", "PROBLEM", 28, 46], ["the SARS illness", "PROBLEM", 91, 107], ["this study", "TEST", 134, 144], ["CD8", "PROBLEM", 172, 175], ["lymphopenia", "PROBLEM", 177, 188], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["CD4", "OBSERVATION", 14, 17], ["CD8+", "OBSERVATION", 23, 27], ["cell lymphopenia", "OBSERVATION", 30, 46], ["lymphopenia", "OBSERVATION", 177, 188]]], ["CD4+ and CD8+ cells fell by approximately one half in the second week of the illness before returning to near normal by the end of week 5.", [["CD4+ and CD8+ cells", "ANATOMY", 0, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 9, 12], ["CD4", "PROTEIN", 0, 3], ["CD8+ cells", "CELL_TYPE", 9, 19], ["CD4", "TEST", 0, 3], ["CD8+ cells", "PROBLEM", 9, 19], ["CD8+ cells", "OBSERVATION", 9, 19], ["illness", "OBSERVATION", 77, 84]]], ["In addition, patients with more severe disease had lower counts that took longer to rise.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["more severe disease", "PROBLEM", 27, 46], ["lower counts", "PROBLEM", 51, 63], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["disease", "OBSERVATION", 39, 46], ["lower counts", "OBSERVATION_MODIFIER", 51, 63]]], ["The data show that the CD4+ and CD8+ counts were lower in more severely ill patients and in those that died.", [["CD4+", "ANATOMY", 23, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD8", "GENE_OR_GENE_PRODUCT", 32, 35], ["patients", "ORGANISM", 76, 84], ["CD4", "PROTEIN", 23, 26], ["CD8", "PROTEIN", 32, 35], ["patients", "SPECIES", 76, 84], ["The data", "TEST", 0, 8], ["the CD4", "TEST", 19, 26], ["CD8+ counts", "TEST", 32, 43], ["more severely", "OBSERVATION_MODIFIER", 58, 71]]], ["The CD4+/CD8+ ratios were not significantly different in the various patient groups.", [["CD4+/CD8+", "ANATOMY", 4, 13], ["CD4", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD8", "GENE_OR_GENE_PRODUCT", 9, 12], ["patient", "ORGANISM", 69, 76], ["CD4", "PROTEIN", 4, 7], ["CD8", "PROTEIN", 9, 12], ["patient", "SPECIES", 69, 76], ["The CD4", "TEST", 0, 7], ["significantly different", "OBSERVATION_MODIFIER", 30, 53]]], ["CD19+ B lymphocytes were the first lymphocytes to numerically recover after two weeks and their recovery was associated with the appearance of SARS-CoV specific IgG and IgM.", [["CD19+ B lymphocytes", "ANATOMY", 0, 19], ["lymphocytes", "ANATOMY", 35, 46], ["SARS", "DISEASE", 143, 147], ["CD19", "GENE_OR_GENE_PRODUCT", 0, 4], ["lymphocytes", "CELL", 35, 46], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 143, 151], ["IgG", "GENE_OR_GENE_PRODUCT", 161, 164], ["IgM.", "GENE_OR_GENE_PRODUCT", 169, 173], ["CD19", "PROTEIN", 0, 4], ["B lymphocytes", "CELL_TYPE", 6, 19], ["lymphocytes", "CELL_TYPE", 35, 46], ["SARS-CoV specific IgG", "PROTEIN", 143, 164], ["SARS-CoV", "SPECIES", 143, 151], ["CD19", "TEST", 0, 4], ["B lymphocytes", "PROBLEM", 6, 19], ["SARS", "PROBLEM", 143, 147], ["CoV specific IgG", "TEST", 148, 164], ["B lymphocytes", "OBSERVATION", 6, 19]]], ["CD16/56+ NK cells also began to decrease in the first week (although there was a rise in NK cells towards the end of week 1) to their lowest levels during week 4, and had not returned to normal by week 5.DiscussionLymphopenia is a prominent part of SARS-CoV infection and lymphocyte counts may be useful in predicting the severity and clinical outcomes.", [["CD16/56+ NK cells", "ANATOMY", 0, 17], ["NK cells", "ANATOMY", 89, 97], ["lymphocyte", "ANATOMY", 272, 282], ["DiscussionLymphopenia", "DISEASE", 204, 225], ["SARS-CoV infection", "DISEASE", 249, 267], ["CD16/56", "GENE_OR_GENE_PRODUCT", 0, 7], ["NK cells", "CELL", 9, 17], ["NK cells", "CELL", 89, 97], ["SARS-CoV", "ORGANISM", 249, 257], ["lymphocyte", "CELL", 272, 282], ["CD16/56", "CELL_LINE", 0, 7], ["NK cells", "CELL_TYPE", 9, 17], ["NK cells", "CELL_TYPE", 89, 97], ["SARS-CoV", "SPECIES", 249, 257], ["NK cells", "PROBLEM", 9, 17], ["a rise in NK cells", "PROBLEM", 79, 97], ["SARS", "PROBLEM", 249, 253], ["CoV infection", "PROBLEM", 254, 267], ["lymphocyte counts", "TEST", 272, 289], ["NK cells", "OBSERVATION", 9, 17], ["decrease", "OBSERVATION_MODIFIER", 32, 40], ["NK cells", "OBSERVATION", 89, 97], ["prominent part", "OBSERVATION_MODIFIER", 231, 245], ["SARS", "OBSERVATION", 249, 253], ["CoV", "OBSERVATION_MODIFIER", 254, 257], ["infection", "OBSERVATION", 258, 267], ["lymphocyte counts", "OBSERVATION", 272, 289]]], ["Total and subset lymphopenia occurs in other acute (e.g. measles, cytomegalovirus) and chronic (e.g. HIV) viral infections in humans and animals, but lymphopenia has not been a feature of other human coronavirus infections in adults.", [["lymphopenia", "DISEASE", 17, 28], ["measles, cytomegalovirus) and chronic (e.g. HIV) viral infections", "DISEASE", 57, 122], ["lymphopenia", "DISEASE", 150, 161], ["coronavirus infections", "DISEASE", 200, 222], ["cytomegalovirus", "ORGANISM", 66, 81], ["humans", "ORGANISM", 126, 132], ["human", "ORGANISM", 194, 199], ["coronavirus", "ORGANISM", 200, 211], ["humans", "SPECIES", 126, 132], ["human", "SPECIES", 194, 199], ["HIV", "SPECIES", 101, 104], ["humans", "SPECIES", 126, 132], ["human coronavirus", "SPECIES", 194, 211], ["Total and subset lymphopenia", "PROBLEM", 0, 28], ["other acute (e.g. measles", "PROBLEM", 39, 64], ["cytomegalovirus", "PROBLEM", 66, 81], ["chronic (e.g. HIV)", "PROBLEM", 87, 105], ["viral infections in humans", "PROBLEM", 106, 132], ["lymphopenia", "PROBLEM", 150, 161], ["other human coronavirus infections", "PROBLEM", 188, 222], ["subset", "OBSERVATION_MODIFIER", 10, 16], ["lymphopenia", "OBSERVATION", 17, 28], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["viral", "OBSERVATION_MODIFIER", 106, 111], ["infections", "OBSERVATION", 112, 122], ["lymphopenia", "OBSERVATION", 150, 161], ["coronavirus", "OBSERVATION_MODIFIER", 200, 211], ["infections", "OBSERVATION", 212, 222]]], ["[15] [16] [17] Lymphopenia has been described in some cases of experimental coronavirus 229E infections in humans.", [["Lymphopenia", "DISEASE", 15, 26], ["coronavirus 229E infections", "DISEASE", 76, 103], ["[15] [16] [17] Lymphopenia", "SIMPLE_CHEMICAL", 0, 26], ["coronavirus 229E", "ORGANISM", 76, 92], ["humans", "ORGANISM", 107, 113], ["coronavirus", "SPECIES", 76, 87], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 107, 113], ["Lymphopenia", "PROBLEM", 15, 26], ["experimental coronavirus 229E infections in humans", "PROBLEM", 63, 113], ["coronavirus 229E", "OBSERVATION", 76, 92]]], ["18 A possible reason for the lymphopenia may be that lymphocytes are directly infected and destroyed by SARS-CoV.", [["lymphocytes", "ANATOMY", 53, 64], ["lymphopenia", "DISEASE", 29, 40], ["SARS", "DISEASE", 104, 108], ["lymphocytes", "CELL", 53, 64], ["SARS-CoV", "ORGANISM", 104, 112], ["lymphocytes", "CELL_TYPE", 53, 64], ["SARS-CoV", "SPECIES", 104, 112], ["the lymphopenia", "PROBLEM", 25, 40], ["lymphocytes", "PROBLEM", 53, 64], ["possible reason for", "UNCERTAINTY", 5, 24], ["lymphopenia", "OBSERVATION", 29, 40], ["lymphocytes", "OBSERVATION", 53, 64]]], ["However, angiotensin-converting enzyme 2 has been identified as a functional cellular receptor for the SARS-CoV, a protein that is not expressed on B or T lymphocytes.", [["cellular", "ANATOMY", 77, 85], ["B", "ANATOMY", 148, 149], ["T lymphocytes", "ANATOMY", 153, 166], ["angiotensin", "CHEMICAL", 9, 20], ["SARS", "DISEASE", 103, 107], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 9, 40], ["cellular", "CELL", 77, 85], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["B", "CELL", 148, 149], ["T lymphocytes", "CELL", 153, 166], ["angiotensin-converting enzyme 2", "PROTEIN", 9, 40], ["SARS-CoV", "PROTEIN", 103, 111], ["B or T lymphocytes", "CELL_TYPE", 148, 166], ["SARS-CoV", "SPECIES", 103, 111], ["angiotensin-converting enzyme", "TEST", 9, 38], ["the SARS", "PROBLEM", 99, 107], ["CoV", "PROBLEM", 108, 111], ["a protein", "TEST", 113, 122]]], ["19, 20 This would suggest that direct viral invasion and destruction of lymphocytes is not a major cause of the acute lymphopenia in SARS, but this requires further study.DiscussionOther possible explanations for the lymphopenia are lymphocyte sequestration in the lung where SARS-CoV damage is most evident, or cytokinemediated altered lymphocyte trafficking.", [["lymphocytes", "ANATOMY", 72, 83], ["lymphocyte", "ANATOMY", 233, 243], ["lung", "ANATOMY", 265, 269], ["lymphocyte", "ANATOMY", 337, 347], ["lymphopenia", "DISEASE", 118, 129], ["SARS", "DISEASE", 133, 137], ["lymphopenia", "DISEASE", 217, 228], ["SARS-CoV damage", "DISEASE", 276, 291], ["lymphocytes", "CELL", 72, 83], ["lymphocyte", "CELL", 233, 243], ["lung", "ORGAN", 265, 269], ["SARS-CoV", "ORGANISM", 276, 284], ["lymphocyte", "CELL", 337, 347], ["lymphocytes", "CELL_TYPE", 72, 83], ["direct viral invasion", "PROBLEM", 31, 52], ["destruction of lymphocytes", "PROBLEM", 57, 83], ["the acute lymphopenia", "PROBLEM", 108, 129], ["SARS", "PROBLEM", 133, 137], ["further study", "TEST", 157, 170], ["the lymphopenia", "PROBLEM", 213, 228], ["lymphocyte sequestration in the lung", "PROBLEM", 233, 269], ["SARS", "PROBLEM", 276, 280], ["CoV damage", "PROBLEM", 281, 291], ["cytokinemediated altered lymphocyte trafficking", "PROBLEM", 312, 359], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["invasion", "OBSERVATION", 44, 52], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["lymphopenia", "OBSERVATION", 118, 129], ["possible explanations for", "UNCERTAINTY", 187, 212], ["lymphopenia", "OBSERVATION", 217, 228], ["lymphocyte sequestration", "OBSERVATION", 233, 257], ["lung", "ANATOMY", 265, 269], ["CoV damage", "OBSERVATION", 281, 291], ["most evident", "UNCERTAINTY", 295, 307], ["lymphocyte trafficking", "OBSERVATION", 337, 359]]], ["There may be immune-mediated lymphocyte destruction (lymphocyte depletion has been noted in autopsies of lymph nodes from SARS cases), 21 bone marrow or thymus suppression, or apoptosis.", [["lymphocyte", "ANATOMY", 29, 39], ["lymphocyte", "ANATOMY", 53, 63], ["lymph nodes", "ANATOMY", 105, 116], ["bone marrow", "ANATOMY", 138, 149], ["thymus", "ANATOMY", 153, 159], ["SARS", "DISEASE", 122, 126], ["bone marrow or thymus suppression", "DISEASE", 138, 171], ["lymphocyte", "CELL", 29, 39], ["lymphocyte", "CELL", 53, 63], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 105, 116], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 138, 149], ["thymus", "ORGAN", 153, 159], ["immune-mediated lymphocyte destruction", "PROBLEM", 13, 51], ["lymphocyte depletion", "PROBLEM", 53, 73], ["lymph nodes", "PROBLEM", 105, 116], ["SARS cases", "TEST", 122, 132], ["21 bone marrow", "PROBLEM", 135, 149], ["thymus suppression", "PROBLEM", 153, 171], ["apoptosis", "PROBLEM", 176, 185], ["may be", "UNCERTAINTY", 6, 12], ["mediated", "OBSERVATION_MODIFIER", 20, 28], ["lymphocyte destruction", "OBSERVATION", 29, 51], ["lymphocyte depletion", "OBSERVATION", 53, 73], ["lymph nodes", "OBSERVATION", 105, 116], ["bone marrow", "ANATOMY", 138, 149], ["thymus", "ANATOMY", 153, 159], ["suppression", "OBSERVATION", 160, 171], ["apoptosis", "OBSERVATION_MODIFIER", 176, 185]]], ["Apoptosis has been observed in vitro in measles-induced lymphopenia, 22 and coronavirus 229E can cause in vitro apoptosis in monocytes/macrophages.", [["monocytes", "ANATOMY", 125, 134], ["macrophages", "ANATOMY", 135, 146], ["Apoptosis", "DISEASE", 0, 9], ["measles", "DISEASE", 40, 47], ["lymphopenia", "DISEASE", 56, 67], ["measles", "ORGANISM", 40, 47], ["coronavirus 229E", "ORGANISM", 76, 92], ["monocytes", "CELL", 125, 134], ["macrophages", "CELL", 135, 146], ["monocytes", "CELL_TYPE", 125, 134], ["macrophages", "CELL_TYPE", 135, 146], ["Apoptosis", "PROBLEM", 0, 9], ["lymphopenia", "PROBLEM", 56, 67], ["coronavirus 229E", "PROBLEM", 76, 92], ["vitro apoptosis in monocytes/macrophages", "PROBLEM", 106, 146], ["lymphopenia", "OBSERVATION", 56, 67], ["vitro apoptosis", "OBSERVATION", 106, 121], ["monocytes", "ANATOMY", 125, 134], ["macrophages", "ANATOMY", 135, 146]]], ["23 Whether different strains of SARS-CoV have variable effects on immune responses and clinical disease (as occurs with experimental measles in macaques) 24 is unknown.", [["SARS", "DISEASE", 32, 36], ["measles", "DISEASE", 133, 140], ["SARS-CoV", "ORGANISM", 32, 40], ["macaques", "ORGANISM", 144, 152], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 32, 36], ["CoV", "PROBLEM", 37, 40], ["variable effects", "PROBLEM", 46, 62], ["immune responses", "PROBLEM", 66, 82], ["clinical disease", "PROBLEM", 87, 103], ["experimental measles in macaques)", "TREATMENT", 120, 153]]], ["It is possible that the SARS-CoV-induced immune suppression predisposes to secondary infections, especially in the more severely ill patients, and it is unknown if there are any longer term effects on humoral or cell-mediated immunity following SARS.DiscussionConflict of interest: No conflict of interest to declare.", [["cell", "ANATOMY", 212, 216], ["SARS", "DISEASE", 24, 28], ["immune suppression", "DISEASE", 41, 59], ["infections", "DISEASE", 85, 95], ["ill", "DISEASE", 129, 132], ["SARS", "DISEASE", 245, 249], ["SARS-CoV", "ORGANISM", 24, 32], ["patients", "ORGANISM", 133, 141], ["cell", "CELL", 212, 216], ["patients", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 24, 32], ["the SARS", "PROBLEM", 20, 28], ["CoV-induced immune suppression", "TREATMENT", 29, 59], ["secondary infections", "PROBLEM", 75, 95], ["SARS", "PROBLEM", 245, 249], ["secondary", "OBSERVATION_MODIFIER", 75, 84], ["infections", "OBSERVATION", 85, 95]]]], "334d9a04eae5c3384228c31cb81973ed6190ba94": [["Telehealth, as defined by Sood et al., is a branch of E-health that uses communications networks for the delivery of healthcare services and medical education from one geographical location to another [1] .", [["medical education", "TREATMENT", 141, 158]]], ["Telehealth and the delivery of virtual telemedicine is globally accepted however * Corresponding author. remains underutilized in orthopaedic surgery practices across the United States [2] .IntroductionSince the onset of the novel coronavirus (COVID-19) many orthopaedic new patient consultations, clinic visits, and elective surgeries have been cancelled or rescheduled following the guidelines set forth by the Centers for Medicare and Medicaid Services (CMS) on March 6, 2020 [3] .", [["coronavirus", "DISEASE", 231, 242], ["coronavirus", "ORGANISM", 231, 242], ["patient", "ORGANISM", 275, 282], ["patient", "SPECIES", 275, 282], ["the novel coronavirus", "PROBLEM", 221, 242], ["elective surgeries", "TREATMENT", 317, 335]]], ["Specifically, the expansion of the Telehealth 1135 Waiver has allowed Medicare to pay for office, hospital, and other visits furnished via telehealth [3] .", [["Telehealth 1135", "CHEMICAL", 35, 50], ["expansion", "OBSERVATION_MODIFIER", 18, 27]]], ["This provision increases the orthopaedic surgeon and patient's capability to communicate virtually, practice shared decision making, provide progress updates safely and effectively, and collect appropriate compensation for the services rendered.ARTICLE IN PRESSJID: JINJ [m5G; September 17, 2020; 17:22 ] There have been few studies analysing the utilization of telemedicine within orthopaedic surgery [ 2 , 4-9 ] .", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["few studies", "TEST", 321, 332], ["orthopaedic surgery", "TREATMENT", 382, 401], ["few", "OBSERVATION_MODIFIER", 321, 324]]], ["Two studies have been completed analysing the effectiveness of virtual postoperative rehabilitation protocols compared to in-person rehabilitation protocols [ 7 , 8 ] .", [["Two studies", "TEST", 0, 11], ["virtual postoperative rehabilitation protocols", "TREATMENT", 63, 109]]], ["Russel et al. found that following total knee arthroplasty, patients who completed a tele-rehabilitation protocol had similar functional and patient reported outcomes compared to the in-person rehab cohort, with high levels of patient reported satisfaction [8] .", [["knee", "ANATOMY", 41, 45], ["knee", "ORGANISM_SUBDIVISION", 41, 45], ["patients", "ORGANISM", 60, 68], ["patient", "ORGANISM", 141, 148], ["patient", "ORGANISM", 227, 234], ["patients", "SPECIES", 60, 68], ["patient", "SPECIES", 141, 148], ["person", "SPECIES", 186, 192], ["patient", "SPECIES", 227, 234], ["total knee arthroplasty", "TREATMENT", 35, 58], ["rehabilitation protocol", "TREATMENT", 90, 113], ["et al", "OBSERVATION", 7, 12], ["knee", "ANATOMY", 41, 45], ["arthroplasty", "OBSERVATION", 46, 58]]], ["Kane et al. reported outcomes on post-operative telemedicine encounters versus inperson encounters following rotator cuff repair.", [["rotator", "ANATOMY", 109, 116], ["rotator cuff", "MULTI-TISSUE_STRUCTURE", 109, 121], ["rotator cuff repair", "TREATMENT", 109, 128], ["rotator", "ANATOMY", 109, 116], ["cuff repair", "OBSERVATION", 117, 128]]], ["They found that patients in both groups had similar overall satisfaction scores, however patients in the telemedicine group required less time off work to come to visits and reported less time off work needed for their caregivers [6] .", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 89, 97]]], ["No studies, to our knowledge, have evaluated the practicality, and effectiveness of the broad adoption of telemedicine in orthopaedic care delivery.ARTICLE IN PRESSWith the systemic pressures of a global pandemic and orthopaedic surgery practices striving to deliver high quality and high value care, it is anticipated that this technology will continue to be adopted as part of our patient care paradigm.ARTICLE IN PRESSTo our knowledge, this is the first study that aims to assess patient and surgeon perception and satisfaction with orthopaedic telemedicine encounters as replacement for in-person visits.Initiation of virtual visitsIn mid-March 2020, following institution and state guidelines regarding social distancing and shelter in place orders to prevent the spread of the COVID-19 pandemic, orthopaedic outpatient clinic operations at our institution were significantly restricted.", [["pandemic", "DISEASE", 204, 212], ["patient", "ORGANISM", 383, 390], ["patient", "ORGANISM", 483, 490], ["patient", "SPECIES", 383, 390], ["patient", "SPECIES", 483, 490], ["person", "SPECIES", 594, 600], ["orthopaedic care delivery", "TREATMENT", 122, 147], ["orthopaedic surgery practices", "TREATMENT", 217, 246], ["replacement", "TREATMENT", 575, 586], ["systemic", "OBSERVATION_MODIFIER", 173, 181], ["pressures", "OBSERVATION_MODIFIER", 182, 191]]], ["We analysed visit volume and visit type data during pre-COVID and the study period to evaluate the effect of the pandemic on our orthopaedic ambulatory outpatient productivity.", [["the study", "TEST", 66, 75]]], ["In-person visits were restricted to only those visits deemed medically necessary and time sensitive for safe patient care.", [["patient", "ORGANISM", 109, 116], ["person", "SPECIES", 3, 9], ["patient", "SPECIES", 109, 116], ["safe patient care", "TREATMENT", 104, 121]]], ["These encounters were available to both established and new patients.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["All patients affected by the clinic closures were contacted to re-schedule their in-person visit.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["person", "SPECIES", 84, 90]]], ["As of April 6, 2020, we were able to offer these patients the option of a telemedicine visit.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["The choice of telemedicine method (video vs phone) was a shared decision between surgeon and patient, considering patient technological capabilities and objectives for the encounter.Pre-pandemic data collectionPre-COVID-19 institutional patient satisfaction data was collected prospectively via a secure patient portal.", [["patient", "ORGANISM", 93, 100], ["patient", "ORGANISM", 114, 121], ["patient", "ORGANISM", 237, 244], ["patient", "ORGANISM", 304, 311], ["patient", "SPECIES", 93, 100], ["patient", "SPECIES", 114, 121], ["patient", "SPECIES", 237, 244], ["patient", "SPECIES", 304, 311], ["Pre-pandemic data collection", "TEST", 182, 210], ["portal", "ANATOMY", 312, 318]]], ["Patients are invited to complete a validated satisfaction survey following all outpatient encounters.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["We used data from January 1, 2020 -February 29, 2020 as our baseline patient satisfaction comparison group.", [["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76]]], ["These surveys are administered by the Patient Experience Team, and survey results are available in an anonymized, aggregated format at regular time intervals to all clinic surgeons.Telehealth data collection and analysisAt the initiation of this project, patient and surgeon surveys were created ( Appendix A ).", [["patient", "ORGANISM", 255, 262], ["Patient", "SPECIES", 38, 45], ["patient", "SPECIES", 255, 262], ["Telehealth data collection", "TEST", 181, 207]]], ["A patient telemedicine satisfaction survey was modelled off the validated pre-pandemic patient satisfaction survey.", [["patient", "ORGANISM", 2, 9], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 2, 9], ["patient", "SPECIES", 87, 94]]], ["How well staff protected your safety (by washing hands, wearing gloves etc.\u2026)) and retained those which were relevant to both in-person and virtual encounters.", [["person", "SPECIES", 129, 135]]], ["Patient and surgeon surveys consisted of multiple-choice responses with an optional free-form response for comments or clarifications.", [["Patient", "SPECIES", 0, 7]]], ["Institutional Review Board (IRB) approval was obtained for surveys, consents, and project protocol.", [["project protocol", "TREATMENT", 82, 98]]], ["Electronic written consent for participation was obtained from surgeons while verbal consent for participation was obtained from patients.Telehealth data collection and analysisAll orthopaedic outpatient schedules from 4/6/2020 to 5/22/2020 for all surgeons were searched for telemedicine encounters.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["Telehealth data collection", "TEST", 138, 164], ["analysis", "TEST", 169, 177]]], ["Orthopaedic clinic patients receiving both surgical and non-surgical care were included in this study.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["both surgical and non-surgical care", "TREATMENT", 38, 73], ["this study", "TEST", 91, 101]]], ["Inclusion criteria: English-speaking individuals 18 years of age or greater and a completed telemedicine encounter.", [["individuals", "ORGANISM", 37, 48]]], ["We excluded patients under 18 years of age as they are not seen in our Adult Orthopaedic clinic.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Patients were contacted via telephone and asked to participate in the survey.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Surveyors attempted to reach patients up to three times, and patients were free to decline participation at any time.", [["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 61, 69]]], ["No incentives were offered for participation, and no funding was necessary for the completion of this study.", [["this study", "TEST", 97, 107]]], ["Following research protocols and IRB guidelines, deidentified survey data was exported from the database.", [["research protocols", "TREATMENT", 10, 28], ["deidentified survey data", "TEST", 49, 73]]], ["Chi-Square analysis was used for categorical variables and t-test for continuous data.", [["Square analysis", "TEST", 4, 19], ["categorical variables", "TEST", 33, 54], ["t-test", "TEST", 59, 65], ["continuous data", "TEST", 70, 85]]], ["Statistical significance was set at p < 0.05.ResultsPre-COVID orthopaedic visit volumes at our institution during January and February totalled; 7990 in-person visits, and 0 telemedicine visits.", [["person", "SPECIES", 153, 159]]], ["During April and May (months during the initial telemedicine implementation as a result of the COVID pandemic), total orthopaedic visit volumes totalled: 1675 in-person visits, 379 video visits and 395 telephone visits.", [["person", "SPECIES", 162, 168]]], ["Thus only 31% of pre-COVID volume was obtained during this time.", [["pre-COVID", "CANCER", 17, 26], ["pre-COVID volume", "TEST", 17, 33]]], ["During our study period, 612 telehealth encounters were completed in the Department of Orthopaedic Surgery by phone or video consultation between April 6, 2020 and May 22, 2020 ( Fig. 1 , Table 1 ).Surgeon response dataAt initiation of the study, the Department of Orthopaedic Surgery had 15 attending surgeons who conducted adult outpatient clinics before the onset of the COVID-19 pandemic.", [["the study", "TEST", 236, 245], ["the COVID", "TEST", 370, 379], ["pandemic", "PROBLEM", 383, 391]]], ["In an effort to collect equal subgroups of video and telephone data, surgeon survey results were collected beyond the timeframe of patient survey responses.", [["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138]]], ["As the learning curve and thus adoption of video visits increased over time this later analysis allowed for improved recruitment of video visit data.", [["the learning curve", "TEST", 3, 21]]], ["Consented surgeons completed 591 (591/612; 96.6% of all telemedicine encounters), and of those, a total of 466 satisfaction surveys were completed (overall response rate 466/591; 78.6%) ( Fig. 2 ) .", [["satisfaction surveys", "TEST", 111, 131], ["response rate", "TEST", 156, 169]]], ["No significant associations were found between visit type and surgeon satisfaction, the goals of the visit being completed successfully, and ability for the virtual visit to replace an in-person visit ( Table 3 ) .", [["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["However, there was a trend towards significance in the ability of a phone visit to replace an in-person visit when stratified by visit type ( p = 0.058).Patient response dataDuring the study period, we attempted to reach 450 patients with 355 patients successfully contacted.", [["patients", "ORGANISM", 225, 233], ["patients", "ORGANISM", 243, 251], ["Patient", "SPECIES", 153, 160], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 243, 251], ["the study", "TEST", 181, 190]]], ["Of those contacted, 299 patients consented to participation in the study and were included in our analysis (response rate 299/450; 66.4%) ( Fig. 2 ) .", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["the study", "TEST", 63, 72], ["our analysis", "TEST", 94, 106], ["response rate", "TEST", 108, 121]]], ["The patient population for the study consisted of patients from a broad range of orthopaedic subspecialty clinics.", [["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 50, 58], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 50, 58], ["the study", "TEST", 27, 36]]], ["Stratification of encounter by visit type can be seen in Table 4 .Patient response dataPatients reported that surgeons were able to be sensitive to their needs and demonstrated appropriate response to their concerns rating the surgeon as 'good' or 'very good' 95% of the time (284/299 and 283/299, respectively) ( Fig. 3 ) .", [["Patient", "SPECIES", 66, 73]]], ["When asked if they would complete another telemedicine encounter again, if given the chance, 92.9% (278/299) of patients reported they would.Patient response dataPre-pandemic, 94.8% (479/505) of patients reported that they perceived surgeon's sensitivity to their needs as 'good' or 'very good', and 94.4% (457/484) rated the surgeon's response to their concerns as 'good' or 'very good. '", [["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 112, 120], ["Patient", "SPECIES", 141, 148], ["patients", "SPECIES", 195, 203], ["-pandemic", "TEST", 165, 174]]], ["Patient response data from pre-pandemic in-person and telemedicine encounters was analysed.", [["Patient", "SPECIES", 0, 7], ["person", "SPECIES", 43, 49]]], ["There was no statistical difference in patient-reported surgeon sensitivity ( \u03c72 = 0.00, p = 1.00) and response to concerns ( \u03c72 = 0.44, p = 0.506).DiscussionThe rapid expansion of telemedicine in the orthopaedic setting during the initial months of the COVID-19 pandemic was driven by public health, institutional guidelines, and changes in reimbursement frameworks to allow for billing comparable to inperson encounters [2] .", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["surgeon sensitivity", "TEST", 56, 75], ["\u03c72", "TEST", 126, 128], ["p", "TEST", 137, 138], ["the COVID", "TEST", 250, 259], ["changes in reimbursement frameworks", "TREATMENT", 331, 366], ["no", "UNCERTAINTY", 10, 12]]], ["It occurred without the knowledge whether telemedicine could adequately replace visits and uncertain attitudes from surgeons and patients.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137]]], ["During our study period, over 600 telemedicine encounters were performed with extremely favourable ratings from patients and surgeons.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120]]], ["Telemedicine appears to have quickly established itself as a useful orthopaedic outpatient care modality in selected patients and will continue to be utilized in the post-pandemic era.DiscussionThe acceptance of orthopaedic telemedicine in our truly outpatient setting is a novel finding.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125]]], ["Pre-pandemic literature largely focused on the utilization of communications technology to facilitate in-patient and in-clinic encounters in settings where access to care by orthopaedic surgeons was limited by large geographic distances [ 5 , 10-12 ] .", [["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["communications technology", "TREATMENT", 62, 87], ["large", "OBSERVATION_MODIFIER", 210, 215]]], ["Since the onset of the COVID-19 pandemic, expanded interest in telemedicine has led to the publishing of guidelines and techniques for videobased physical assessment without trained assistants [13] .", [["the COVID", "TEST", 19, 28], ["pandemic", "PROBLEM", 32, 40], ["videobased physical assessment", "TEST", 135, 165]]], ["Most recently, Tenforde et al. surveyed patients and providers completing telemedicine encounters from a physical medicine and rehabilitation practice where 119 patients and 13 physiatrists conveyed overall positive and useful ratings of the encounters [14] .", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 161, 169]]], ["In our practice of patients receiving both surgical and non-surgical care, 95.0% rated providers as good or very good which is comparable to prepandemic in patient encounters (95.0%).", [["patients", "ORGANISM", 19, 27], ["patient", "ORGANISM", 156, 163], ["patients", "SPECIES", 19, 27], ["patient", "SPECIES", 156, 163], ["both surgical", "TREATMENT", 38, 51], ["non-surgical care", "TREATMENT", 56, 73]]], ["Additionally, responsiveness to concerns was also the same (95.0 vs 94.4%) with no statistical difference between in-person and telemedicine ratings.DiscussionThere is limited information regarding physician or surgeon attitudes on telehealth encounters performed without a trained representative with the patient.", [["patient", "ORGANISM", 306, 313], ["person", "SPECIES", 117, 123], ["patient", "SPECIES", 306, 313]]], ["At our institution, we had similar satisfaction with both video and telephone encounters with no significant difference between modalities.", [["significant difference between modalities", "PROBLEM", 97, 138]]], ["This suggests that telemedicine, either via phone or video, can be utilized appropriately in all facets of outpatient orthopaedic care.", [["outpatient orthopaedic care", "TREATMENT", 107, 134]]], ["We did not stratify the results of our patient satisfaction data by age, however, there has been a previously documented influence in telehealth satisfaction [ 15 , 16 ] .DiscussionThe current study, while an important first question in evaluating telehealth applications, does not provide a complete picture of the nuances and outcomes important to its eventual success.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["The current study", "TEST", 181, 198]]], ["However, the efficacy and safety of this technology must also be proven, something that will require additional study and further review.", [["additional study", "TEST", 101, 117], ["further review", "TEST", 122, 136]]], ["Further investigation is required to evaluate potential variables that may modulate the effectiveness of telemedicine care in orthopaedics.", [["Further investigation", "TEST", 0, 21], ["telemedicine care", "TREATMENT", 105, 122]]], ["There were several limitations of our survey-based study.", [["our survey", "TEST", 34, 44], ["based study", "TEST", 45, 56]]], ["Given the current pandemic setting, many patients expressed concern for exposure when presenting to the outpatient clinics of the medical centre which may have enhanced the patient's willingness to perform telemedicine.", [["patients", "ORGANISM", 41, 49], ["patient", "ORGANISM", 173, 180], ["patients", "SPECIES", 41, 49], ["patient", "SPECIES", 173, 180]]], ["Patient satisfaction and willingness to repeat telemedicine encounters may be diminished if concern for exposure is diminished, and furthermore patient satisfaction could be related more simply to the fact that they did not have to present to an institution treating Covid-19 patients.", [["patient", "ORGANISM", 144, 151], ["patients", "ORGANISM", 276, 284], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 144, 151], ["patients", "SPECIES", 276, 284], ["diminished", "PROBLEM", 116, 126]]], ["Additionally, our patient response rate was 66.4% and therefore does not represent the entire population of patients participating in telemedicine visits; however it approaches 70% which is good for an unsolicited telephone survey.", [["patient", "ORGANISM", 18, 25], ["patients", "ORGANISM", 108, 116], ["patient", "SPECIES", 18, 25], ["patients", "SPECIES", 108, 116], ["our patient response rate", "TEST", 14, 39]]], ["Additionally, the discrepancy between the patient and surgeon response rate (66.4% v 78.6%) can likely be contributed to the fact that all providers who consented were included and more likely engaged in the project given their commitment to the study.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["surgeon response rate", "TEST", 54, 75], ["the study", "TEST", 242, 251]]], ["Second, the expansion of telemedicine was enabled in part by the CMS waiver allowing for increased reimbursement for remote encounters.", [["expansion", "OBSERVATION_MODIFIER", 12, 21]]], ["Third, the decision to indicate a patient for in-person vs telemedicine encounter was at the discretion of the surgeon.", [["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41]]], ["While there are described, validated telehealth physical examination findings these remain limited [ 9 , 17 , 18 ] .", [["validated telehealth physical examination", "TEST", 27, 68]]], ["Additionally, visits requiring imaging or small procedures (suture removal etc.) cannot currently be addressed through a telemedicine visit.", [["imaging", "TEST", 31, 38], ["small procedures", "TREATMENT", 42, 58], ["suture removal", "TREATMENT", 60, 74], ["small", "OBSERVATION_MODIFIER", 42, 47]]], ["Thus, our patient population represents a highly selected population.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["highly", "OBSERVATION_MODIFIER", 42, 48]]], ["For this reason, we are not suggesting that a blanket replacement of all in-person visits is a viable solution, rather, is successful when providers participate in the triage of clinical encounter type.", [["a blanket replacement", "TREATMENT", 44, 65], ["not suggesting", "UNCERTAINTY", 24, 38]]], ["While this does not disqualify our favourable results, we acknowledge that telemedicine in the current form will not be a replacement for many orthopaedic encounters.", [["a replacement", "TREATMENT", 120, 133]]], ["Lastly, this study occurred during a period of rapid and unexpected implementation of telemedicine at the time of the pandemic.", [["this study", "TEST", 8, 18], ["telemedicine", "TREATMENT", 86, 98], ["the pandemic", "PROBLEM", 114, 126]]], ["This required a steep learning curve for patients and providers which was not without nuance.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["a steep learning curve", "TREATMENT", 14, 36]]], ["This suggests that overall, an algorithmic approach incorporating visit type, chief complaint, and the potential need for additional imaging/physical examination may further refine the deployment of telemedicine.ARTICLE IN PRESSFuture directions in the maturation of telemedicine applications in orthopaedic surgery are numerous, especially gaining a better understanding of what criteria make a telemedicine visit a reasonable or even favourable option for a patient encounter.", [["patient", "ORGANISM", 460, 467], ["patient", "SPECIES", 460, 467], ["additional imaging/physical examination", "TEST", 122, 161], ["telemedicine applications", "TREATMENT", 267, 292], ["orthopaedic surgery", "TREATMENT", 296, 315], ["overall", "OBSERVATION_MODIFIER", 19, 26]]], ["This may include factors such as body area (i.e. hand vs. spine), acuity of the presenting problem or whether a patient is new or established in the practice.", [["body area", "ANATOMY", 33, 42], ["hand", "ANATOMY", 49, 53], ["spine", "ANATOMY", 58, 63], ["body", "ORGANISM_SUBDIVISION", 33, 37], ["hand", "ORGANISM_SUBDIVISION", 49, 53], ["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["body area (i.e. hand vs. spine)", "PROBLEM", 33, 64], ["spine", "ANATOMY", 58, 63]]], ["Additionally, further research into the economic impact of telemedicine on the delivery of care both at an institutional and societal level will be critical to determining the value of this mode of care.ConclusionOur findings suggest that there is utility for the incorporation for telemedicine into outpatient orthopaedic care.", [["the delivery of care", "TREATMENT", 75, 95], ["outpatient orthopaedic care", "TREATMENT", 300, 327]]], ["Telemedicine does not appear to be a replacement for all in-person clinic encounters, however, when used in the appropriate context patients and surgeons viewed the encounters favourably and this tool successfully facilitates the delivery of orthopaedic outpatient care.Declaration of Competing InterestNone of our authors have conflicts of interests to disclose.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["a replacement", "TREATMENT", 35, 48], ["orthopaedic outpatient care", "TREATMENT", 242, 269], ["replacement", "OBSERVATION", 37, 48]]], ["We have no sources of funding for this manuscript to declare.Appendix A. Survey InstrumentsFaculty phone survey We are calling to ask you to participate in a brief phone survey as part of a research study about your recent telehealth doctor's visit.", [["no sources of", "UNCERTAINTY", 8, 21]]], ["The purpose of this research is to evaluate patient and doctor's satisfaction with phone or video visits and should only take about one to two minutes.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51]]]], "ee2254bc1c223852d30fe7d8fcf44dee6c8dd854": [["25.6-57.6) of cases, while the rate of perinatal death was 7.0% (95% CI 1.", [["death", "DISEASE", 49, 54], ["perinatal death", "TEST", 39, 54], ["CI", "TEST", 69, 71]]], ["None of the 41 84 newborns assessed showed clinical signs of vertical transmission.", [["newborns", "ORGANISM", 18, 26], ["vertical transmission", "PROBLEM", 61, 82], ["vertical transmission", "OBSERVATION", 61, 82]]]], "PMC7252092": [["IntroductionThe Coronavirus Disease 2019 (COVID-19) epidemic began in Wuhan, China, in December 2019.1 On January 1st, 2020, WHO announced that this outbreak represents an international public health emergency, affecting 2,725,920 people by April 24, 2020, causing, 191,061 deaths.2 On February 11, The International Committee on Taxonomy of Viruses has made public the name of the virus causing COVID-19: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).3", [["Coronavirus Disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["deaths", "DISEASE", 274, 280], ["COVID-19", "CHEMICAL", 396, 404], ["acute respiratory syndrome coronavirus", "DISEASE", 413, 451], ["people", "ORGANISM", 231, 237], ["COVID-19", "ORGANISM", 396, 404], ["people", "SPECIES", 231, 237], ["COVID-19: severe acute respiratory syndrome coronavirus", "SPECIES", 396, 451], ["SARS-CoV-2", "SPECIES", 455, 465], ["The Coronavirus Disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["epidemic", "PROBLEM", 52, 60], ["COVID", "TEST", 396, 401], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 406, 451], ["SARS", "TEST", 455, 459], ["CoV", "TEST", 460, 463], ["Coronavirus Disease", "OBSERVATION", 16, 35], ["severe", "OBSERVATION_MODIFIER", 406, 412], ["acute", "OBSERVATION_MODIFIER", 413, 418], ["respiratory syndrome", "OBSERVATION", 419, 439]]]], "PMC7438844": [["IntroductionThe severe acute respiratory syndrome coronavirus2 (SARS-CoV2) causative agent of the coronavirus disease of 2019 (COVID-19), belongs to the coronaviridae family.", [["acute respiratory syndrome coronavirus2", "DISEASE", 23, 62], ["SARS-CoV2)", "DISEASE", 64, 74], ["coronavirus disease", "DISEASE", 98, 117], ["COVID-19", "CHEMICAL", 127, 135], ["SARS-CoV2", "ORGANISM", 64, 73], ["COVID-19", "ORGANISM", 127, 135], ["coronaviridae", "GENE_OR_GENE_PRODUCT", 153, 166], ["coronaviridae family", "PROTEIN", 153, 173], ["coronavirus", "SPECIES", 98, 109], ["severe acute respiratory syndrome coronavirus2 (SARS-CoV2)", "SPECIES", 16, 74], ["The severe acute respiratory syndrome coronavirus2", "PROBLEM", 12, 62], ["the coronavirus disease", "PROBLEM", 94, 117], ["COVID", "TEST", 127, 132], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome", "OBSERVATION", 29, 49], ["coronavirus disease", "OBSERVATION", 98, 117]]], ["The first outbreak of SARS-CoV2 infection is associated with the wet markets of Wuhan, China, suggesting the zoonotic origin of this virus (Mackenzie and Smith, 2020).", [["SARS-CoV2 infection", "DISEASE", 22, 41], ["SARS-CoV2", "ORGANISM", 22, 31], ["SARS", "PROBLEM", 22, 26], ["CoV2 infection", "PROBLEM", 27, 41], ["outbreak", "OBSERVATION_MODIFIER", 10, 18], ["SARS", "OBSERVATION", 22, 26], ["CoV2", "OBSERVATION_MODIFIER", 27, 31], ["infection", "OBSERVATION", 32, 41], ["zoonotic", "OBSERVATION_MODIFIER", 109, 117]]], ["Although SARS viruses are known to infect animals, in certain cases, the viruses may cross species barrier and infect humans (Rabi et al., 2020).", [["SARS viruses", "DISEASE", 9, 21], ["SARS viruses", "ORGANISM", 9, 21], ["humans", "ORGANISM", 118, 124], ["humans", "SPECIES", 118, 124], ["SARS viruses", "SPECIES", 9, 21], ["humans", "SPECIES", 118, 124], ["SARS viruses", "PROBLEM", 9, 21], ["the viruses", "PROBLEM", 69, 80]]], ["Since the initial outbreak of COVID-19, it has become a serious threat to public health worldwide (Rabi et al., 2020).", [["COVID-19", "CHEMICAL", 30, 38], ["COVID", "TEST", 30, 35], ["serious", "OBSERVATION_MODIFIER", 56, 63]]], ["As of 5th July, 2020 COVID-19 has spread to more than 216 countries and territories, with 11,046,917 confirmed cases and 526,465 deaths across the globe.", [["deaths", "DISEASE", 129, 135], ["COVID", "TEST", 21, 26], ["globe", "ANATOMY", 147, 152]]], ["Nonetheless, European regions report 199,510 deaths with more than 2 million confirmed cases (WHO, 2020 COVID-19 dashboard, July 5th, 2020).IntroductionCOVID-19 symptoms majorly include breathing difficulty, lung infection, pneumonia, and fever (Aghagoli et al., 2020).", [["lung", "ANATOMY", 208, 212], ["deaths", "DISEASE", 45, 51], ["breathing difficulty", "DISEASE", 186, 206], ["lung infection", "DISEASE", 208, 222], ["pneumonia", "DISEASE", 224, 233], ["fever", "DISEASE", 239, 244], ["lung", "ORGAN", 208, 212], ["IntroductionCOVID", "TEST", 140, 157], ["symptoms", "PROBLEM", 161, 169], ["breathing difficulty", "PROBLEM", 186, 206], ["lung infection", "PROBLEM", 208, 222], ["pneumonia", "PROBLEM", 224, 233], ["fever", "PROBLEM", 239, 244], ["lung", "ANATOMY", 208, 212], ["infection", "OBSERVATION", 213, 222], ["pneumonia", "OBSERVATION", 224, 233]]], ["Emerging data depicts that COVID-19 patients have various aspects associated with hospitalization and severity.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 27, 32], ["severity", "PROBLEM", 102, 110]]], ["Nevertheless, the risk factors associated with SARS-CoV2 infection can be one or more such as cardiovascular diseases, hypertension, lung diseases, diabetes, etc. which may enhance susceptibility, complications, and mortality (Clerkin et al., 2020; Guo et al., 2020; Richardson et al., 2020; Yang et al., 2020).", [["cardiovascular", "ANATOMY", 94, 108], ["lung", "ANATOMY", 133, 137], ["SARS-CoV2 infection", "DISEASE", 47, 66], ["cardiovascular diseases", "DISEASE", 94, 117], ["hypertension", "DISEASE", 119, 131], ["lung diseases", "DISEASE", 133, 146], ["diabetes", "DISEASE", 148, 156], ["SARS-CoV2", "ORGANISM", 47, 56], ["lung", "ORGAN", 133, 137], ["the risk factors", "PROBLEM", 14, 30], ["SARS", "PROBLEM", 47, 51], ["CoV2 infection", "PROBLEM", 52, 66], ["cardiovascular diseases", "PROBLEM", 94, 117], ["hypertension", "PROBLEM", 119, 131], ["lung diseases", "PROBLEM", 133, 146], ["diabetes", "PROBLEM", 148, 156], ["complications", "PROBLEM", 197, 210], ["infection", "OBSERVATION", 57, 66], ["hypertension", "OBSERVATION", 119, 131], ["lung", "ANATOMY", 133, 137], ["diseases", "OBSERVATION", 138, 146], ["diabetes", "OBSERVATION", 148, 156]]], ["Interestingly, an increase in the number of COVID-19 patients with comorbidities is reported (Guo et al., 2020).", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["COVID", "TEST", 44, 49], ["comorbidities", "PROBLEM", 67, 80], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["number", "OBSERVATION_MODIFIER", 34, 40]]], ["The reasons for the exclusive relation of certain comorbidities with COVID-19 may be many.", [["COVID-19", "CHEMICAL", 69, 77], ["certain comorbidities", "PROBLEM", 42, 63], ["COVID", "TEST", 69, 74]]], ["It is reported that the virus attacks the smallest of the blood vessels\u2019 endothelial lining, thereby leading to circulation problems and impaired vessels functioning in various organs (Sardu et al., 2020).", [["blood vessels", "ANATOMY", 58, 71], ["endothelial lining", "ANATOMY", 73, 91], ["vessels", "ANATOMY", 146, 153], ["organs", "ANATOMY", 177, 183], ["impaired vessels functioning", "DISEASE", 137, 165], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 58, 71], ["endothelial lining", "TISSUE", 73, 91], ["vessels", "MULTI-TISSUE_STRUCTURE", 146, 153], ["organs", "ORGAN", 177, 183], ["the virus attacks", "PROBLEM", 20, 37], ["circulation problems", "PROBLEM", 112, 132], ["impaired vessels functioning in various organs", "PROBLEM", 137, 183], ["virus", "OBSERVATION", 24, 29], ["smallest", "OBSERVATION_MODIFIER", 42, 50], ["blood vessels", "ANATOMY", 58, 71], ["endothelial", "ANATOMY", 73, 84], ["lining", "ANATOMY_MODIFIER", 85, 91], ["circulation", "OBSERVATION_MODIFIER", 112, 123], ["impaired", "OBSERVATION_MODIFIER", 137, 145], ["vessels", "OBSERVATION", 146, 153], ["organs", "ANATOMY", 177, 183]]], ["This can also explain the high vulnerability of patients with comorbidities like hypertension, obesity, diabetes, and cardiovascular disease.", [["cardiovascular", "ANATOMY", 118, 132], ["hypertension", "DISEASE", 81, 93], ["obesity", "DISEASE", 95, 102], ["diabetes", "DISEASE", 104, 112], ["cardiovascular disease", "DISEASE", 118, 140], ["patients", "ORGANISM", 48, 56], ["cardiovascular", "ANATOMICAL_SYSTEM", 118, 132], ["patients", "SPECIES", 48, 56], ["comorbidities", "PROBLEM", 62, 75], ["hypertension", "PROBLEM", 81, 93], ["obesity", "PROBLEM", 95, 102], ["diabetes", "PROBLEM", 104, 112], ["cardiovascular disease", "PROBLEM", 118, 140], ["high vulnerability", "OBSERVATION_MODIFIER", 26, 44], ["hypertension", "OBSERVATION", 81, 93], ["obesity", "OBSERVATION", 95, 102], ["diabetes", "OBSERVATION", 104, 112], ["cardiovascular disease", "OBSERVATION", 118, 140]]], ["Besides, renal histopathological findings of COVID-19 patients show damaged endothelium (Su et al., 2020).", [["renal", "ANATOMY", 9, 14], ["endothelium", "ANATOMY", 76, 87], ["renal", "ORGAN", 9, 14], ["patients", "ORGANISM", 54, 62], ["endothelium", "TISSUE", 76, 87], ["patients", "SPECIES", 54, 62], ["COVID", "TEST", 45, 50], ["damaged endothelium", "PROBLEM", 68, 87], ["renal", "ANATOMY", 9, 14], ["histopathological", "OBSERVATION", 15, 32], ["damaged endothelium", "OBSERVATION", 68, 87]]], ["Additionally, studies have established the presence of inflammatory cells and viral elements within the endothelial cells of COVID-19 patients.", [["inflammatory cells", "ANATOMY", 55, 73], ["endothelial cells", "ANATOMY", 104, 121], ["inflammatory cells", "CELL", 55, 73], ["endothelial cells", "CELL", 104, 121], ["COVID-19", "CELL", 125, 133], ["patients", "ORGANISM", 134, 142], ["inflammatory cells", "CELL_TYPE", 55, 73], ["viral elements", "DNA", 78, 92], ["endothelial cells", "CELL_TYPE", 104, 121], ["patients", "SPECIES", 134, 142], ["studies", "TEST", 14, 21], ["inflammatory cells", "PROBLEM", 55, 73], ["viral elements", "PROBLEM", 78, 92], ["COVID", "TEST", 125, 130], ["inflammatory cells", "OBSERVATION", 55, 73], ["viral elements", "OBSERVATION", 78, 92], ["endothelial cells", "OBSERVATION", 104, 121]]], ["Bilateral diffuse alveolar damage with cellular fibromyxoid exudates and pulmonary oedema is observed in post-mortem samples of COVID-19 patients (Xu et al., 2020).", [["alveolar", "ANATOMY", 18, 26], ["cellular fibromyxoid exudates", "ANATOMY", 39, 68], ["pulmonary", "ANATOMY", 73, 82], ["post-mortem samples", "ANATOMY", 105, 124], ["alveolar damage", "DISEASE", 18, 33], ["pulmonary oedema", "DISEASE", 73, 89], ["alveolar", "MULTI-TISSUE_STRUCTURE", 18, 26], ["cellular", "CELL", 39, 47], ["fibromyxoid exudates", "TISSUE", 48, 68], ["pulmonary", "ORGAN", 73, 82], ["post-mortem samples", "CANCER", 105, 124], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["Bilateral diffuse alveolar damage", "PROBLEM", 0, 33], ["cellular fibromyxoid exudates", "PROBLEM", 39, 68], ["pulmonary oedema", "PROBLEM", 73, 89], ["diffuse", "OBSERVATION_MODIFIER", 10, 17], ["alveolar", "ANATOMY_MODIFIER", 18, 26], ["damage", "OBSERVATION", 27, 33], ["cellular", "OBSERVATION_MODIFIER", 39, 47], ["fibromyxoid exudates", "OBSERVATION", 48, 68], ["pulmonary", "ANATOMY", 73, 82], ["oedema", "OBSERVATION", 83, 89]]], ["Therefore, the multi-organ failure observed in COVID-19 may be due to damage to the endothelium caused by either direct virus infection or immune cells recruitment to the site of infection (Zaim et al., 2020).", [["multi-organ", "ANATOMY", 15, 26], ["endothelium", "ANATOMY", 84, 95], ["immune cells", "ANATOMY", 139, 151], ["site", "ANATOMY", 171, 175], ["multi-organ failure", "DISEASE", 15, 34], ["COVID-19", "CHEMICAL", 47, 55], ["damage to the endothelium", "DISEASE", 70, 95], ["infection", "DISEASE", 126, 135], ["infection", "DISEASE", 179, 188], ["COVID-19", "CHEMICAL", 47, 55], ["COVID-19", "GENE_OR_GENE_PRODUCT", 47, 55], ["endothelium", "TISSUE", 84, 95], ["immune cells", "CELL", 139, 151], ["immune cells", "CELL_TYPE", 139, 151], ["the multi-organ failure", "PROBLEM", 11, 34], ["COVID", "TEST", 47, 52], ["damage to the endothelium", "PROBLEM", 70, 95], ["direct virus infection", "PROBLEM", 113, 135], ["immune cells recruitment", "TREATMENT", 139, 163], ["infection", "PROBLEM", 179, 188], ["multi-organ", "ANATOMY", 15, 26], ["failure", "OBSERVATION", 27, 34], ["endothelium", "ANATOMY", 84, 95], ["immune cells", "OBSERVATION", 139, 151], ["infection", "OBSERVATION", 179, 188]]], ["Fascinating studies also suggest an enhanced death rate for COVID-19 patients who possess one of the comorbidities mentioned above.", [["death", "DISEASE", 45, 50], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Fascinating studies", "TEST", 0, 19], ["an enhanced death rate", "PROBLEM", 33, 55], ["the comorbidities", "PROBLEM", 97, 114], ["enhanced", "OBSERVATION_MODIFIER", 36, 44], ["death", "OBSERVATION", 45, 50], ["comorbidities", "OBSERVATION", 101, 114]]], ["A summarized report addressed that the overall case-fatality rate (2.3%) increased for COVID-19 patients with already prevailing comorbid conditions such as cardiovascular disease (10.5%), diabetes (7.3%), chronic respiratory disease (6.3%) and hypertension (6.0%) (Wu and McGoogan, 2020).", [["cardiovascular", "ANATOMY", 157, 171], ["respiratory", "ANATOMY", 214, 225], ["cardiovascular disease", "DISEASE", 157, 179], ["diabetes", "DISEASE", 189, 197], ["chronic respiratory disease", "DISEASE", 206, 233], ["hypertension", "DISEASE", 245, 257], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["fatality rate", "TEST", 52, 65], ["already prevailing comorbid conditions", "PROBLEM", 110, 148], ["cardiovascular disease", "PROBLEM", 157, 179], ["diabetes", "PROBLEM", 189, 197], ["chronic respiratory disease", "PROBLEM", 206, 233], ["hypertension", "PROBLEM", 245, 257], ["cardiovascular", "ANATOMY", 157, 171], ["chronic", "OBSERVATION_MODIFIER", 206, 213], ["respiratory disease", "OBSERVATION", 214, 233], ["hypertension", "OBSERVATION", 245, 257]]], ["A prospective cohort study related the prevalence of acute kidney injury in COVID-19 patients with in-hospital mortality (Cheng et al., 2020).", [["kidney", "ANATOMY", 59, 65], ["acute kidney injury", "DISEASE", 53, 72], ["kidney", "ORGAN", 59, 65], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["A prospective cohort study", "TEST", 0, 26], ["acute kidney injury", "PROBLEM", 53, 72], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["kidney", "ANATOMY", 59, 65], ["injury", "OBSERVATION", 66, 72]]], ["Moreover, considering various reports on COVID-19 comorbid hospitalized cases and deaths we quantitatively analyzed the relation of hospitalized cases and death reports with one or more comorbidities in this pandemic situation.IntroductionFurthermore, there might be a correlation between COVID-19 medications and deaths due to comorbidity in COVID-19.", [["deaths", "DISEASE", 82, 88], ["death", "DISEASE", 155, 160], ["deaths", "DISEASE", 314, 320], ["COVID-19 medications", "TREATMENT", 289, 309], ["comorbidity", "PROBLEM", 328, 339], ["COVID", "TEST", 343, 348]]], ["The medication regimen may vary among countries.", [["The medication regimen", "TREATMENT", 0, 22]]], ["Notably, it increases perplexity in this concern.", [["increases", "OBSERVATION_MODIFIER", 12, 21], ["perplexity", "OBSERVATION", 22, 32]]], ["Thus death reports associated with particular comorbidity may also vary among countries.", [["death", "DISEASE", 5, 10], ["particular comorbidity", "PROBLEM", 35, 57]]], ["Hence, there is a need for prudent selection of medication for COVID-19 patients with already prevailing comorbidities.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["prudent selection of medication", "TREATMENT", 27, 58], ["COVID", "TREATMENT", 63, 68], ["already prevailing comorbidities", "PROBLEM", 86, 118]]], ["Our study provides a glimpse of the need for repurposed COVID-19 drugs on associated comorbidity based on previous studies.", [["COVID-19", "CHEMICAL", 56, 64], ["Our study", "TEST", 0, 9], ["repurposed COVID-19 drugs", "TREATMENT", 45, 70], ["associated comorbidity", "PROBLEM", 74, 96], ["previous studies", "TEST", 106, 122]]], ["This may further help for better design of the COVID-19 medication regimen in patients with prevailing health conditions.Data Collection ::: Materials and MethodsWe acquired the data of COVID-19 patients with associated comorbidities from countries, namely France, Italy, Netherlands, Spain, and Sweden.", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 195, 203], ["the COVID-19 medication regimen", "TREATMENT", 43, 74], ["COVID", "TEST", 186, 191], ["associated comorbidities", "PROBLEM", 209, 233]]], ["Namely, the open access portals of European Centre for Disease Prevention and Control (ECDC), French Public Health Agency, Italian National Institute of Health, National Institute of Public Health and the Environment Netherlands, The Institute of Health Carlos III Spain, The Public Health Agency of Sweden have been accessed.", [["Disease Prevention", "TREATMENT", 55, 73]]], ["The information about numbers of hospitalized or deceased COVID-19 patients with associated comorbidities from individual countries was already provided in their respective reports.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["associated comorbidities", "PROBLEM", 81, 105]]], ["We selected, assembled, and categorized the data based on hospitalized and deceased COVID-19 patients with associated comorbidities in Table 1.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["One patient may have been included in more than one comorbidity group.Data Collection ::: Materials and MethodsThe retrieved data ranges within a time interval until 23rd April 2020.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Methods", "TREATMENT", 104, 111]]], ["Specifically, for France, Netherlands, Spain, and Sweden the timespan for hospitalized as well as death data was 16/03/2020 to 21/04/2020, 27/02/2020 to 10/04/2020, 31/01/2020 to 22/04/2020 and 13/04/2020 to 19/04/2020, respectively.", [["death", "DISEASE", 98, 103], ["death data", "TEST", 98, 108]]], ["In the case of France, the data for comorbidities like hypertension and liver diseases was available for 16/03/2020 to 04/04/2020 period only.", [["liver", "ANATOMY", 72, 77], ["hypertension", "DISEASE", 55, 67], ["liver diseases", "DISEASE", 72, 86], ["liver", "ORGAN", 72, 77], ["comorbidities", "PROBLEM", 36, 49], ["hypertension", "PROBLEM", 55, 67], ["liver diseases", "PROBLEM", 72, 86], ["hypertension", "OBSERVATION", 55, 67], ["liver", "ANATOMY", 72, 77], ["diseases", "OBSERVATION", 78, 86]]], ["For Italy, the deceased patient\u2019s data was obtained from the report of the Italian National Institute of Health, the timespan for which was 21/02/2020 to 23/04/2020.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31]]], ["The hospitalized patients data was absent in this report, so it has been obtained from ECDC rapid risk assessment report 8th update on COVID-19 where timespan for patient\u2019s data is not available.", [["patients", "ORGANISM", 17, 25], ["patient", "ORGANISM", 163, 170], ["patients", "SPECIES", 17, 25], ["patient", "SPECIES", 163, 170], ["COVID", "TEST", 135, 140], ["patient\u2019s data", "TEST", 163, 177]]], ["We have also verified this translation results using other platforms like Bing Microsoft Translator, 20202 and Yandex.Translate, 20203.Data Collection ::: Materials and MethodsWe performed a literature survey for adverse effects of medications generally given to individuals with included comorbidities or for COVID-19 treatments.", [["medications", "TREATMENT", 232, 243], ["comorbidities", "PROBLEM", 289, 302], ["COVID-19 treatments", "TREATMENT", 310, 329]]], ["These medications and their possible mechanism have been included in Table 2.Statistical Analysis ::: Materials and MethodsA two-sample t-test between the proportions of hospitalized and deceased patients with various comorbidities (heart diseases, diabetes, kidney, liver diseases, immunodeficiency, and neurological disorders) from different countries (France, Italy, Netherlands, Spain, and Sweden) was performed separately to determine whether there was a significant difference between hospitalized patients and the subsequent deaths due to particular comorbidity with respect to the percent of affected individuals in the respective country.", [["heart", "ANATOMY", 233, 238], ["kidney", "ANATOMY", 259, 265], ["liver", "ANATOMY", 267, 272], ["neurological", "ANATOMY", 305, 317], ["heart diseases", "DISEASE", 233, 247], ["diabetes", "DISEASE", 249, 257], ["kidney, liver diseases", "DISEASE", 259, 281], ["immunodeficiency", "DISEASE", 283, 299], ["neurological disorders", "DISEASE", 305, 327], ["deaths", "DISEASE", 532, 538], ["patients", "ORGANISM", 196, 204], ["heart", "ORGAN", 233, 238], ["kidney", "ORGAN", 259, 265], ["liver", "ORGAN", 267, 272], ["patients", "ORGANISM", 504, 512], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 504, 512], ["These medications", "TREATMENT", 0, 17], ["MethodsA", "TEST", 116, 124], ["sample t-test", "TEST", 129, 142], ["various comorbidities", "PROBLEM", 210, 231], ["heart diseases", "PROBLEM", 233, 247], ["diabetes", "PROBLEM", 249, 257], ["kidney, liver diseases", "PROBLEM", 259, 281], ["immunodeficiency", "PROBLEM", 283, 299], ["neurological disorders", "PROBLEM", 305, 327], ["particular comorbidity", "PROBLEM", 546, 568], ["heart", "ANATOMY", 233, 238], ["diseases", "OBSERVATION", 239, 247], ["kidney", "ANATOMY", 259, 265], ["liver", "ANATOMY", 267, 272], ["immunodeficiency", "OBSERVATION", 283, 299], ["significant", "OBSERVATION_MODIFIER", 460, 471]]], ["The t-statistic was significant at the 0.05 critical alpha level, p < 0.05 at CI-95%.ResultsThe number of hospitalized COVID-19 patients with at least one comorbidity along with the death reports, as a consequence of the disease, from various countries is enlisted in Table 1.", [["death", "DISEASE", 182, 187], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["CI", "TEST", 78, 80], ["the disease", "PROBLEM", 217, 228], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["disease", "OBSERVATION", 221, 228]]], ["The death proportions due to Heart Diseases including, cardiovascular diseases and hypertension, were significantly higher (p < 0.0001) compared to the total hospitalized patients in Italy, Sweden, and Spain.", [["Heart", "ANATOMY", 29, 34], ["cardiovascular", "ANATOMY", 55, 69], ["death", "DISEASE", 4, 9], ["Heart Diseases", "DISEASE", 29, 43], ["cardiovascular diseases", "DISEASE", 55, 78], ["hypertension", "DISEASE", 83, 95], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["The death proportions", "PROBLEM", 0, 21], ["Heart Diseases", "PROBLEM", 29, 43], ["cardiovascular diseases", "PROBLEM", 55, 78], ["hypertension", "PROBLEM", 83, 95], ["Heart", "ANATOMY", 29, 34], ["Diseases", "OBSERVATION", 35, 43], ["cardiovascular", "ANATOMY", 55, 69], ["diseases", "OBSERVATION", 70, 78], ["hypertension", "OBSERVATION", 83, 95], ["significantly", "OBSERVATION_MODIFIER", 102, 115], ["higher", "OBSERVATION_MODIFIER", 116, 122]]], ["Although the proportion of death reports with respect to hospitalized patients is higher while not significant (p = 0.1468) for the Netherlands.", [["death", "DISEASE", 27, 32], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["In addition, the estimated deaths due to cardiovascular diseases are significantly (p < 0.0001) higher than hypertension (p = 0.231) in France.", [["cardiovascular", "ANATOMY", 41, 55], ["deaths", "DISEASE", 27, 33], ["cardiovascular diseases", "DISEASE", 41, 64], ["hypertension", "DISEASE", 108, 120], ["the estimated deaths", "PROBLEM", 13, 33], ["cardiovascular diseases", "PROBLEM", 41, 64], ["hypertension", "PROBLEM", 108, 120], ["cardiovascular", "ANATOMY", 41, 55], ["diseases", "OBSERVATION", 56, 64]]], ["The population of deceased diabetic patients to hospitalized patients is highly significant (p < 0.0001) in Italy and Spain, unlike the Netherlands (p = 0.3906) and Sweden (p = 0.5814).", [["diabetic", "DISEASE", 27, 35], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 61, 69], ["significant", "OBSERVATION_MODIFIER", 80, 91]]], ["However, France shows significance in death reports due to diabetes (p = 0.0134) compared to the hospitalized population.", [["death", "DISEASE", 38, 43], ["diabetes", "DISEASE", 59, 67], ["death", "PROBLEM", 38, 43], ["diabetes", "PROBLEM", 59, 67]]], ["Furthermore, lung diseases being most widely associated with COVID-19 death influence a majority of individuals in various countries.", [["lung", "ANATOMY", 13, 17], ["lung diseases", "DISEASE", 13, 26], ["death", "DISEASE", 70, 75], ["lung", "ORGAN", 13, 17], ["lung diseases", "PROBLEM", 13, 26], ["COVID-19 death", "PROBLEM", 61, 75], ["lung", "ANATOMY", 13, 17], ["diseases", "OBSERVATION", 18, 26]]], ["However, the deaths due to lung disorders are significantly higher compared to those hospitalized in countries like Italy (p < 0.0001), Spain (p < 0.0001), France (p = 0.0007), and Sweden (p = 0.0492).", [["lung", "ANATOMY", 27, 31], ["deaths", "DISEASE", 13, 19], ["lung disorders", "DISEASE", 27, 41], ["lung", "ORGAN", 27, 31], ["lung disorders", "PROBLEM", 27, 41], ["lung", "ANATOMY", 27, 31], ["disorders", "OBSERVATION", 32, 41], ["significantly", "OBSERVATION_MODIFIER", 46, 59], ["higher", "OBSERVATION_MODIFIER", 60, 66]]], ["Further, the Netherlands has higher while no significant (p = 0.4008) deaths due to chronic lung disorder compared to hospitalized patients.", [["lung", "ANATOMY", 92, 96], ["deaths", "DISEASE", 70, 76], ["chronic lung disorder", "DISEASE", 84, 105], ["lung", "ORGAN", 92, 96], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["chronic lung disorder", "PROBLEM", 84, 105], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["no", "UNCERTAINTY", 42, 44], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["lung", "ANATOMY", 92, 96], ["disorder", "OBSERVATION", 97, 105]]], ["Moreover, deaths due to kidney diseases (Italy- p < 0.0001; Sweden- p < 0.0001; Netherlands- p = 0.0001; France- p = 0.0033) and neurological ailments (France- p = 0.0001; Netherlands- p < 0.0001) is greater than the total hospitalized patients affected by the particular comorbidity in these countries.", [["kidney", "ANATOMY", 24, 30], ["neurological", "ANATOMY", 129, 141], ["deaths", "DISEASE", 10, 16], ["kidney diseases (Italy- p < 0.0001; Sweden- p < 0.0001; Netherlands- p = 0.0001; France- p = 0.0033) and neurological ailments", "DISEASE", 24, 150], ["kidney", "ORGAN", 24, 30], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 236, 244], ["kidney diseases", "PROBLEM", 24, 39], ["neurological ailments", "TEST", 129, 150], ["kidney", "ANATOMY", 24, 30], ["diseases", "OBSERVATION", 31, 39]]], ["We obtain a significant population of immunodeficient patients dead compared to hospitalized patients in France (p = 0.0264).", [["immunodeficient", "ORGANISM", 38, 53], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 93, 101], ["immunodeficient patients dead", "PROBLEM", 38, 67], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["population", "OBSERVATION_MODIFIER", 24, 34], ["immunodeficient", "OBSERVATION", 38, 53]]], ["On the contrary, we have seen a significant reduction in the number of immunodeficient deceased individuals compared to the total hospital admitted population in the Netherlands (p = 0.0058).", [["a significant reduction", "PROBLEM", 30, 53], ["immunodeficient deceased individuals", "PROBLEM", 71, 107], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["reduction", "OBSERVATION_MODIFIER", 44, 53], ["number", "OBSERVATION_MODIFIER", 61, 67], ["immunodeficient", "OBSERVATION", 71, 86]]], ["Also, immunodeficiency seems to have no effect with respect to mortality on the hospitalized patients of Sweden (p = 1).", [["immunodeficiency", "DISEASE", 6, 22], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["immunodeficiency", "PROBLEM", 6, 22], ["immunodeficiency", "OBSERVATION", 6, 22]]], ["Deaths due to Liver diseases are least affected by SARS-CoV2 infection compared to other comorbidities under investigation.", [["Liver", "ANATOMY", 14, 19], ["Liver diseases", "DISEASE", 14, 28], ["SARS-CoV2 infection", "DISEASE", 51, 70], ["Liver", "ORGAN", 14, 19], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 51, 60], ["Liver diseases", "PROBLEM", 14, 28], ["SARS", "PROBLEM", 51, 55], ["CoV2 infection", "PROBLEM", 56, 70], ["Liver", "ANATOMY", 14, 19], ["diseases", "OBSERVATION", 20, 28], ["SARS", "OBSERVATION_MODIFIER", 51, 55], ["infection", "OBSERVATION", 61, 70]]], ["The deaths due to liver diseases are not statistically significant compared to the total hospitalized patients for the same comorbidity (Italy- p = 0.1619; Netherlands- p = 1; Sweden- p = 1).ResultsIn Table 2, the drugs which are used to treat the particular comorbidity or for COVID-19 treatment and further the possible adverse outcomes are enlisted.", [["liver", "ANATOMY", 18, 23], ["deaths", "DISEASE", 4, 10], ["liver diseases", "DISEASE", 18, 32], ["liver", "ORGAN", 18, 23], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["The deaths", "PROBLEM", 0, 10], ["liver diseases", "PROBLEM", 18, 32], ["the drugs", "TREATMENT", 210, 219], ["the particular comorbidity", "PROBLEM", 244, 270], ["COVID-19 treatment", "TREATMENT", 278, 296], ["adverse outcomes", "PROBLEM", 322, 338], ["liver", "ANATOMY", 18, 23], ["diseases", "OBSERVATION", 24, 32]]], ["Mainly the drugs were Losartan and other ACE inhibitors (ACEi), angiotensin-receptor blockers (ARBS), Chloroquine, Hydroxychloroquine, Ruxolitinib, Remdesivir, and Tocilizumab.", [["Losartan", "CHEMICAL", 22, 30], ["ACEi", "CHEMICAL", 57, 61], ["angiotensin", "CHEMICAL", 64, 75], ["ARBS", "CHEMICAL", 95, 99], ["Chloroquine", "CHEMICAL", 102, 113], ["Hydroxychloroquine", "CHEMICAL", 115, 133], ["Ruxolitinib", "CHEMICAL", 135, 146], ["Remdesivir", "CHEMICAL", 148, 158], ["Tocilizumab", "CHEMICAL", 164, 175], ["Losartan", "CHEMICAL", 22, 30], ["Chloroquine", "CHEMICAL", 102, 113], ["Hydroxychloroquine", "CHEMICAL", 115, 133], ["Ruxolitinib", "CHEMICAL", 135, 146], ["Remdesivir", "CHEMICAL", 148, 158], ["Tocilizumab", "CHEMICAL", 164, 175], ["Losartan", "SIMPLE_CHEMICAL", 22, 30], ["ACE", "GENE_OR_GENE_PRODUCT", 41, 44], ["ACEi", "SIMPLE_CHEMICAL", 57, 61], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 64, 93], ["ARBS", "SIMPLE_CHEMICAL", 95, 99], ["Chloroquine", "SIMPLE_CHEMICAL", 102, 113], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 115, 133], ["Ruxolitinib", "SIMPLE_CHEMICAL", 135, 146], ["Remdesivir", "SIMPLE_CHEMICAL", 148, 158], ["Tocilizumab", "SIMPLE_CHEMICAL", 164, 175], ["the drugs", "TREATMENT", 7, 16], ["Losartan", "TREATMENT", 22, 30], ["other ACE inhibitors", "TREATMENT", 35, 55], ["ACEi", "TREATMENT", 57, 61], ["angiotensin-receptor blockers", "TREATMENT", 64, 93], ["ARBS", "TREATMENT", 95, 99], ["Chloroquine", "TREATMENT", 102, 113], ["Hydroxychloroquine", "TREATMENT", 115, 133], ["Ruxolitinib", "TREATMENT", 135, 146], ["Remdesivir", "TREATMENT", 148, 158], ["Tocilizumab", "TREATMENT", 164, 175]]], ["Surprisingly, most of the drugs were affecting patients with cardiovascular diseases and hypertension, followed by diabetes, kidney, and neurological diseases.DiscussionAccording to a study, approximately 25% of COVID-19 positive people had at least one comorbidity associated (Guan et al., 2020).", [["cardiovascular", "ANATOMY", 61, 75], ["kidney", "ANATOMY", 125, 131], ["neurological", "ANATOMY", 137, 149], ["cardiovascular diseases", "DISEASE", 61, 84], ["hypertension", "DISEASE", 89, 101], ["diabetes, kidney, and neurological diseases", "DISEASE", 115, 158], ["patients", "ORGANISM", 47, 55], ["cardiovascular", "ANATOMICAL_SYSTEM", 61, 75], ["kidney", "ORGAN", 125, 131], ["people", "ORGANISM", 230, 236], ["patients", "SPECIES", 47, 55], ["people", "SPECIES", 230, 236], ["cardiovascular diseases", "PROBLEM", 61, 84], ["hypertension", "PROBLEM", 89, 101], ["diabetes", "PROBLEM", 115, 123], ["kidney, and neurological diseases", "PROBLEM", 125, 158], ["a study", "TEST", 182, 189], ["COVID", "TEST", 212, 217], ["hypertension", "OBSERVATION", 89, 101], ["kidney", "ANATOMY", 125, 131], ["neurological diseases", "OBSERVATION", 137, 158]]], ["The major COVID-19 related comorbidities, namely hypertension, cardiovascular diseases, diabetes, kidney diseases, and neurological complications in various countries, are evaluated in the present article.", [["cardiovascular", "ANATOMY", 63, 77], ["kidney", "ANATOMY", 98, 104], ["neurological", "ANATOMY", 119, 131], ["hypertension", "DISEASE", 49, 61], ["cardiovascular diseases", "DISEASE", 63, 86], ["diabetes", "DISEASE", 88, 96], ["kidney diseases", "DISEASE", 98, 113], ["neurological complications", "DISEASE", 119, 145], ["kidney", "ORGAN", 98, 104], ["hypertension", "PROBLEM", 49, 61], ["cardiovascular diseases", "PROBLEM", 63, 86], ["diabetes", "PROBLEM", 88, 96], ["kidney diseases", "PROBLEM", 98, 113], ["neurological complications in various countries", "PROBLEM", 119, 166], ["hypertension", "OBSERVATION", 49, 61], ["cardiovascular diseases", "OBSERVATION", 63, 86], ["diabetes", "OBSERVATION", 88, 96], ["kidney", "ANATOMY", 98, 104], ["diseases", "OBSERVATION", 105, 113], ["neurological", "OBSERVATION_MODIFIER", 119, 131], ["complications", "OBSERVATION", 132, 145]]], ["In addition, the majority of the dysfunctions mentioned above are often associated with endothelial deterioration, indicating that endothelium can be the target of SARS-CoV2 (Chen et al., 2020).DiscussionOur study reveals that the country-wide pattern of COVID-19 associated comorbidities in hospitalized and deceased patients remains evidently similar (Table 1).", [["endothelial", "ANATOMY", 88, 99], ["endothelium", "ANATOMY", 131, 142], ["SARS", "DISEASE", 164, 168], ["endothelial", "CELL", 88, 99], ["endothelium", "TISSUE", 131, 142], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 164, 173], ["patients", "ORGANISM", 318, 326], ["patients", "SPECIES", 318, 326], ["the dysfunctions", "PROBLEM", 29, 45], ["endothelial deterioration", "PROBLEM", 88, 113], ["DiscussionOur study", "TEST", 194, 213], ["COVID-19 associated comorbidities", "PROBLEM", 255, 288], ["majority", "OBSERVATION_MODIFIER", 17, 25], ["dysfunctions", "OBSERVATION", 33, 45], ["endothelial", "ANATOMY", 88, 99], ["deterioration", "OBSERVATION", 100, 113]]], ["Notably we found that heart diseases, including hypertension along with cardiovascular diseases, are the most frequent association with SARS-CoV2 infection in most countries (Italy, France, Spain, and Sweden) except the Netherlands.", [["heart", "ANATOMY", 22, 27], ["cardiovascular", "ANATOMY", 72, 86], ["heart diseases", "DISEASE", 22, 36], ["hypertension", "DISEASE", 48, 60], ["cardiovascular diseases", "DISEASE", 72, 95], ["SARS-CoV2 infection", "DISEASE", 136, 155], ["heart", "ORGAN", 22, 27], ["heart diseases", "PROBLEM", 22, 36], ["hypertension", "PROBLEM", 48, 60], ["cardiovascular diseases", "PROBLEM", 72, 95], ["SARS", "PROBLEM", 136, 140], ["CoV2 infection", "PROBLEM", 141, 155], ["heart", "ANATOMY", 22, 27], ["diseases", "OBSERVATION", 28, 36], ["hypertension", "OBSERVATION", 48, 60], ["cardiovascular diseases", "OBSERVATION", 72, 95], ["SARS", "OBSERVATION", 136, 140], ["infection", "OBSERVATION", 146, 155]]], ["Similar reports of a high prevalence of cardiovascular disease and hypertension among hospitalized and diseased patients were demonstrated by Richardson et al. (2020), Wu and McGoogan (2020), and Zhou et al., 2020 in case reports from China and the United States, respectively.", [["cardiovascular", "ANATOMY", 40, 54], ["cardiovascular disease", "DISEASE", 40, 62], ["hypertension", "DISEASE", 67, 79], ["cardiovascular", "ANATOMICAL_SYSTEM", 40, 54], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["cardiovascular disease", "PROBLEM", 40, 62], ["hypertension", "PROBLEM", 67, 79], ["high", "OBSERVATION_MODIFIER", 21, 25], ["cardiovascular disease", "OBSERVATION", 40, 62], ["hypertension", "OBSERVATION", 67, 79]]], ["Importantly, SARS-CoV2 associated pneumonia in heart patients may develop hypoxemia due to hindrance in gas exchange (Li B. et al., 2020).", [["heart", "ANATOMY", 47, 52], ["SARS", "DISEASE", 13, 17], ["pneumonia", "DISEASE", 34, 43], ["hypoxemia", "DISEASE", 74, 83], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 13, 22], ["heart", "ORGAN", 47, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["pneumonia", "PROBLEM", 34, 43], ["hypoxemia", "PROBLEM", 74, 83], ["hindrance in gas exchange", "PROBLEM", 91, 116], ["pneumonia", "OBSERVATION", 34, 43], ["heart", "ANATOMY", 47, 52], ["hypoxemia", "OBSERVATION", 74, 83], ["gas exchange", "OBSERVATION", 104, 116]]], ["This may drive complications in cardiac functions and increase the risk of death.", [["cardiac", "ANATOMY", 32, 39], ["death", "DISEASE", 75, 80], ["cardiac", "ORGAN", 32, 39], ["complications in cardiac functions", "PROBLEM", 15, 49], ["death", "PROBLEM", 75, 80]]], ["Interestingly, our study depicts a profound proportion of deaths due to heart diseases, including cardiovascular diseases and hypertension.", [["heart", "ANATOMY", 72, 77], ["cardiovascular", "ANATOMY", 98, 112], ["deaths", "DISEASE", 58, 64], ["heart diseases", "DISEASE", 72, 86], ["cardiovascular diseases", "DISEASE", 98, 121], ["hypertension", "DISEASE", 126, 138], ["heart", "ORGAN", 72, 77], ["cardiovascular", "ANATOMICAL_SYSTEM", 98, 112], ["our study", "TEST", 15, 24], ["heart diseases", "PROBLEM", 72, 86], ["cardiovascular diseases", "PROBLEM", 98, 121], ["hypertension", "PROBLEM", 126, 138], ["heart", "ANATOMY", 72, 77], ["diseases", "OBSERVATION", 78, 86], ["cardiovascular", "ANATOMY", 98, 112], ["diseases", "OBSERVATION", 113, 121], ["hypertension", "OBSERVATION", 126, 138]]], ["Also, our investigation reflects that the majority of the drugs used in the case of COVID-19 treatment are related to heart ailments, such as cardiovascular diseases and hypertension (Table 2).", [["heart", "ANATOMY", 118, 123], ["cardiovascular", "ANATOMY", 142, 156], ["COVID-19", "CHEMICAL", 84, 92], ["heart ailments", "DISEASE", 118, 132], ["cardiovascular diseases", "DISEASE", 142, 165], ["hypertension", "DISEASE", 170, 182], ["COVID-19", "CHEMICAL", 84, 92], ["heart", "ORGAN", 118, 123], ["our investigation", "TEST", 6, 23], ["the drugs", "TREATMENT", 54, 63], ["COVID-19 treatment", "TREATMENT", 84, 102], ["heart ailments", "PROBLEM", 118, 132], ["cardiovascular diseases", "PROBLEM", 142, 165], ["hypertension", "PROBLEM", 170, 182], ["heart", "ANATOMY", 118, 123], ["ailments", "OBSERVATION", 124, 132], ["hypertension", "OBSERVATION", 170, 182]]], ["Further, ACE2, serine protease 2 (TMPRSS2), basigin (CD147), cathepsin B and L and sialic acid receptor expressed by the endothelial cells are used by SARS-CoV2 to gain entry into the host (Sardu et al., 2020).", [["endothelial cells", "ANATOMY", 121, 138], ["sialic acid", "CHEMICAL", 83, 94], ["serine", "CHEMICAL", 15, 21], ["sialic acid", "CHEMICAL", 83, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["serine protease 2", "GENE_OR_GENE_PRODUCT", 15, 32], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 34, 41], ["basigin", "GENE_OR_GENE_PRODUCT", 44, 51], ["CD147", "GENE_OR_GENE_PRODUCT", 53, 58], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 61, 72], ["L", "GENE_OR_GENE_PRODUCT", 77, 78], ["sialic acid receptor", "GENE_OR_GENE_PRODUCT", 83, 103], ["endothelial cells", "CELL", 121, 138], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 151, 160], ["ACE2", "PROTEIN", 9, 13], ["serine protease 2", "PROTEIN", 15, 32], ["TMPRSS2", "PROTEIN", 34, 41], ["basigin", "PROTEIN", 44, 51], ["CD147", "PROTEIN", 53, 58], ["cathepsin B", "PROTEIN", 61, 72], ["L", "PROTEIN", 77, 78], ["sialic acid receptor", "PROTEIN", 83, 103], ["endothelial cells", "CELL_TYPE", 121, 138], ["ACE2", "TEST", 9, 13], ["serine protease", "TREATMENT", 15, 30], ["TMPRSS2", "TEST", 34, 41], ["basigin (CD147", "TREATMENT", 44, 58], ["cathepsin B and L and sialic acid receptor", "TREATMENT", 61, 103], ["the endothelial cells", "TREATMENT", 117, 138], ["endothelial cells", "OBSERVATION", 121, 138]]], ["Besides, ACEi/ARBs exert protective effects on patients with hypertension and heart disorders; however, the effect diminishes on the binding of virus spike protein to ACE2 (Sardu et al., 2020).", [["heart", "ANATOMY", 78, 83], ["ACEi", "CHEMICAL", 9, 13], ["ARBs", "CHEMICAL", 14, 18], ["hypertension", "DISEASE", 61, 73], ["heart disorders", "DISEASE", 78, 93], ["ACEi", "SIMPLE_CHEMICAL", 9, 13], ["ARBs", "SIMPLE_CHEMICAL", 14, 18], ["patients", "ORGANISM", 47, 55], ["heart", "ORGAN", 78, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["virus spike protein", "PROTEIN", 144, 163], ["ACE2", "PROTEIN", 167, 171], ["patients", "SPECIES", 47, 55], ["ACEi", "TREATMENT", 9, 13], ["ARBs", "TREATMENT", 14, 18], ["hypertension", "PROBLEM", 61, 73], ["heart disorders", "PROBLEM", 78, 93], ["ACE2", "TEST", 167, 171], ["hypertension", "OBSERVATION", 61, 73], ["heart", "ANATOMY", 78, 83], ["disorders", "OBSERVATION", 84, 93]]], ["Chloroquine and Hydroxychloroquine, widely used drugs for SARS-CoV2 infection, were also reported to induce arrhythmias along with atrial and ventricular antiarrhythmic effects (Teixeira et al., 2002; Malviya, 2020).", [["atrial", "ANATOMY", 131, 137], ["ventricular", "ANATOMY", 142, 153], ["Chloroquine", "CHEMICAL", 0, 11], ["Hydroxychloroquine", "CHEMICAL", 16, 34], ["SARS-CoV2 infection", "DISEASE", 58, 77], ["arrhythmias", "DISEASE", 108, 119], ["Chloroquine", "CHEMICAL", 0, 11], ["Hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 16, 34], ["SARS-CoV2", "ORGANISM", 58, 67], ["atrial", "MULTI-TISSUE_STRUCTURE", 131, 137], ["ventricular", "MULTI-TISSUE_STRUCTURE", 142, 153], ["Chloroquine", "TREATMENT", 0, 11], ["Hydroxychloroquine", "TREATMENT", 16, 34], ["drugs", "TREATMENT", 48, 53], ["SARS", "PROBLEM", 58, 62], ["CoV2 infection", "PROBLEM", 63, 77], ["arrhythmias", "PROBLEM", 108, 119], ["atrial and ventricular antiarrhythmic effects", "PROBLEM", 131, 176], ["atrial", "ANATOMY", 131, 137], ["ventricular", "ANATOMY", 142, 153], ["antiarrhythmic", "OBSERVATION", 154, 168]]], ["Intriguingly reports from government medicine agencies of most of the countries like Italy, Spain, and France (Italian Medicines Agency, 2020; National Agency for the Safety of Medicines and Health Products, 2020; Spanish Agency for Medicines and Health Products, 2020) have earlier advised the use of Chloroquine and Hydroxychloroquine against COVID-19.DiscussionFurther, the virus is known to initiate diabetes by intensifying the condition of insulin resistance or by targeting the pancreatic islets.", [["pancreatic islets", "ANATOMY", 485, 502], ["Chloroquine", "CHEMICAL", 302, 313], ["Hydroxychloroquine", "CHEMICAL", 318, 336], ["COVID-19", "CHEMICAL", 345, 353], ["diabetes", "DISEASE", 404, 412], ["Chloroquine", "CHEMICAL", 302, 313], ["Hydroxychloroquine", "CHEMICAL", 318, 336], ["COVID-19", "CHEMICAL", 345, 353], ["Chloroquine", "SIMPLE_CHEMICAL", 302, 313], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 318, 336], ["insulin", "GENE_OR_GENE_PRODUCT", 446, 453], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 485, 502], ["pancreatic islets", "CELL_TYPE", 485, 502], ["Chloroquine", "TREATMENT", 302, 313], ["Hydroxychloroquine", "TREATMENT", 318, 336], ["COVID", "TREATMENT", 345, 350], ["the virus", "PROBLEM", 373, 382], ["diabetes", "PROBLEM", 404, 412], ["insulin resistance", "TREATMENT", 446, 464], ["insulin resistance", "OBSERVATION", 446, 464], ["pancreatic", "ANATOMY", 485, 495]]], ["ACE2 can serve as a therapeutic target and may aid in microcirculation in the islets (Sardu et al., 2020).", [["islets", "ANATOMY", 78, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["islets", "MULTI-TISSUE_STRUCTURE", 78, 84], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4]]], ["Several studies have already demonstrated that diabetic patients have increased susceptibility to COVID-19 (Remuzzi and Remuzzi, 2020).", [["diabetic", "DISEASE", 47, 55], ["COVID-19", "CHEMICAL", 98, 106], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Several studies", "TEST", 0, 15], ["increased susceptibility", "PROBLEM", 70, 94], ["COVID", "TEST", 98, 103], ["diabetic", "OBSERVATION", 47, 55], ["increased", "OBSERVATION_MODIFIER", 70, 79]]], ["Nevertheless, our study shows that the population of deceased diabetic patients to the total hospitalized patients with diabetes is higher in Italy and Spain, unlike the Netherlands and Sweden.DiscussionA case report of 5700 SARS-CoV2 infected patients from New York have reported an association of chronic lung disorders with COVID-19 (Richardson et al., 2020).", [["lung", "ANATOMY", 307, 311], ["diabetic", "DISEASE", 62, 70], ["diabetes", "DISEASE", 120, 128], ["SARS-CoV2 infected", "DISEASE", 225, 243], ["chronic lung disorders", "DISEASE", 299, 321], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 106, 114], ["SARS-CoV2", "ORGANISM", 225, 234], ["patients", "ORGANISM", 244, 252], ["lung", "ORGAN", 307, 311], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 244, 252], ["our study", "TEST", 14, 23], ["diabetes", "PROBLEM", 120, 128], ["chronic lung disorders", "PROBLEM", 299, 321], ["diabetes", "OBSERVATION", 120, 128], ["higher", "OBSERVATION_MODIFIER", 132, 138], ["chronic", "OBSERVATION_MODIFIER", 299, 306], ["lung", "ANATOMY", 307, 311], ["disorders", "OBSERVATION", 312, 321]]], ["Our data from included countries also depicts similar observations in COVID-19 patients.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Our data", "TEST", 0, 8]]], ["Importantly the deaths due to lung pathologies are significantly high compared to those hospitalized in Italy, Spain, France, and Sweden, contrary to the Netherlands.", [["lung", "ANATOMY", 30, 34], ["deaths", "DISEASE", 16, 22], ["lung pathologies", "DISEASE", 30, 46], ["lung", "ORGAN", 30, 34], ["lung pathologies", "PROBLEM", 30, 46], ["lung", "ANATOMY", 30, 34], ["pathologies", "OBSERVATION", 35, 46], ["significantly", "OBSERVATION_MODIFIER", 51, 64], ["high", "OBSERVATION_MODIFIER", 65, 69]]], ["Studies suggest that the SARS-CoV2 infection may efficiently serve as an additional factor to develop severe lung pathology (Li H. et al., 2020).", [["lung", "ANATOMY", 109, 113], ["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 35, 44], ["SARS-CoV2", "ORGANISM", 25, 34], ["lung", "ORGAN", 109, 113], ["Studies", "TEST", 0, 7], ["the SARS-CoV2 infection", "PROBLEM", 21, 44], ["severe lung pathology", "PROBLEM", 102, 123], ["SARS", "OBSERVATION", 25, 29], ["infection", "OBSERVATION", 35, 44], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["lung", "ANATOMY", 109, 113], ["pathology", "OBSERVATION", 114, 123]]], ["Hypoxia, pulmonary distress after SARS-CoV2 infection may hamper the anti-coagulating action of the endothelium by promoting thrombosis (Sardu et al., 2020; Tang et al., 2020).", [["pulmonary", "ANATOMY", 9, 18], ["endothelium", "ANATOMY", 100, 111], ["Hypoxia", "DISEASE", 0, 7], ["pulmonary distress", "DISEASE", 9, 27], ["SARS", "DISEASE", 34, 38], ["infection", "DISEASE", 44, 53], ["thrombosis", "DISEASE", 125, 135], ["pulmonary", "ORGAN", 9, 18], ["endothelium", "TISSUE", 100, 111], ["Hypoxia", "PROBLEM", 0, 7], ["pulmonary distress", "PROBLEM", 9, 27], ["SARS", "PROBLEM", 34, 38], ["CoV2 infection", "PROBLEM", 39, 53], ["promoting thrombosis", "PROBLEM", 115, 135], ["pulmonary", "ANATOMY", 9, 18], ["distress", "OBSERVATION", 19, 27], ["infection", "OBSERVATION", 44, 53], ["endothelium", "ANATOMY", 100, 111], ["thrombosis", "OBSERVATION", 125, 135]]], ["Treatment of such patients with Ruxolitinib, an antiviral, may result in pulmonary complications such as the rarely observed acute respiratory distress syndrome, and pulmonary hypertension exacerbations (Low et al., 2015; Kerget et al., 2017).DiscussionThe electron microscopic analysis reveals viral particles in the endothelial lining of glomerular capillary loops (Su et al., 2020).", [["pulmonary", "ANATOMY", 73, 82], ["respiratory", "ANATOMY", 131, 142], ["pulmonary", "ANATOMY", 166, 175], ["endothelial lining", "ANATOMY", 318, 336], ["glomerular capillary loops", "ANATOMY", 340, 366], ["Ruxolitinib", "CHEMICAL", 32, 43], ["acute respiratory distress syndrome", "DISEASE", 125, 160], ["pulmonary hypertension", "DISEASE", 166, 188], ["Ruxolitinib", "CHEMICAL", 32, 43], ["patients", "ORGANISM", 18, 26], ["Ruxolitinib", "SIMPLE_CHEMICAL", 32, 43], ["pulmonary", "ORGAN", 73, 82], ["pulmonary", "ORGAN", 166, 175], ["endothelial lining", "TISSUE", 318, 336], ["glomerular capillary loops", "TISSUE", 340, 366], ["patients", "SPECIES", 18, 26], ["Ruxolitinib", "TREATMENT", 32, 43], ["an antiviral", "TREATMENT", 45, 57], ["pulmonary complications", "PROBLEM", 73, 96], ["acute respiratory distress syndrome", "PROBLEM", 125, 160], ["pulmonary hypertension exacerbations", "PROBLEM", 166, 202], ["The electron microscopic analysis", "TEST", 253, 286], ["viral particles", "PROBLEM", 295, 310], ["pulmonary", "ANATOMY", 73, 82], ["complications", "OBSERVATION", 83, 96], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["respiratory distress", "OBSERVATION", 131, 151], ["syndrome", "OBSERVATION", 152, 160], ["pulmonary", "ANATOMY", 166, 175], ["hypertension", "OBSERVATION", 176, 188], ["viral particles", "OBSERVATION", 295, 310], ["endothelial", "ANATOMY_MODIFIER", 318, 329], ["lining", "ANATOMY_MODIFIER", 330, 336], ["glomerular", "ANATOMY_MODIFIER", 340, 350], ["capillary loops", "ANATOMY", 351, 366]]], ["These findings strengthen the association of COVID-19 with kidney disorders underlying endothelial function in it.", [["kidney", "ANATOMY", 59, 65], ["endothelial", "ANATOMY", 87, 98], ["kidney disorders", "DISEASE", 59, 75], ["COVID-19", "GENE_OR_GENE_PRODUCT", 45, 53], ["kidney", "ORGAN", 59, 65], ["endothelial", "TISSUE", 87, 98], ["COVID", "PROTEIN", 45, 50], ["COVID", "TEST", 45, 50], ["kidney disorders", "PROBLEM", 59, 75], ["kidney", "ANATOMY", 59, 65], ["disorders", "OBSERVATION", 66, 75], ["endothelial function", "OBSERVATION", 87, 107]]], ["A study showed that more than 20% of critically ill COVID-19 patients were diagnosed with acute kidney injury (Richardson et al., 2020).", [["kidney", "ANATOMY", 96, 102], ["critically ill", "DISEASE", 37, 51], ["acute kidney injury", "DISEASE", 90, 109], ["patients", "ORGANISM", 61, 69], ["kidney", "ORGAN", 96, 102], ["patients", "SPECIES", 61, 69], ["A study", "TEST", 0, 7], ["critically ill COVID", "PROBLEM", 37, 57], ["acute kidney injury", "PROBLEM", 90, 109], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["kidney", "ANATOMY", 96, 102], ["injury", "OBSERVATION", 103, 109]]], ["Our study clearly demonstrates a significant population of the deceased with kidney disorders compared to hospitalized patients for all the countries under consideration.", [["kidney", "ANATOMY", 77, 83], ["kidney disorders", "DISEASE", 77, 93], ["kidney", "ORGAN", 77, 83], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["Our study", "TEST", 0, 9], ["kidney disorders", "PROBLEM", 77, 93], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["population", "OBSERVATION", 45, 55], ["kidney", "ANATOMY", 77, 83], ["disorders", "OBSERVATION", 84, 93]]], ["Besides, COVID-19 patients with cytokine release syndrome may develop acute kidney injury as an outcome of elevated vascular permeability, intrarenal inflammation, volume depletion, and cardiomyopathy (Ronco and Reis, 2020).", [["kidney", "ANATOMY", 76, 82], ["vascular", "ANATOMY", 116, 124], ["intrarenal", "ANATOMY", 139, 149], ["acute kidney injury", "DISEASE", 70, 89], ["inflammation", "DISEASE", 150, 162], ["cardiomyopathy", "DISEASE", 186, 200], ["patients", "ORGANISM", 18, 26], ["kidney", "ORGAN", 76, 82], ["vascular", "MULTI-TISSUE_STRUCTURE", 116, 124], ["intrarenal", "MULTI-TISSUE_STRUCTURE", 139, 149], ["cytokine", "PROTEIN", 32, 40], ["patients", "SPECIES", 18, 26], ["cytokine release syndrome", "PROBLEM", 32, 57], ["acute kidney injury", "PROBLEM", 70, 89], ["elevated vascular permeability", "PROBLEM", 107, 137], ["intrarenal inflammation", "PROBLEM", 139, 162], ["volume depletion", "PROBLEM", 164, 180], ["cardiomyopathy", "PROBLEM", 186, 200], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["kidney", "ANATOMY", 76, 82], ["injury", "OBSERVATION", 83, 89], ["elevated", "OBSERVATION", 107, 115], ["vascular", "ANATOMY", 116, 124], ["permeability", "OBSERVATION", 125, 137], ["intrarenal", "ANATOMY", 139, 149], ["inflammation", "OBSERVATION", 150, 162], ["volume depletion", "OBSERVATION", 164, 180], ["cardiomyopathy", "OBSERVATION", 186, 200]]], ["The treatment for COVID-19 includes Remdesivir and Losartan which have possible renal side-effects (Grein et al., 2020).", [["renal", "ANATOMY", 80, 85], ["COVID-19", "CHEMICAL", 18, 26], ["Remdesivir", "CHEMICAL", 36, 46], ["Losartan", "CHEMICAL", 51, 59], ["COVID-19", "CHEMICAL", 18, 26], ["Remdesivir", "CHEMICAL", 36, 46], ["Losartan", "CHEMICAL", 51, 59], ["COVID-19", "SIMPLE_CHEMICAL", 18, 26], ["Remdesivir", "SIMPLE_CHEMICAL", 36, 46], ["Losartan", "SIMPLE_CHEMICAL", 51, 59], ["renal", "ORGAN", 80, 85], ["The treatment", "TREATMENT", 0, 13], ["COVID", "TEST", 18, 23], ["Remdesivir", "TREATMENT", 36, 46], ["Losartan", "TREATMENT", 51, 59], ["renal side-effects", "PROBLEM", 80, 98], ["renal", "ANATOMY", 80, 85]]], ["Prior knowledge of an individual\u2019s medical history can facilitate better treatment to COVID-19 patients rather than adding up to the disease misery.DiscussionOther comorbidities like immunodeficient conditions and neurological diseases are reported for some countries namely France, the Netherlands, and Sweden.", [["neurological", "ANATOMY", 214, 226], ["immunodeficient conditions", "DISEASE", 183, 209], ["neurological diseases", "DISEASE", 214, 235], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["DiscussionOther comorbidities", "PROBLEM", 148, 177], ["immunodeficient conditions", "PROBLEM", 183, 209], ["neurological diseases", "PROBLEM", 214, 235]]], ["Patients with immunodeficiency include individuals with compromised immune systems like AIDS or undergoing any immunosuppressive therapy.", [["immunodeficiency", "DISEASE", 14, 30], ["AIDS", "DISEASE", 88, 92], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["immunodeficiency", "PROBLEM", 14, 30], ["individuals", "PROBLEM", 39, 50], ["compromised immune systems", "PROBLEM", 56, 82], ["AIDS", "PROBLEM", 88, 92], ["any immunosuppressive therapy", "TREATMENT", 107, 136], ["immunodeficiency", "OBSERVATION", 14, 30]]], ["Notably, the antiviral therapies given to AIDS patients may slightly benefit in COVID-19 recovery as well (H\u00e4rter et al., 2020).", [["AIDS", "DISEASE", 42, 46], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["the antiviral therapies", "TREATMENT", 9, 32]]], ["Further, since the immune system is suppressed, these patients are highly susceptible to opportunistic pathogens, including SARS-CoV2.", [["immune system", "ANATOMY", 19, 32], ["opportunistic pathogens", "DISEASE", 89, 112], ["SARS-CoV2", "DISEASE", 124, 133], ["patients", "ORGANISM", 54, 62], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 124, 133], ["patients", "SPECIES", 54, 62], ["opportunistic pathogens", "PROBLEM", 89, 112], ["SARS", "PROBLEM", 124, 128]]], ["Therefore, we obtained variations in death reports compared to hospitalized patients from different countries.", [["death", "DISEASE", 37, 42], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84]]], ["Briefly, severe COVID-19 patients report acute cerebrovascular disease, conscious disturbance, and muscle injury.", [["cerebrovascular", "ANATOMY", 47, 62], ["muscle", "ANATOMY", 99, 105], ["acute cerebrovascular disease", "DISEASE", 41, 70], ["conscious disturbance", "DISEASE", 72, 93], ["muscle injury", "DISEASE", 99, 112], ["patients", "ORGANISM", 25, 33], ["muscle", "ORGAN", 99, 105], ["patients", "SPECIES", 25, 33], ["severe COVID", "PROBLEM", 9, 21], ["acute cerebrovascular disease", "PROBLEM", 41, 70], ["conscious disturbance", "PROBLEM", 72, 93], ["muscle injury", "PROBLEM", 99, 112], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["cerebrovascular", "ANATOMY", 47, 62], ["disease", "OBSERVATION", 63, 70], ["muscle", "ANATOMY", 99, 105], ["injury", "OBSERVATION", 106, 112]]], ["Plausibly SARS-CoV2 may invade the cerebrovascular and nervous system using ACE2 receptors, or the patients with a priori abnormal neurological conditions might be prone to SARS-CoV2 (Liguori et al., 2020).", [["cerebrovascular", "ANATOMY", 35, 50], ["nervous system", "ANATOMY", 55, 69], ["neurological", "ANATOMY", 131, 143], ["SARS", "DISEASE", 10, 14], ["SARS", "DISEASE", 173, 177], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 10, 19], ["cerebrovascular", "ANATOMICAL_SYSTEM", 35, 50], ["nervous system", "ANATOMICAL_SYSTEM", 55, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["patients", "ORGANISM", 99, 107], ["ACE2 receptors", "PROTEIN", 76, 90], ["patients", "SPECIES", 99, 107], ["ACE2 receptors", "TREATMENT", 76, 90], ["a priori abnormal neurological conditions", "PROBLEM", 113, 154], ["cerebrovascular", "ANATOMY", 35, 50], ["nervous system", "ANATOMY", 55, 69]]], ["COVID-19 patients with neurological conditions may result in poor prognosis and might die due to unrevealed complications.", [["neurological", "ANATOMY", 23, 35], ["neurological conditions", "DISEASE", 23, 46], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["neurological conditions", "PROBLEM", 23, 46], ["complications", "PROBLEM", 108, 121]]], ["A case study by Mao et al. (2020) demonstrated that neural manifestations were significantly more common in severe infections compared with non-severe infections.", [["neural", "ANATOMY", 52, 58], ["infections", "DISEASE", 115, 125], ["infections", "DISEASE", 151, 161], ["A case study", "TEST", 0, 12], ["neural manifestations", "PROBLEM", 52, 73], ["severe infections", "PROBLEM", 108, 125], ["non-severe infections", "PROBLEM", 140, 161], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["infections", "OBSERVATION", 115, 125], ["non-severe", "OBSERVATION_MODIFIER", 140, 150], ["infections", "OBSERVATION", 151, 161]]], ["Losartan and Tocilizumab recommended for COVID-19 are previously reported to have adverse neurological effects.", [["neurological", "ANATOMY", 90, 102], ["Losartan", "CHEMICAL", 0, 8], ["Tocilizumab", "CHEMICAL", 13, 24], ["Losartan", "CHEMICAL", 0, 8], ["Tocilizumab", "CHEMICAL", 13, 24], ["Losartan", "SIMPLE_CHEMICAL", 0, 8], ["Tocilizumab", "SIMPLE_CHEMICAL", 13, 24], ["Losartan", "TREATMENT", 0, 8], ["Tocilizumab", "TREATMENT", 13, 24], ["COVID", "TREATMENT", 41, 46], ["adverse neurological effects", "PROBLEM", 82, 110]]], ["Thus a proper combination of medication may be adopted.DiscussionConclusively, COVID-19 associated comorbidities and deaths were ostensibly similar in some parts of the world.", [["deaths", "DISEASE", 117, 123], ["medication", "TREATMENT", 29, 39], ["associated comorbidities", "PROBLEM", 88, 112], ["deaths", "PROBLEM", 117, 123]]], ["How fast we are able to identify the virus-induced disorder in a person with certain comorbidity is equally important.", [["disorder", "DISEASE", 51, 59], ["person", "SPECIES", 65, 71], ["the virus-induced disorder", "PROBLEM", 33, 59], ["certain comorbidity", "PROBLEM", 77, 96]]], ["It will enable to render the person with a suitable treatment plan within a safer timeframe.", [["person", "SPECIES", 29, 35], ["a suitable treatment plan", "TREATMENT", 41, 66]]], ["In addition, the outcomes of COVID-19 may be independent of the comorbidities; we have efficiently corroborated available data based on hospitalized and deceased COVID-19 patients with associated comorbidities.", [["COVID-19", "CHEMICAL", 29, 37], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["COVID", "TEST", 29, 34], ["the comorbidities", "PROBLEM", 60, 77], ["associated comorbidities", "PROBLEM", 185, 209]]], ["For example, in terms of hospitalized cases, the patients in ICU are included or excluded is not specified in the report from Netherlands.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["Information regarding comorbidity patients of several categories is not presented in the case of Spain.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["Many of the other comorbidities like smoking, obesity, cancer, etc. couldn\u2019t be considered in the study due to lack of information in most reports.", [["cancer", "ANATOMY", 55, 61], ["smoking", "CHEMICAL", 37, 44], ["obesity", "DISEASE", 46, 53], ["cancer", "DISEASE", 55, 61], ["cancer", "CANCER", 55, 61], ["obesity", "PROBLEM", 46, 53], ["cancer", "PROBLEM", 55, 61], ["the study", "TEST", 94, 103], ["comorbidities", "OBSERVATION", 18, 31], ["obesity", "OBSERVATION", 46, 53], ["cancer", "OBSERVATION", 55, 61]]], ["Furthermore, the information about hospitalization average length was not available in the reports from where the data is collected because the data was regarding on-going cases and not with respect to any completed trials or reports.", [["the data", "TEST", 110, 118]]], ["Nonetheless, cardiovascular diseases and diabetes were the most prominent of all in Italy, France, and Spain.", [["cardiovascular", "ANATOMY", 13, 27], ["cardiovascular diseases", "DISEASE", 13, 36], ["diabetes", "DISEASE", 41, 49], ["cardiovascular", "ANATOMICAL_SYSTEM", 13, 27], ["cardiovascular diseases", "PROBLEM", 13, 36], ["diabetes", "PROBLEM", 41, 49], ["cardiovascular", "ANATOMY", 13, 27], ["diseases", "OBSERVATION", 28, 36], ["diabetes", "OBSERVATION", 41, 49], ["most prominent", "OBSERVATION_MODIFIER", 59, 73]]], ["However, the pattern of the deceased population due to COVID-19 associated comorbidities, including cardiovascular diseases, diabetes, and chronic lung ailments for the Netherlands, is contrary to other countries.", [["cardiovascular", "ANATOMY", 100, 114], ["lung", "ANATOMY", 147, 151], ["cardiovascular diseases", "DISEASE", 100, 123], ["diabetes", "DISEASE", 125, 133], ["chronic lung ailments", "DISEASE", 139, 160], ["lung", "ORGAN", 147, 151], ["the deceased population", "PROBLEM", 24, 47], ["COVID-19 associated comorbidities", "PROBLEM", 55, 88], ["cardiovascular diseases", "PROBLEM", 100, 123], ["diabetes", "PROBLEM", 125, 133], ["chronic lung ailments", "PROBLEM", 139, 160], ["cardiovascular", "ANATOMY", 100, 114], ["diseases", "OBSERVATION", 115, 123], ["diabetes", "OBSERVATION", 125, 133], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["lung", "ANATOMY", 147, 151], ["ailments", "OBSERVATION", 152, 160]]], ["The possible higher association of these diseases with COVID-19 might be due to altered physiological conditions of an individual or plausibly due to side effects of the drugs used in the country as a prescription to treat COVID-19.", [["COVID-19", "CHEMICAL", 55, 63], ["COVID", "DISEASE", 223, 228], ["COVID-19", "CHEMICAL", 55, 63], ["COVID-19", "CHEMICAL", 223, 231], ["COVID-19", "GENE_OR_GENE_PRODUCT", 55, 63], ["these diseases", "PROBLEM", 35, 49], ["COVID", "TEST", 55, 60], ["altered physiological conditions", "PROBLEM", 80, 112], ["the drugs", "TREATMENT", 166, 175], ["COVID", "TEST", 223, 228], ["possible", "UNCERTAINTY", 4, 12], ["higher", "OBSERVATION_MODIFIER", 13, 19], ["diseases", "OBSERVATION", 41, 49]]], ["This clearly shows that prior knowledge of an individual\u2019s health is critical to avoid fatal repercussions of COVID-19 treatment.Data Availability StatementAll datasets presented in this study are included in the article/supplementary material.Author ContributionsHJ, SJ, OI, and BB were involved in the final development of the project and manuscript preparation.", [["COVID-19", "CHEMICAL", 110, 118], ["COVID-19", "CHEMICAL", 110, 118], ["COVID-19 treatment", "TREATMENT", 110, 128], ["this study", "TEST", 182, 192], ["OI", "PROBLEM", 272, 274], ["BB", "TREATMENT", 280, 282], ["manuscript preparation", "TREATMENT", 341, 363]]], ["SJ, OI, and BB wrote the manuscript draft.", [["OI", "DISEASE", 4, 6], ["OI", "PROBLEM", 4, 6], ["BB", "TREATMENT", 12, 14]]], ["SJ, OI, NV, BB, and HJ analyzed the data.", [["BB", "TREATMENT", 12, 14], ["HJ", "TREATMENT", 20, 22]]], ["BB, NV, OI, AD, SC, and DK extracted the data.", [["OI", "DISEASE", 8, 10], ["AD", "DISEASE", 12, 14], ["BB", "MULTI-TISSUE_STRUCTURE", 0, 2], ["OI", "PROBLEM", 8, 10], ["NV", "OBSERVATION", 4, 6]]]], "PMC7476505": [["IntroductionThe COVID-19 pandemic is not the great equalizer.", [["The COVID", "TREATMENT", 12, 21]]], ["Vulnerability to COVID-19 based on preexisting health conditions collides with long-standing U.S. health disparities by income, education, and race-ethnicity, especially in midlife (Azar et al., 2020; Case & Deaton, 2015; Center for Disease Control & Prevention, 2020a; Cummings et al., 2020; Petrilli et al., 2020; Hertz, Unger, Cornell, & Saunders, 2005; Hicken, Lee, Morenoff, House, & Williams, 2013; National Center for Health Statistics, 2019; Richardson et al., 2020).", [["COVID", "TEST", 17, 22]]], ["Blacks and socioeconomically disadvantaged groups are more likely to have at least one health condition that increases vulnerability to COVID-19 (Adams, Grandpre, & Katz, 2020; Raifman & Raifman, 2020; Selden & Berdahl, 2020).", [["COVID-19", "CHEMICAL", 136, 144], ["COVID", "TEST", 136, 141]]], ["COVID-19 hospitalization rates are higher for Blacks and Hispanics than non-Hispanic Whites (Center for Disease Control & Prevention, 2020b) but data on hospitalization by education and household income are limited and not available at the national level.IntroductionThis brief provides U.S. nationally representative estimates of disparities in vulnerability to severe complications from COVID-19 arising from preexisting conditions across socioeconomic status and race-ethnicity.", [["COVID", "TEST", 0, 5], ["hospitalization rates", "TEST", 9, 30], ["Disease Control", "TREATMENT", 104, 119], ["severe complications", "PROBLEM", 363, 383], ["COVID", "TEST", 389, 394], ["preexisting conditions", "PROBLEM", 411, 433], ["race-ethnicity", "PROBLEM", 466, 480], ["severe", "OBSERVATION_MODIFIER", 363, 369], ["complications", "OBSERVATION", 370, 383]]], ["To translate disparities in preexisting health conditions into vulnerability to hospitalization from COVID-19, we use estimates of the effects of health conditions and age on the likelihood of hospitalization for respiratory conditions before the COVID-19 pandemic validated against patients hospitalized due to COVID-19 (DeCaprio et al., 2020).", [["respiratory", "ANATOMY", 213, 224], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291], ["respiratory conditions", "PROBLEM", 213, 235], ["the COVID", "TEST", 243, 252], ["COVID", "TEST", 312, 317]]], ["We combine these estimated effects with data on the prevalence of preexisting health conditions reported in the Panel Study of Income Dynamics (PSID) for nationally representative estimates of disparities in vulnerability to hospitalization for COVID-19 arising from preexisting conditions for U.S. adults.IntroductionIndividual-level information on socioeconomic characteristics in the PSID expands knowledge of unequal impacts of COVID-19 across education and income beyond studies that used aggregate census data to infer COVID-19 disparities by socioeconomic status (Azar et al., 2020; Price-Haywood, Burton, Fort, & Seonane, 2020).", [["preexisting health conditions", "PROBLEM", 66, 95], ["COVID", "TEST", 245, 250], ["COVID", "TEST", 432, 437]]], ["Our results complement existing work on race-ethnic disparities in vulnerability to COVID-19.", [["COVID-19", "CHEMICAL", 84, 92], ["COVID", "TEST", 84, 89]]], ["We show that gaps in vulnerability by socioeconomic status and race-ethnicity emerge early in life when they may intersect with disparities in exposure through work (Mongey, Pilossoph, & Weinberg, 2020).Panel Study of Income Dynamics ::: Study Data and MethodsThe PSID is a U.S. national longitudinal survey that began in 1968.", [["Study Data", "TEST", 238, 248], ["gaps", "OBSERVATION_MODIFIER", 13, 17], ["vulnerability", "OBSERVATION_MODIFIER", 21, 34]]], ["Observations with missing data on age, educational attainment, household income, race-ethnicity, or preexisting health conditions were dropped for an analytic sample size of 13,150.Panel Study of Income Dynamics ::: Study Data and MethodsEducation is categorized as no more than 12 years (high school/GED or less), 13-15 years (some college), and at least 16 years (BA degree or more).", [["preexisting health conditions", "PROBLEM", 100, 129], ["an analytic sample size", "TEST", 147, 170], ["Study Data", "TEST", 216, 226]]], ["Sample size is too small to report estimates for non-Hispanic other race.", [["size", "OBSERVATION_MODIFIER", 7, 11], ["too small to", "OBSERVATION_MODIFIER", 15, 27]]], ["Estimates of income (McGonagle, Schoeni, Sastry, & Freedman, 2012) and the distribution of gender, age, education, and race-ethnicity from the PSID (Appendix Tables A-1 and A-2) match estimates from the U.S. survey used for official poverty and income data.Panel Study of Income Dynamics ::: Study Data and MethodsThe PSID asks whether a person was ever told by a health professional they have health conditions including asthma, diabetes, heart disease, heart attack, hypertension, lung disease, neurological conditions, cancer, stroke, and kidney disease.", [["heart", "ANATOMY", 440, 445], ["heart", "ANATOMY", 455, 460], ["lung", "ANATOMY", 483, 487], ["neurological", "ANATOMY", 497, 509], ["cancer", "ANATOMY", 522, 528], ["kidney", "ANATOMY", 542, 548], ["asthma", "DISEASE", 422, 428], ["diabetes", "DISEASE", 430, 438], ["heart disease", "DISEASE", 440, 453], ["heart attack", "DISEASE", 455, 467], ["hypertension", "DISEASE", 469, 481], ["lung disease", "DISEASE", 483, 495], ["neurological conditions", "DISEASE", 497, 520], ["cancer", "DISEASE", 522, 528], ["stroke", "DISEASE", 530, 536], ["kidney disease", "DISEASE", 542, 556], ["heart", "ORGAN", 440, 445], ["heart", "ORGAN", 455, 460], ["lung", "ORGAN", 483, 487], ["cancer", "CANCER", 522, 528], ["kidney", "ORGAN", 542, 548], ["person", "SPECIES", 338, 344], ["Study Data", "TEST", 292, 302], ["asthma", "PROBLEM", 422, 428], ["diabetes", "PROBLEM", 430, 438], ["heart disease", "PROBLEM", 440, 453], ["heart attack", "PROBLEM", 455, 467], ["hypertension", "PROBLEM", 469, 481], ["lung disease", "PROBLEM", 483, 495], ["neurological conditions", "PROBLEM", 497, 520], ["cancer", "PROBLEM", 522, 528], ["stroke", "PROBLEM", 530, 536], ["kidney disease", "PROBLEM", 542, 556], ["Appendix", "ANATOMY", 149, 157], ["heart", "ANATOMY", 440, 445], ["disease", "OBSERVATION", 446, 453], ["heart", "ANATOMY", 455, 460], ["attack", "OBSERVATION", 461, 467], ["hypertension", "OBSERVATION", 469, 481], ["lung", "ANATOMY", 483, 487], ["disease", "OBSERVATION", 488, 495], ["cancer", "OBSERVATION", 522, 528], ["stroke", "OBSERVATION", 530, 536], ["kidney", "ANATOMY", 542, 548], ["disease", "OBSERVATION", 549, 556]]], ["We create an indicator of severe obesity (BMI \u2265 40) from reported height and weight.", [["obesity", "DISEASE", 33, 40], ["severe obesity", "PROBLEM", 26, 40], ["BMI", "TEST", 42, 45], ["weight", "TEST", 77, 83], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["obesity", "OBSERVATION", 33, 40]]], ["Appendix B reports question wording and how PSID estimates of health condition prevalence compare to other national data sources.Relative Vulnerability Index ::: Study Data and MethodsTo translate differences in health conditions and age into predictions about the likelihood of serious complications from COVID-19 requires information on the size of effects of complications from different preexisting conditions and on the interactions of these effects with age, but evidence on the size of the effects of individual preexisting conditions on severe illness from COVID-19 is limited (Center for Disease Control & Prevention, 2020c).", [["illness", "DISEASE", 552, 559], ["COVID-19", "CHEMICAL", 565, 573], ["Study Data", "TEST", 162, 172], ["serious complications", "PROBLEM", 279, 300], ["COVID", "TEST", 306, 311], ["complications", "PROBLEM", 362, 375], ["different preexisting conditions", "PROBLEM", 381, 413], ["individual preexisting conditions", "PROBLEM", 508, 541], ["severe illness", "PROBLEM", 545, 559], ["COVID", "TEST", 565, 570], ["Vulnerability Index", "OBSERVATION", 138, 157], ["serious", "OBSERVATION_MODIFIER", 279, 286], ["complications", "OBSERVATION", 287, 300], ["size", "OBSERVATION_MODIFIER", 485, 489], ["severe", "OBSERVATION_MODIFIER", 545, 551]]], ["We use estimated effects of preexisting conditions and age from DeCaprio et al. (2020)\u2019s model predicting pre-pandemic in-patient hospitalizations associated with acute respiratory distress syndrome, pneumonia (not caused by tuberculosis), influenza, acute bronchitis and other upper respiratory infections.", [["respiratory", "ANATOMY", 169, 180], ["respiratory", "ANATOMY", 284, 295], ["acute respiratory distress syndrome", "DISEASE", 163, 198], ["pneumonia", "DISEASE", 200, 209], ["tuberculosis", "DISEASE", 225, 237], ["influenza", "DISEASE", 240, 249], ["bronchitis", "DISEASE", 257, 267], ["upper respiratory infections", "DISEASE", 278, 306], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["preexisting conditions", "PROBLEM", 28, 50], ["acute respiratory distress syndrome", "PROBLEM", 163, 198], ["pneumonia", "PROBLEM", 200, 209], ["tuberculosis", "PROBLEM", 225, 237], ["influenza", "PROBLEM", 240, 249], ["acute bronchitis", "PROBLEM", 251, 267], ["other upper respiratory infections", "PROBLEM", 272, 306], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory distress", "OBSERVATION", 169, 189], ["pneumonia", "OBSERVATION", 200, 209], ["tuberculosis", "OBSERVATION", 225, 237], ["acute", "OBSERVATION_MODIFIER", 251, 256], ["bronchitis", "OBSERVATION", 257, 267], ["upper", "ANATOMY_MODIFIER", 278, 283], ["respiratory", "ANATOMY", 284, 295], ["infections", "OBSERVATION", 296, 306]]], ["Based on medical claims for over 2 million persons, the model uses multivariable logistic regression to predict hospitalizations from these respiratory infections with individual-level data on preexisting health conditions and recent hospitalization (risk factors), gender, and age.", [["respiratory infections", "DISEASE", 140, 162], ["persons", "ORGANISM", 43, 50], ["persons", "SPECIES", 43, 50], ["these respiratory infections", "PROBLEM", 134, 162], ["preexisting health conditions", "PROBLEM", 193, 222], ["respiratory", "ANATOMY", 140, 151], ["infections", "OBSERVATION", 152, 162]]], ["The model was validated on approximately 14,000 patients hospitalized due to COVID-19.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 77, 82]]], ["We apply the coefficient estimates from the regression to the PSID data to create for each sample member a value for the relative vulnerability index, VIi, which is the odds that individual i has severe illness relative to that for a 30-year-old female with no risk factors.", [["female", "ORGANISM", 246, 252], ["severe illness", "PROBLEM", 196, 210], ["risk factors", "PROBLEM", 261, 273]]], ["Details of the method are in Appendix B.Relative Vulnerability Index ::: Study Data and MethodsThe index connects individuals\u2019 age and health conditions to an externally validated measure of the risk of hospitalization for severe complications of COVID-19.", [["COVID-19", "CHEMICAL", 247, 255], ["Study Data", "TEST", 73, 83], ["severe complications", "PROBLEM", 223, 243], ["COVID", "TEST", 247, 252], ["Appendix", "ANATOMY", 29, 37], ["index", "OBSERVATION_MODIFIER", 99, 104]]], ["The index provides a more complete measure of vulnerability than counts of conditions because the index allows certain conditions to increase vulnerability to COVID-19 more than others and for these effects to vary with age (Appendix Fig. B-2).Statistical Analyses ::: Study Data and MethodsThe analysis describes disparities in the prevalence of risk factors to inform the analysis of group differences in relative vulnerability to severe complications.", [["B-2", "GENE_OR_GENE_PRODUCT", 239, 242], ["The index", "TEST", 0, 9], ["the index", "TEST", 94, 103], ["COVID", "TEST", 159, 164], ["Study Data", "TEST", 269, 279], ["The analysis", "TEST", 291, 303], ["risk factors", "PROBLEM", 347, 359], ["the analysis", "TEST", 370, 382], ["severe complications", "PROBLEM", 433, 453], ["Appendix", "ANATOMY", 225, 233], ["severe", "OBSERVATION_MODIFIER", 433, 439], ["complications", "OBSERVATION", 440, 453]]], ["We test whether differences are statistically significant from the base category (age 25-44; BA or more; top income quartile; NH White).", [["the base category", "TEST", 63, 80], ["base", "ANATOMY_MODIFIER", 67, 71]]], ["We tabulate the percent of the population with 0, 1, 2 and 3+ risk factors by age group and by age group within education, income quartile, and race-ethnicity.Statistical Analyses ::: Study Data and MethodsSecond, we calculate median values of the relative vulnerability index by age group and number of risk factors and by age group within education, income quartile, and race-ethnicity.", [["Study Data", "TEST", 184, 194], ["percent", "OBSERVATION_MODIFIER", 16, 23]]]], "PMC7455521": [["IntroductionSuicide is a major public health problem, and is one of the leading causes of mortality globally (Naghavi, 2019).", [["IntroductionSuicide", "DISEASE", 0, 19]]], ["The reported deaths due to suicide in India is highest among countries worldwide (Dandona et al., 2018).", [["deaths", "DISEASE", 13, 19]]], ["Also, repeated insensible media coverage may act as a source of misinformation that suicide is an acceptable solution to ongoing difficulties in life.", [["repeated insensible media coverage", "TREATMENT", 6, 40]]], ["This has been supported by the bulk of available literature, with a recent meta-analysis reporting a 13% increased risk of suicide (95% confidence interval of 8-18%; median follow-up duration of 28 days) in the period following the media report of celebrity suicide death (Niederkrotenthaler et al., 2020).", [["suicide death", "DISEASE", 258, 271]]], ["Media reporting of suicide is a double-edged sword, with inappropriate and sensational reporting of suicide news leading to copycat phenomenon or Werther effect.", [["copycat phenomenon", "PROBLEM", 124, 142], ["Werther effect", "PROBLEM", 146, 160]]], ["Whereas, sensible media reporting of suicide along with media involvement in spreading preventive information shown to minimise copycat e\ufb00ects, and has been shown to be e\ufb00ective in reducing suicide deaths (Cheng et al., 2018).", [["deaths", "DISEASE", 198, 204]]], ["This includes reporting upon how people could adopt alternative coping strategies to deal with life stresses or depressed mood along with sharing links of educative websites or suicide helplines; and has been shown to be associated with decreased suicide suicidal behaviour and ideation in vulnerable population (Niederkrotenthaler et al., 2010; Till et al., 2017).", [["depressed mood", "DISEASE", 112, 126], ["suicide helplines", "DISEASE", 177, 194], ["suicidal behaviour", "DISEASE", 255, 273], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["alternative coping strategies", "TREATMENT", 52, 81], ["life stresses", "PROBLEM", 95, 108], ["depressed mood", "PROBLEM", 112, 126], ["decreased suicide suicidal behaviour", "PROBLEM", 237, 273]]], ["Therefore, media reporting of suicide-related preventive information has been associated with positive effects on subsequent suicide rates and ideation.", [["subsequent suicide rates", "PROBLEM", 114, 138], ["ideation", "PROBLEM", 143, 151]]], ["In recent years, internet is being increasingly used by the public for seeking health-related information; and information related to mental health related disorders or problems also being widely available online (Amante et al., 2015).", [["mental health related disorders", "PROBLEM", 134, 165]]], ["It is understandable, that several researchers have expressed concerns about vulnerable individuals either using internet to access pro-suicide information (e.g. methods of suicide) or inadvertently being exposed to online news or information which negatively affects their thoughts or mood and promote suicidal behaviours in them (Arendt and Scherr, 2017; Till and Niederkrotenthaler, 2014).", [["suicidal behaviours", "DISEASE", 303, 322]]], ["However, internet also provides a host of suicide prevention related information and resources which could in turn decrease the risk of suicide (Biddle et al., 2008).", [["suicide prevention", "TREATMENT", 42, 60]]], ["Thus, it is important to explore the quality of online media reporting of celebrity suicide in India.", [["celebrity suicide", "DISEASE", 74, 91]]], ["This would in turn help in better understanding the role played by this new electronic medium in either predisposing or protecting people with suicidal ideas or death wishes.IntroductionThere has been limited literature available assessing the quality of media reporting of suicide in India.", [["death", "DISEASE", 161, 166], ["people", "ORGANISM", 131, 137], ["people", "SPECIES", 131, 137]]], ["Most of the studies assessed media reporting of suicide in general population, and only one study had focused on celebrity suicide specifically (Harshe et al., 2016).", [["the studies", "TEST", 8, 19], ["one study", "TEST", 88, 97]]], ["However, that study took death of Robin Williams (Hollywood movie actor of US origin) as the reference event and was done about four years back.", [["death", "DISEASE", 25, 30]]], ["Further, all the available studies have assessed newspapers in a particular region and were conducted prior to Press Council of India (PCI) issuing media reporting guidelines on suicide and mental illness in India.", [["suicide and mental illness", "DISEASE", 178, 204], ["the available studies", "TEST", 13, 34], ["India (PCI", "TREATMENT", 128, 138], ["mental illness", "PROBLEM", 190, 204]]], ["The PCI has adopted the guidelines of World Health Organization (WHO) report on Preventing Suicide (Press Council of India, 2020).", [["Suicide", "DISEASE", 91, 98], ["The PCI", "TREATMENT", 0, 7], ["PCI", "OBSERVATION", 4, 7]]], ["It forbids undue repetition of stories, placing stories in prominent positions, explicit description of the suicide method, providing details about the suicide location, using sensational headlines and reporting photographs of the person.", [["person", "SPECIES", 231, 237]]], ["There might be some change in the quality of media reporting of suicide in recent years, more specifically after the PCI guidelines.", [["the PCI guidelines", "TREATMENT", 113, 131], ["some", "OBSERVATION_MODIFIER", 15, 19], ["change", "OBSERVATION_MODIFIER", 20, 26]]], ["Moreover, to the best of our knowledge there has been no study from Indian context yet exploring the association between media reporting of death of celebrity by suicide and subsequent suicidal behaviour in the general population.IntroductionThe official figures for deaths due to suicide in India is released by the National Crimes Record Bureau (NCRB) in India.", [["death", "DISEASE", 140, 145], ["suicidal behaviour", "DISEASE", 185, 203], ["deaths", "DISEASE", 267, 273], ["study", "TEST", 57, 62], ["subsequent suicidal behaviour", "PROBLEM", 174, 203]]], ["Moreover, any other system of directly recording suicide statistics in India will face the challenges associated with collecting vital statistics through sub-optimal existing vital registration system, misclassification, and under-reporting of suicide deaths due to associated legal complications and social stigma around suicide death in the family(Armstrong and Vijayakumar, 2018).", [["deaths", "DISEASE", 252, 258], ["death", "DISEASE", 330, 335], ["suicide deaths", "PROBLEM", 244, 258], ["legal complications", "PROBLEM", 277, 296], ["legal complications", "OBSERVATION", 277, 296]]], ["Additionally, the restrictions imposed on movement of people and social distancing guidelines to be followed during the current COVID-19 pandemic, makes it even more difficult to access the study population in a systematic manner for assessment of suicide risk using traditional research methods (Bidarbakhtnia, 2020).IntroductionThe above described limitations could be addressed by employing research methods and techniques involving the study of internet-based search behaviours and social media content.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60], ["the study", "TEST", 186, 195], ["suicide risk", "PROBLEM", 248, 260], ["the study", "TEST", 436, 445]]], ["The evidence supporting correlation between increased online search interest for particular suicide-related search queries using Google search engine and the actual number of suicides in that region during that particular time-period has been increasing over the past two decades (Lee, 2020).", [["increasing", "OBSERVATION_MODIFIER", 243, 253]]], ["Moreover, recent studies have shown that data obtained using Google Trends for suicide-seeking keywords could be used for predicting actual monthly suicide numbers at the Country level (Kristoufek et al., 2016).", [["recent studies", "TEST", 10, 24]]], ["Thus, in the present study we monitored the changes in internet search volumes for keywords representing suicide-seeking and help-seeking behaviours using the Google Trends platform as a proxy marker to assess the impact of recent celebrity suicide in India.IntroductionSushant Singh Rajput (SSR) was a much-loved Indian actor who died by suicide on June 14, 2020.", [["the present study", "TEST", 9, 26]]], ["This was reported by various national and international media, and was considered as the reference event in this study.", [["this study", "TEST", 108, 118]]], ["Thus, the present study aimed to assess the quality of online media reporting of a celebrity suicide in India, and evaluate its adherence with the WHO guidelines for responsible media reporting of suicide.", [["the present study", "TEST", 6, 23]]], ["This would provide indirect evidence for either existence or absence of the Werther and the Papageno effect at the population level in India.Materials and MethodThe online media reports related to the theme of death of SSR by suicide on 14th June were retrieved using the Google News online platform (https://news.google.com).", [["death", "DISEASE", 210, 215]]], ["The search was conducted on 20th June, 2020 in the tor browser, using search terms \u201cSushant\u201d, \u201cSingh\u201d, \u201cRajput\u201d, \u201cdied\u201d, \u201cdeath\u201d and \u201csuicide\u201d.", [["death", "DISEASE", 122, 127]]], ["A total of 214 reports published on various international, national, and regional online news and entertainment media portals were retrieved.", [["entertainment media portals", "TREATMENT", 98, 125]]], ["Fourteen of them contained either only videos or were not related to theme of the present study, and were excluded.", [["the present study", "TEST", 78, 95]]], ["Thus, a total of 200 articles were selected for further analysis.Materials and MethodThe news headlines were analysed to generate a word cloud (using a word cloud generator available at https://www.wordclouds.com) representing the commonly used terms in the online media reports covering SSR death.", [["death", "DISEASE", 292, 297], ["further analysis", "TEST", 48, 64], ["a word cloud generator", "TREATMENT", 150, 172]]], ["Two trained researchers independently reviewed and extracted information following the above described procedure.", [["the above described procedure", "TREATMENT", 83, 112]]], ["Any discrepancy or disagreement between the two researchers was resolved by consensus.", [["Any discrepancy", "PROBLEM", 0, 15]]], ["The data were analysed using SPSS version 23.0 (IBM Corp, Armonk, NY).", [["The data", "TEST", 0, 8], ["SPSS version", "TEST", 29, 41]]], ["The descriptive (frequency and percentage) and inferential statistics (chi-square and Fishers\u2019 exact test) were conducted.", [["exact test", "TEST", 95, 105]]], ["A p-value of less than 0.05 was considered significant for all tests.Materials and MethodThe Google Trends utilizes an algorithm to give normalized relative search volume (RSV) for the keyword(s) searched for a specified geographical region and time period.", [["RSV", "SPECIES", 172, 175], ["A p-value", "TEST", 0, 9], ["all tests", "TEST", 59, 68], ["an algorithm", "TEST", 116, 128]]], ["The RSV represents how frequently a given search query has been searched on the Google search engine, compared to the total number/volume of Google searches conducted in the same geographical region over the selected time period.", [["RSV", "ORGANISM", 4, 7], ["RSV", "SPECIES", 4, 7], ["RSV", "OBSERVATION", 4, 7]]], ["The RSV values range from zero (representing very low search volumes) to 100 (peak search volume for that query).", [["RSV", "ORGANISM", 4, 7], ["RSV", "SPECIES", 4, 7], ["The RSV values", "TEST", 0, 14], ["peak search volume", "TEST", 78, 96], ["RSV", "OBSERVATION", 4, 7]]], ["Google Trend analysis was conducted to evaluate the online search interest for keywords representing suicide-seeking and help-seeking behaviours of the population for the month of June 2020.", [["Trend analysis", "TEST", 7, 21]]], ["The initial list was made based on the review of available literature, which was finalized by the process of consensus building between two authors R.G. and S.S (qualified psychiatrists with clinical and research experience of working with people with mental illness and suicidal ideas/attempts) based on the face validity of search terms.", [["illness", "DISEASE", 259, 266], ["people", "ORGANISM", 240, 246], ["people", "SPECIES", 240, 246], ["mental illness", "PROBLEM", 252, 266]]], ["The examples of suicide-seeking keywords included in the study were \u2018commit suicide\u2019, \u2018suicide method\u2019, and \u2018kill myself\u2019.", [["suicide\u2019", "DISEASE", 76, 84]]], ["The four Google Trends options of Region, Time, Category, and Search type were specified as India, from 1 June to 30 June 2020, all categories, and web search in the present study.", [["the present study", "TEST", 162, 179]]], ["The \u201cplus\u201d (+) function from google trends was used to integrate the search volume (RSV) of all suicide-seeking terms and help-seeking keywords.", [["RSV", "SPECIES", 84, 87]]], ["A Graph showing daily variation in RSV for suicide-seeking and help-seeking keywords was constructed.", [["RSV", "ORGANISM", 35, 38], ["RSV", "SPECIES", 35, 38], ["A Graph", "TEST", 0, 7], ["RSV", "PROBLEM", 35, 38]]], ["The change in mean RSV value for the suicide-seeking and help-seeking keywords after the reference event, when compared to baseline was analysed by applying the Mann Whitney-U test.", [["RSV", "SPECIES", 19, 22], ["The change in mean RSV value", "PROBLEM", 0, 28], ["change", "OBSERVATION_MODIFIER", 4, 10], ["mean RSV", "OBSERVATION", 14, 22]]], ["The complete list of keywords used in this study along with other details pertaining to the Google Trends methodology are described in Supplementary Table 2.Materials and MethodThe information used in this study involved published online media reports and data related to the volume of anonymized web searches made during a given time period, both of which were freely available in the public domain.", [["this study", "TEST", 38, 48], ["this study", "TEST", 201, 211]]], ["Further, no patient or participant was approached directly in this study.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19], ["participant", "SPECIES", 23, 34], ["this study", "TEST", 62, 72]]], ["Apart from the words in the name of SSR, the most commonly used words were \"suicide\", \"death\", \"actor\", \"police\", \"Bollywood\", \"Mumbai\", \"Rhea\", and \"Kapoor\" in decreasing order of frequency.", [["death", "DISEASE", 87, 92]]], ["This suggested that a significant proportion of headlines used words like suicide, police or Bollywood to sensationalize or glamourize the headlines, with no significant difference between news media (37.5%; 37/122) and entertainment media (42.0%; 37/88) headlines (\u03c72 =0.426, p = 0.56).", [["entertainment media", "TEST", 220, 239], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["no", "UNCERTAINTY", 155, 157], ["significant", "OBSERVATION_MODIFIER", 158, 169]]], ["The location of suicide was mentioned in two news media (1.8%) and two (2.3%) entertainment media headlines.Analysis of media reports ::: ResultsThe selected media reports were published from various media platforms: international news group, 9% (n = 18); national news group, 28.5% (n = 57); regional news group, 18.5% (n = 37); and entertainment blogs, 44% (n = 88).", [["regional news group", "TEST", 293, 312], ["entertainment blogs", "TEST", 334, 353], ["suicide", "OBSERVATION", 16, 23]]], ["Seventeen news media platforms had reported the story four or more times in the immediate one-week period following the SSR suicide, with Hindustan Times (6), NDTV (6), Republic World (6), Times of India (5), DNA (5), India TV (4), The Indian Express (4) and Times Now (4) contributing to 41.5% (n = 83/200) of the articles.", [["DNA", "CELLULAR_COMPONENT", 209, 212], ["India TV", "TEST", 218, 226]]], ["There was significant association between the type of news media and the use of sensational language [\u03c72(3) = 9.774 (p < 0.021)].", [["sensational language", "TEST", 80, 100], ["significant", "OBSERVATION_MODIFIER", 10, 21]]], ["There was significant association between the type of news media and provision of information about where to seek help [\u03c72(1) = 15.98 (p < 0.001)].", [["significant", "OBSERVATION_MODIFIER", 10, 21]]], ["Final social media posts were shared more by national media compared to international, regional and entertainment media [\u03c72(3) = 9.91 (p < 0.019)].Google Trends analysis ::: ResultsThe median and inter-quartile range (IQR) values of RSV for suicide-seeking keywords in the two-weeks before and after the death of SSR on 14 June 2020 were 12 (IQR: 11.5-13.5) and 22 (IQR: 18-25) respectively.", [["death", "DISEASE", 304, 309], ["RSV", "ORGANISM", 233, 236], ["RSV", "SPECIES", 233, 236], ["RSV", "PROBLEM", 233, 236], ["IQR", "TEST", 342, 345], ["IQR", "TEST", 366, 369]]], ["Whereas, the median and IQR values of RSV for suicide-seeking keywords in the two-weeks before and after the death of SSR were 11 (10-11.5) and 14 (13-19) respectively.", [["death", "DISEASE", 109, 114], ["RSV", "ORGANISM", 38, 41], ["RSV", "SPECIES", 38, 41], ["SSR", "TEST", 118, 121]]], ["There was a significant increase in RSV for suicide-seeking (U = 0.5; Z= -4.62; p < 0.001) and help-seeking (U = 6.5; Z=-4.39; p < 0.001) keywords after the reference event, when compared to baseline.", [["RSV", "ORGANISM", 36, 39], ["RSV", "SPECIES", 36, 39], ["a significant increase in RSV", "PROBLEM", 10, 39], ["Z", "TEST", 70, 71], ["U", "TEST", 109, 110], ["Z", "TEST", 118, 119], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["increase", "OBSERVATION_MODIFIER", 24, 32], ["RSV", "OBSERVATION", 36, 39]]], ["However, the online peak search volume and search interest for suicide-seeking was greater than help-seeking as shown in Fig. 2.DiscussionThe present study analysed the online media reports related to the theme of a popular Bollywood movie actor\u2019s suicide, and compared it against the WHO media reporting guidelines for suicide.", [["The present study", "TEST", 138, 155]]], ["Further, the change in online search interest for different keywords related to \u201csuicide-seeking\u201d and \u201chelp-seeking\u201d behaviours after this event were analysed to explore for possible Werther and Papageno effects.DiscussionA substantial proportion of articles did not follow most of the recommendations.", [["Papageno", "SIMPLE_CHEMICAL", 195, 203]]], ["About 58% articles used sensational language, 59.5% articles mentioned suicide site, 17% articles suggested possible cause for suicide which was not related to poor mental health.", [["suicide site", "PROBLEM", 71, 83], ["suicide", "PROBLEM", 127, 134], ["poor mental health", "PROBLEM", 160, 178], ["possible", "UNCERTAINTY", 108, 116]]], ["A study assessing the quality of suicide reporting in Indian print media found increase in prominence of suicide reports after the celebrity suicide (Harshe et al., 2016).", [["A study", "TEST", 0, 7], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["prominence", "OBSERVATION_MODIFIER", 91, 101]]], ["It speculated that the most likely reason for sensationalism in media reporting of suicide might be to enhance the readership.", [["sensationalism", "DISEASE", 46, 60], ["sensationalism in media", "PROBLEM", 46, 69], ["most likely", "UNCERTAINTY", 23, 34]]], ["Further, only 13% articles provided information about where to seek help for suicidal thoughts.", [["suicidal thoughts", "DISEASE", 77, 94], ["suicidal thoughts", "PROBLEM", 77, 94]]], ["A previous study evaluating the newspaper coverage of celebrity suicide in United States against \u2018Mindset\u2019 recommendations for reporting suicide, found 46% articles provided details about suicide method and only 11% provided information about help-seeking (Carmichael and Whitley, 2019).", [["celebrity suicide", "DISEASE", 54, 71], ["A previous study", "TEST", 0, 16]]], ["Previous studies from India found minimal adherence to media reporting recommendations for suicide in the print media.", [["Previous studies", "TEST", 0, 16], ["minimal", "OBSERVATION_MODIFIER", 34, 41]]], ["The high frequency of harmful reporting characteristics observed in the present study is consistent with the low adherence to WHO guidelines reported in other neighbouring Asian countries as well (Arafat et al., 2020a).", [["the present study", "TEST", 68, 85], ["high", "OBSERVATION_MODIFIER", 4, 8], ["consistent with", "UNCERTAINTY", 89, 104]]], ["The headlines of the online reports included in the current study used the term \u2018suicide\u2019 in 18% articles.", [["the current study", "TEST", 48, 65]]], ["Previous studies on print media from India reported \u201csuicide\u201d mentioned in headlines of 68.6% articles (Chandra et al., 2014) and 30.31% articles (Harshe et al., 2016).DiscussionRefreshingly, in the present study 81.5% articles did not use the word \u2018commit\u2019 or related terms while reporting suicide, and 65.5% articles did not mention the suicide method in the reports.", [["Previous studies", "TEST", 0, 16]]], ["This is a welcome improvement in media reportage of suicide, which might be due to the positive effect of PCI adopting guidelines on media reporting of suicide in September 2019 based on the WHO guidelines (Vijayakumar, 2019).", [["PCI adopting guidelines", "TREATMENT", 106, 129]]], ["Publication of photograph of a person with mental illness without the individual\u2019s or his/her next of kin\u2019s consent in case of suicide violates section 24 (1) of the Mental Health Care Act, 2017 in India (Mental Healthcare Act, 2017).", [["illness", "DISEASE", 50, 57], ["person", "SPECIES", 31, 37], ["mental illness", "PROBLEM", 43, 57]]], ["This is in line with a study on print media from India, that reported vernacular newspapers to be more compliant with WHO suicide reporting guidelines compared to English language newspapers (Menon et al., 2020).DiscussionMoreover, in terms of providing potentially helpful information, only one article provided research findings and population level statistics regarding suicide.", [["a study", "TEST", 21, 28]]], ["It helps in increasing the awareness about mental health problems among the general population and encourage them to seek treatment for the same.", [["mental health problems", "PROBLEM", 43, 65], ["treatment", "TREATMENT", 122, 131], ["increasing", "OBSERVATION_MODIFIER", 12, 22]]], ["A previous study assessing South Indian newspapers found that a few articles recognised the link between suicide and psychiatric disorders or substance use disorders (Menon et al., 2020).", [["psychiatric disorders", "DISEASE", 117, 138], ["substance use disorders", "DISEASE", 142, 165], ["A previous study", "TEST", 0, 16], ["psychiatric disorders", "PROBLEM", 117, 138]]], ["Similarly, previous studies from India evaluating the reporting of suicides in newspapers found that only few articles tried to educate public about the issue of suicide by including opinion from health professionals, research findings or information about suicide prevention programmes (Chandra et al., 2014; Harshe et al., 2016; Menon et al., 2020).DiscussionOne possible solution is to have a uniform national suicide reporting guideline for the media of the entire country.", [["previous studies", "TEST", 11, 27]]], ["A continuous collaborative approach involving both mental health experts and media professionals should be adopted to sensitize them about the available research evidence backing these media reporting guidelines has been shown to successful in improving adherence to media reporting guidelines (Bohanna and Wang, 2012).", [["A continuous collaborative approach", "TREATMENT", 0, 35]]], ["Also, there should be regular workshops held for media professionals to provide them with adequate training and support in covering mental health and suicide-related topics.DiscussionThe findings from google trend analysis showed a significant increase in online search interest for terms representing both suicide-seeking and help-seeking behaviours after the SSR death.", [["suicide-seeking and help-seeking behaviours", "DISEASE", 307, 350], ["death", "DISEASE", 365, 370], ["media professionals", "TREATMENT", 49, 68], ["adequate training", "TREATMENT", 90, 107], ["google trend analysis", "TEST", 201, 222], ["the SSR death", "PROBLEM", 357, 370], ["significant", "OBSERVATION_MODIFIER", 232, 243], ["increase", "OBSERVATION_MODIFIER", 244, 252]]], ["There are several possible mechanisms described in the literature to explain the observed increase in suicidal behaviour among the general population associated with media reporting of celebrity suicide (Niederkrotenthaler et al., 2020).", [["suicidal behaviour", "DISEASE", 102, 120], ["suicidal behaviour", "PROBLEM", 102, 120], ["increase", "OBSERVATION_MODIFIER", 90, 98]]], ["First, people may identify with the deceased celebrities, which is usually more common in case of entertainment celebrities due to their strong public identity and following.", [["people", "ORGANISM", 7, 13], ["people", "SPECIES", 7, 13]]], ["Third, media reporting about the method of celebrity suicide might increase the cognitive availability of that method and remove ambivalence about which method to choose for suicide in vulnerable individuals, leading to an increase in suicide by the same method among the vulnerable population.", [["increase", "OBSERVATION_MODIFIER", 223, 231], ["vulnerable", "OBSERVATION_MODIFIER", 272, 282], ["population", "OBSERVATION", 283, 293]]], ["Interestingly, there was also smaller but significant increase in the internet search volume for help-seeking keywords.", [["smaller", "OBSERVATION_MODIFIER", 30, 37], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["increase", "OBSERVATION_MODIFIER", 54, 62]]], ["The peak search volume for help-seeking and suicide-seeking keywords was observed on the day of SSR\u2019s death, with a lower peak RSV and subsequently lower daily RSVs for help-seeking terms as compared to suicide-seeking terms among the general population.", [["death", "DISEASE", 102, 107], ["RSV", "ORGANISM", 127, 130], ["RSV", "SPECIES", 127, 130], ["a lower peak RSV", "PROBLEM", 114, 130]]], ["This suggests a weaker Papageno effect as compared to the Werther effect, possibly due to poor adherence to the WHO suicide reporting guidelines by the online and other types of media in India while covering the celebrity suicide (Newslaundry, 2020).DiscussionThere only a few studies that have assessed the fidelity of suicide reporting in India, with almost of the studies having evaluated the quality of media reporting of suicide in general population and included only few print media newspapers.", [["a weaker Papageno effect", "PROBLEM", 14, 38], ["a few studies", "TEST", 271, 284], ["the studies", "TEST", 363, 374], ["weaker", "OBSERVATION_MODIFIER", 16, 22], ["Papageno effect", "OBSERVATION", 23, 38]]], ["Thus, our study provides valuable addition to bridge these gaps in the existing literature on media reporting of celebrity suicide from India.", [["our study", "TEST", 6, 15]]], ["Further, a wide range of online media reports were analysed in this study for the first time in Indian settings to the best of our knowledge.", [["this study", "TEST", 63, 73]]], ["Further, the use of a novel Google Trends analysis to show an increased online search interest for suicide-seeking keywords immediately after the reference celebrity suicide provided support for the existence of Werther effect in the Indian context.", [["Trends analysis", "TEST", 35, 50], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["However, there are certain limitations as well which should be kept in mind while interpreting the findings of this study.", [["this study", "TEST", 111, 121]]], ["The study focussed only on English language media reports.", [["The study", "TEST", 0, 9]]], ["This might be an important area for future research, since studies from Western countries suggest television coverage or social media (e.g. Twitter) to be associated with increased suicide rates (Jashinsky et al., 2014).", [["increased suicide rates", "PROBLEM", 171, 194]]], ["Further, the relationship between people searching for suicide-seeking keywords might not be as clear as that observed for people with certain infectious disease like the influenza, with Google Trends analysis of data about searching for disease symptoms or other disease-related information being used to predict their incidences or outbreaks prior to the traditional methods of reporting an outbreak (Cao et al., 2017; Ginsberg et al., 2009; Zhang et al., 2018).", [["infectious disease", "DISEASE", 143, 161], ["influenza", "DISEASE", 171, 180], ["people", "ORGANISM", 34, 40], ["people", "ORGANISM", 123, 129], ["people", "SPECIES", 34, 40], ["people", "SPECIES", 123, 129], ["certain infectious disease", "PROBLEM", 135, 161], ["the influenza", "PROBLEM", 167, 180], ["disease symptoms", "PROBLEM", 238, 254], ["other disease", "PROBLEM", 258, 271]]], ["This is likely due to the fact that that someone who searched about suicide might not be actually suicidal, and may or may not kill themselves during the specified study period.", [["likely due to", "UNCERTAINTY", 8, 21]]], ["However, the search methodology used for doing the Google Trends analysis in the present study is in accordance with the guidelines for conducting a robust Google Trends research (Nuti et al., 2014).ConclusionThe quality of media reporting of celebrity suicide on online media in India is poor when compared to adherence with the WHO guidelines or the PCI guidelines.", [["online media", "TREATMENT", 264, 276], ["the PCI guidelines", "TREATMENT", 348, 366]]], ["Further, compliance with recommendations of including potentially helpful information about creating awareness about suicide and possible ways of seeking help for suicidal thoughts was very low, with only few articles 13% articles providing information about where to seek help for suicidal thoughts or ideation.", [["suicidal thoughts", "DISEASE", 163, 180], ["suicidal thoughts", "DISEASE", 282, 299], ["suicidal thoughts", "PROBLEM", 163, 180], ["ideation", "PROBLEM", 303, 311]]], ["There was a significantly greater increase in the online search interest for suicide-seeking keywords after the recent celebrity suicide.", [["significantly", "OBSERVATION_MODIFIER", 12, 25], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42]]], ["This in turn provides support for a strong Werther effect, possibly associated with poor quality of media reporting of celebrity suicide.", [["support", "TREATMENT", 22, 29]]]]}